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ABSTRACT 
Prenatal nutritional supplementation and autism spectrum disorders in two European population-
based cohorts 
Elizabeth Anne DeVilbiss, MPH, MS 
 
 
 
Objective: In two prospective population-based cohorts, we examined whether prenatal nutrient 
supplementation is protective against autism and its sub-components, and whether associations 
depend upon relevant genotypes.   
Study design: The Stockholm Youth Cohort (SYC) is a total population register-based cohort of 
children living in Stockholm County, Sweden.  Self-reported supplement and drug use was 
assessed at first antenatal visit.  ASD was ascertained after 4 to 15 years of follow-up covering all 
pathways to ASD care and services in Stockholm County.  Intellectual disability was ascertained 
through two Stockholm-based registers.  The Avon Longitudinal Study of Parents and their 
Children, UK (ALSPAC) is a population-based prospective birth cohort study based in Avon, 
England.  Nutritional supplements were reported at 18-weeks gestation regarding use during 
pregnancy.  Factor analysis produced seven factor scores related to autism and 1 combined score 
based on traits assessed at multiple ages, and IQ scores were obtained at 8.5 years of age. 
Methods: In the SYC, adjusted odds ratios (ORs) and 95% confidence intervals (CI) were 
estimated using multivariable regression, sibling controls, and propensity score matching.  In 
ALSPAC, linear regression was used to calculate β estimates with 95% confidence intervals (CI) 
for factor scores and IQ.  Supplementation was examined in main effects models and in 
interaction models with maternal and child genetic variants involved in folate metabolism. 
Results: In the SYC, maternal multivitamin use was associated with lower odds of ASD with ID 
in the child relative to mothers who did not use folic acid, iron, or multivitamins in regression 
(OR: 0.69 [95% CI: 0.57 to 0.84], sibling control (0.77 [0.52 to 1.15]), and propensity score 
matched (0.68 [0.54 to 0.86]) analyses.  Findings were not specific to ASD, as similar estimates 
were found for ID only.  There was no consistent evidence that either iron or folic acid use were 
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associated with lower risk of ASD.   
In ALSPAC, vitamin supplementation was associated with higher language acquisition skills, 
while folic acid use were associated with lower articulation scores; both of these relationships 
were also observed for higher dietary folate.  Vitamin and folic acid supplementation were 
associated with higher IQ scores in the child; associations between folic acid supplementation and 
IQ appeared to depend upon child MTHFR677 genotype.  There was no strong evidence of 
relationships between iron and ASD sub-components. 
Conclusions:  Our findings suggest that maternal nutrition may be related to specific features of 
autism such as cognition and facets of language development, and may depend upon genes 
involved in folate metabolism, specifically child MTFHR677.  Further scrutiny of maternal 
nutrition and its role in the etiology of autism, cognition, and language development is warranted.
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OVERVIEW 
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Introduction 
Maternal nutrition has been shown to influence neurodevelopment.[1-3]  In particular, 
maternal folate status regulated by dietary and genetic factors early in pregnancy may influence 
risk of autism spectrum disorders (ASD)[4].  Evidence is inconsistent regarding whether prenatal 
nutrient supplementation is protective against autism and its sub-components, and whether 
associations depend on relevant genotypes.  Few studies have accounted for the possibility that 
sub-components may have varying etiologies.[5-7] 
An American case-control study reported reduced ASD risk with prenatal vitamins,[8] 
folic acid,[9] and iron.[10]  Interestingly, lower mean folic acid intake was found for children 
with ASD with a lower cognitive function but not for ASD with higher functioning, suggesting 
that nutrients may differentially affect ASD risk depending on co-occurrence with intellectual 
disability.  In the prospective Norwegian Mother and Child Cohort study (MoBa), maternal folic 
acid intake, but not other vitamins and minerals, in the peri-conceptional period and early 
pregnancy, was associated with lower risk of autistic disorder.[11]  The Danish National Birth 
Cohort (DNBC) study reported null associations between folic acid and multivitamin intake and 
ASD or any of its subtypes.[12]   
Studies have linked self-reported folic acid supplementation or dietary folate during 
pregnancy with both reduced and strengthened ASD traits.[13-18]  Discrepancies may be due to 
dissimilarities in trait etiology[19, 20] differences in timing of folic acid initiation, dose, 
frequency, or duration, and/or methodological inconsistencies including timing of outcome 
assessment and assessment instruments.[4, 20]  To date, all published studies of maternal folate 
biomarkers and child ASD or autistic traits have found null relationships.[21, 22]  However, these 
biomarker studies also evaluated nutrient intake and reported associations with reduced ASD 
symptoms.  The body of evidence does not seem to support a protective association between 
maternal multivitamins[23-27], folic acid and/or dietary folate intake[17, 23, 28, 29], or 
supplementary and/or dietary iron intake[23-25, 28, 30] and child cognition.  Most biomarker 
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folate studies also have not found associations between maternal plasma or blood folate and 
cognitive function.[29, 31-34] 
Schmidt et al (2011)[8] explored effect modification between nutritional factors and 
functional genetic variants involved in folate metabolism as carried by the mother or child and 
risk of ASD.  They found significant interaction effects between periconceptional prenatal 
vitamin use and maternal MTHFR 677 TT, CBS rs234715 GT + TT, and child COMT 472 AA 
genotypes, with greater autism risk observed for variant genotypes and among mothers not taking 
prenatal vitamins.  Another study reported that low daily folate intake (< 400 mg/d) was 
associated with lower mental development in the child at 1, 3, 6, and 12 months only among 
MTHFR677 TT mothers.[35] 
 
Aims 
To provide richer etiological context, the following aims involve investigation of ASD 
sub-components. 
Aim 1: In the Stockholm Youth Cohort (SYC), investigate self-report of maternal nutritional 
supplementation with folic acid, iron, and multivitamins and ASD and intellectual disability.  Use 
multiple analytic strategies to help clarify these relationships. 
Aim 2: In the Avon Longitudinal Study of Parents and their Children, UK (ALSPAC), investigate 
maternal nutritional supplementation with folic acid, iron, and vitamins as they relate to autism 
sub-components.   
Aim 3: In ALSPAC, examine potential interactions between maternal nutrient supplementation 
and relevant genetic variants as they relate to autism sub-components. 
 
Organization of the dissertation 
This dissertation consists of 5 chapters.  Following the abridged background information 
in this overview, Chapter 1 contains expanded background information relevant to autism, 
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maternal nutrient supplementation, and genes involved in one-carbon metabolism.  Chapter 2 is a 
review paper that includes an overview of what is known about the role of folate in the etiology 
of neurodevelopmental disorders; a summary of relevant biological, genetic and epigenetic 
mechanisms; and evidence from human observational studies and randomized controlled trials 
that have examined the relationship between maternal folate and ASD or related traits.  Chapters 
3 is the Stockholm Youth Cohort study, designed to evaluate whether maternal supplementation 
with folic acid, iron, and multivitamins nutrient supplementation is associated with reduced risk 
of ASD and ID, and Chapter 4 is the ALSPAC study, investigating relationships between 
maternal nutrient supplementation, relevant genetic variants, and ASD sub-components.  Chapter 
5 contains a summary of findings and future directions. 
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Autism spectrum disorders  
ASD Phenotypes and Diagnosis 
Autism spectrum disorder (ASD), or autism, is conventionally regarded as a pervasive 
and lifelong neurodevelopmental disorder characterized by deficits in reciprocal social 
interactions and communication, and repetitive behaviors and restricted interests.[1]  Within these 
domains, individuals with ASD may have behaviors at the lower extremes of normally distributed 
continuums.[2, 3]  Multi-system comorbidities commonly accompany the behavioral features 
among individuals affected with ASD.  Comorbidities involve not only the nervous system 
(intellectual disability, anxiety, attention problems, sleep disruption, sensory differences, 
epilepsy), but also the gastrointestinal (reflux, food selectivity), and immune systems (recurrent 
infections),[4, 5] possibly reflecting common underlying mechanisms.[6]  Due to its heterogenity, 
autism could be viewed as a syndrome consisting of a variety of phenotypes, or traits.[7]  While 
specific sets tend to occur together,[8] each individual with autism exhibits a unique set of 
phenotypes,[9] each of which may vary in severity and etiology.[10]  The combination of 
phenotypes displayed by an individual with ASD is a reflection of that person’s unique genetics 
and early environmental influences.[7] 
ASD can be difficult to diagnose due to its heterogenous presentation and absence of 
known biomarkers.[4]  Diagnosis is based on International Classification of Disease (ICD) or 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria.  Diagnostic tools 
developed from DSM criteria include the revised Autism Diagnostic Interview (ADI-R)[11] and 
the Autism Diagnostic Observation Schedule (ADOS).[12]  Clinical signs are usually present by 
3 years of age.[13]  
Epidemiology 
While autism was first described by Dr. Leo Kanner in 1943,[14] and Dr. Hans Asperger 
in 1944,[15] references to individuals meeting the clinical profile have gone back several 
centuries.[4]  ASD was believed to be rare through the 1980s, having a prevalence between 3 and 
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5 in 10,000 individuals.[6, 16]  Measured rates of autism prevalence began increasing in the 
1980s.[17]  In U.S. surveillance populations, measured rates have increased from 1 in 152 to 1 in 
68 children 8 years of age between 2002 and 2010[18], but remained stable between 2010 and 
2012.[19]  ASD is now thought to be only second to intellectual disability in prevalence of 
serious developmental disabilities in the U.S.[4]  ASD is observed in all populations, and the 
increasing trend of measured autism rates has also been observed in the U.K.[20] and 
Taiwan.[21]  These prevalence figures do not take into account that ASD is 4 to 5 times more 
common among boys than among girls (1 in 42 and 1 in 189, respectively, in U.S. 
populations).[18, 22]  
Changes in diagnostic practices, increased awareness, and changes in other modifiable 
risk factors (e.g., advanced parental age) may partially account for the increase in ASD 
prevalence.  A register-based study in Denmark reported that for children born between January 
1, 1980, and December 31, 1991, 33% (95% CI: 0%-70%) of the increase in reported ASD 
prevalence was explained by changes in diagnostic criteria, while 60% (95% CI: 33%-87%) could 
be explained by diagnostic changes and inclusion of outpatient contacts combined.[23] 
About 53% of the increase in autism diagnoses within a California sample could be 
explained by changes in diagnostic practices (26%),[24] increased awareness (16%),[25] and 
advanced parental age (11%).[26, 27]  Reported rates in the 1960s only included autistic disorder, 
excluding Childhood Disintegrative Disorder, Pervasive Developmental Disorder Not Otherwise 
Specified (PDD-NOS), and Asperger Disorder,[1]  while current rates report autism as a single 
category, per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-
5).[1]  There is also the potential for overascertainment, given that symptoms of these disorders 
may resemble or arise with intellectual disability, attention deficit hyperactivity disorder, or 
obsessive-compulsive disorder.[28] 
Neuropathology 
Postnatal brain overgrowth has been observed among individuals with ASD, especially in 
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regions necessary for executing high-order social and cognitive processes.[29]  In particular, 
overgrowth has been observed in the prefrontal cortex, responsible for concentration and 
judgment, and in the prefrontal cortex, responsible for comprehension of language and 
emotion.[30-39]  Neuroimaging studies have reported differences in synchronization across 
cortical networks, with lowered functional connectivity relating to social cognition, language, 
working memory, and problem solving in individuals with ASD.[1]  
Cortical overgrowth may be the result of an excess of neurons in the frontal and 
prefrontal cortices reported among children with autism,[40] with rapid neuron formation 
potentially interfering with experience-dependent maturation and specialization.[41]  Since 
cortical layer formation and neuronal differentiation occur in prenatal development,[40] these 
processes may become dysregulated in individuals with ASD prenatally.  Neuroanatomical 
findings in postmortem brain samples also support a prenatal onset of ASD.[42, 43]  
Neurogenesis begins in the cerebral cortex at 9-10 weeks gestation and steadily increases in most 
cortical regions until 24-26 weeks gestation.[44]  Cortical synapses increase six-fold from 28 
weeks gestation to 15 months of age, which is when peak synaptic density peaks in the prefrontal 
cortex.[45] 
Genetic risk factors  
The causes of ASD can only be articulated in up to 15% of cases in which specific 
genetic variants have been identified,[46] most commonly with rare inherited conditions such as 
Fragile X Syndrome, Rett Syndrome, and Tuberous Sclerosis.  No identified single genetic 
aberration accounts for more than 1% of cases, suggesting extreme genetic heterogeneity among 
affected individuals.  Hundreds of genes are estimated to be involved in ASD,[47] but none of the 
identified genetic causes are specific to the disorder.[1]  These genes have been identified through 
genome-wide association studies (GWAS) and whole genome and exome sequencing.  
Postsynaptic density genes such as Neurexin 1, Neuroligins, and SHANK3 have been identified 
as ASD risk factors through the study of rare inherited conditions that are caused by de novo 
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mutations and are associated with increased risk of ASD.  Some genetic risk factors involve organ 
systems besides the nervous system, such as the immune and gastrointestinal systems, which may 
play a role in ASD comorbidities.[6]  Copy number variations are large-scale deletions of 
duplications of chromosome regions.[48]  A systematic review[49, 50] cited that cytogenetically 
detectable chromosome abnormalities were found in 7.4% (129/1749) of ASD cases (range: 0-
54%). 
Monozygotic twins are genetically identical, while dizygotic twins are as genetically 
comparable as singleton full siblings but share the same prenatal environment.  Diagnostic 
concordance studies have produced monozygotic concordance rates ranging from 50-100% and 
dizygotic concordance rates ranging from 0-36%,[51-55] with inter-study variability a function of 
case definition (ASD or autism) and child sex.  The largest of these studies cites ASD 
concordance figures of 76% for 128 monozygotic twin pairs and 18-34% for 186 opposite sex 
and 254 same sex dizygotic pairs, respectively.[53]  Comparatively, families with one affected 
child have had sibling recurrence rates ranging from 13%[56] to 19%[57].  
Dizygotic concordance figures suggest the relative contribution of shared environmental 
influences, while the absence of full concordance between monozygotic pairs and the range of 
symptom variation within concordant pairs[58] indicate a role of non-shared environmental 
influences.  Recent large studies cited highly variable contributions of shared and non-shared 
environmental factors in ASD twin liability (shared: 5 and 58%, unshared: 4 and 46%).[52, 56] 
Epigenetics 
Differential genetic expression among monozygotic twins discordant for ASD is 
regulated by epigenetics,[59, 60] the modulator through which environmental factors can 
influence genetic expression.  Environmental factors may influence genetic expression 
independent of or dependent upon genotype.  If vulnerability to environmental factors is 
influenced by genotype, gene-environment interaction is present. 
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Epigenetic marks define the chromatin state,[61] permitting or preventing transcriptional 
regulator complexes access to DNA sequences.[62]  Histone tail methylation is associated with 
the tight winding of DNA around histones such that gene transcription machinery is unable to 
associate with the DNA.[62, 63]  Since DNA methylation is crucial in properly controlling 
genetic information, both hyper- and hypomethylation are implicated in inappropriate regulation 
of gene function.[64] 
One-carbon metabolism 
In one-carbon (folate) metabolism, the methyl groups necessary for DNA methylation are 
derived from dietary methyl group intake; folate is said to be the predominant dietary methyl 
donor.[65, 66]  Folate (as methyl-tetrahydrofolate, 5-MTHF) can donate a methyl group to the 
amino acid homocysteine, using Vitamin B12 as a cofactor,[67] and Vitamin B6 is required for the 
conversion of tetrahydrofolate to 5,10-MTHF.[68]  Since the reaction cannot proceed in the 
absence of B12, deficiency of B12 results in functional deficiency of folate, though deficiency 
during pregnancy is rare due to large maternal storage.[69]  Since this transfer lowers 
homocysteine concentrations,[70] folic acid and vitamin B12 are both inversely related to 
homocysteine levels;[68, 71-73] homocysteine is commonly used as an indicator of functional 
folate status.[74-76] 
DNA methylation 
DNA methylation patterns are dependent upon the availability of methyl donors and 
cofactors and the proper functioning of one-carbon metabolism.  Embryonic DNA could become 
hypomethylated if maternal plasma does not contain sufficient levels of methyl donors (such as 
folate) and cofactors (such as vitamin B12) at critical periods in development.[77]  While 
methylation patterns of the genome are first established in the peri-conceptional period, 
widespread changes in DNA methylation continue throughout gestation.  Dietary deficiency of 
methyl donors has been associated with DNA hypomethylation in the brains[78] and 
placentas[79] of animals, and in genes controlling brain development in rat fetuses.[80]   
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Embryonic hypomethylation could also result from polymorphisms in maternal genes 
coding for key enzymes involved in one-carbon metabolism.  If any of the enzymes on the 
pathway between folate and 5-MTHF acquire functional mutations, it may impair the ability of 
folate and/or folic acid to be converted to 5-MTHF and act as an efficient methyl donor.  
Polymorphisms in the MTHFR gene, which metabolizes folate into a form capable of methyl 
donation, can reduce enzymatic activity, attenuating the ability of folate to be an effective methyl 
donor.[81-83]  This connects the status of epigenetic modifications to the functioning of the one-
carbon metabolic pathway.[81, 84]   
Since DNA methylation of gene promoter regions represses downstream gene expression, 
hypomethylation can result in inappropriate transcription of genes that might otherwise be 
repressed.  Failure to repress genes appropriately has been connected to neurodevelopmental 
disorders,[60] with epigenetic changes implicated in the development of Rett, Angelman, and 
Fragile X syndromes.[85]  DNA hypomethylation has also been associated with ASD.[86, 87] 
The MeCP2 gene, associated with Rett Syndrome, is involved in DNA methylation, 
involving the covalent addition of a methyl or hydroxy methyl to DNA cytosine nucleotides.[88] 
Maternal nutrition 
Folate and folic acid 
Folate is a water-soluble B complex vitamin (vitamin B9).[67]  Folate is the natural form 
of the B vitamin, while folic acid is the synthetic oxidized form of folate used in supplements and 
food fortification.[89] Since folate cannot be synthesized by humans,[90] it must be obtained 
from dietary sources including liver, kidney, leafy green vegetables, some citrus fruits, whole 
grains, potatoes, and dairy.[91] 
The fetus is dependent upon maternal intake of folate through active placental 
transport.[92]  Brain folate concentrations are elevated in the fetus early in gestation.[92]  Women 
of childbearing age are typically recommended to take at least 400 µg folic acid daily for the 
prevention of neural tube defects, while recommendations for high-risk women are 4 or 5 g per 
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day.[93-96]  In the U.S., folic acid supplementation recommendations were put forth by the CDC 
in 1992[97] and cereal fortification of cereal grain products with folate (140 µg/ 100 g) began in 
1996,[98] resulting in an elevation in median serum folate from 12.6 ug/L in 1994 to 18.7 ug/L in 
1998.[98]  Grain fortification is generally not an established practice in the rest of the world, 
including Europe.   
While folate is perhaps most well known for its role in DNA methylation, it is also 
involved in the myelination of nerves, DNA and neurotransmitter synthesis, and the methylation 
of phospholipids in neuronal membranes.[67, 99-102]  Due to its role in DNA synthesis, folate 
deficiency may result in deficient DNA repair, inducing DNA damage and neuronal death.[68]  
This is supported by work that has shown that dietary maternal folic acid intake affects the 
development of the neocortex and other regions of the brain by reducing the number of progenitor 
cells through its influence on cell mitosis and apoptosis.[103]  The neocortex is the part of the 
brain responsible for cognition, attention and social competence, which can be aberrant in ASD. 
Iron 
Iron is a large, charged ion that provides a binding site for oxygen in hemoglobin, 
facilitating oxygen delivery to the tissues of multi-cellular organisms.[104]  Sixty-five to 75% of 
the iron in an average person resides in hemoglobin in red blood cells.[104]  Iron-deficiency 
anemia is the most common nutritional anemia, and typically results from inadequate dietary iron 
intake or excessive blood loss.[104]  The World Health Organization estimates that iron 
deficiency and its resultant anemia affects 52% of pregnant women in developing countries 
worldwide.[105]  The developing fetus is dependent upon maternal sources of iron.[106]  Since in 
pregnancy, a large portion of maternal iron stores is diverted to the fetus,[104] maternal 
deficiency can cause fetal and infantile deficiency.[107, 108]  Iron is involved in the myelination 
of nerves and in neurotransmitter synthesis.[109] 
Sweden recommendations and use 
Nordic Nutritional Recommendations (NNR) advise that women consume 400 µg folic 
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acid per day during childbearing age and 500 µg folic acid per day during pregnancy, and 15 mg 
iron per day[110]. In one study of Swedish women conducted 2006-2009, dietary folic acid and 
iron intake alone was insufficient to meet these guidelines[110].  After accounting for 
supplementary intake, daily intake estimates among pregnant women were 430 µg folic acid and 
15.0 mg iron. 
The official recommendation from the National Board of Health and Welfare since 1996 
is to take a folic acid supplement with 400 µg per day, beginning one month prior to conception 
and continuing through the end of the first trimester.[111]  In a study conducted in southwest 
Sweden in 2013, 30% of pregnant women reported using folic acid-containing supplements 
during the first trimester.[112]  Regarding iron supplementation, guidelines from the Swedish 
Society of Obstetrics and Gynecology from 1991 through the study period recommended 
initiation of iron supplementation of 100 mg per day in weeks 20-24 (this recommendation was 
removed in 2008), while women with anemia should commence iron supplementation 
immediately at 200 mg daily.[113] 
U.K. recommendations and use 
The British Nutrition Foundation cites 300 µg folic acid per day for pregnant women and 
14.8 mg iron for females 15-50 years of age as Reference Nutrient Intakes.[114]  These are the 
quantities of nutrients that are considered sufficient to ensure that the needs of 97.5% of the group 
are met.  Pregnant women in the Avon Longitudinal Study of Parents and Children (ALSPAC) 
based in southwest England reported mean dietary folate and iron intakes of 250 µg and 10.4 mg, 
respectively.[115]  Cohorts of other pregnant women in the UK reported similar intakes 251 µg 
and 10.0 mg[116] and 242 µg and 10.5 mg[117] folate and iron, respectively. 
The Royal College of Obstetrics and Gynecologists recommends 400 µg supplementary 
folic acid per day preconception through the 1st trimester of pregnancy and 5 mg per day for high-
risk pregnant women.[118, 119]  Iron supplementation is only advised for pregnant women who 
are anemic or at risk of becoming anemic.  In a study conducted in England in 2001, 43% of 
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mothers reported taking folic acid-containing supplements prior to pregnancy and 67% reported 
use in the first trimester.  In this group of women, combined daily dietary and supplementary 
intake was around 510 µg.[120]  
Maternal nutrition and ASD 
Maternal nutrition has been shown to influence neurodevelopment.[121-131]  The 
success of folic acid fortification and supplementation in prevention of neural tube defects 
(NTDs) is well known, as folic acid is documented to prevent up to 75% of NTDs.[132-134]  
Since U.S. fortification was introduced, incidences of NTDs have been reduced by between 35% 
and 78%.[63, 89, 135-137]  The evidence for gestational nutrition influencing the risk of ASD is 
mixed.[138]  Two population-based studies[139, 140] reported reduced risk of ASD with 
maternal folic acid supplementation and intake in the peri-conceptional period and early 
pregnancy, while another reported no associations between early folate supplementation and ASD 
risk.[141]  One study reported a protective association between prenatal vitamins, but not 
ordinary multivitamins,[142] while another also reported no associations between early 
multivitamin supplementation and ASD risk.[141]  A protective association has also been 
reported between prenatal maternal iron[143] and ASD. 
Maternal nutrition and autism-related traits 
Studies have similarly linked self-reported folic acid use during pregnancy with both 
reduced and strengthened ASD traits.  Prospective cohort studies have linked self-reported 
maternal folic acid or dietary folate with traits related to autism including improved receptive and 
expressive communication at 18 months,[144] higher vocabulary scores,[145] a reduced risk of 
severe language delay,[146] but also unfavorable development of the personal-social domain at 3 
years of age,[147] improved verbal and social competence, but not executive functioning scores 
at 4 years,[148] and less autistic traits at 6 years.[149]   
One biomarker study reported an association between higher maternal plasma folate and 
higher cognitive test scores at 9-10 years.[131]  Others found no associations between maternal 
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blood or plasma folate and neurodevelopment at 18 months (16-36 w gestation)[150] or 5 years 
(19-37 w gestation)[151].  There were also no associations observed between maternal blood 
folate and social responsiveness at 4-5 years (11-21 w gestation)[152] and cognitive function at 
6.5 years (20 and 30 w gestation and delivery).[153] 
A dietary deficiency of vitamin B12 was negatively associated with mental development at 
1, 3, 6, and 12 months.[126]  Children of mothers with low plasma B12 (lowest decile) performed 
more slowly on a sustained attention task than children of mothers with high plasma B12 (highest 
decile), but there was no difference in the two groups for intelligence.[154]  A biomarker study 
did not report an association between vitamin B12 and cognitive test scores at 9-10 years.[131] 
Early life iron deficiency is associated with impaired cognition, socialization, and 
language development,[155-157] and poor iron status has also been associated with ASD.[158, 
159]  In a randomized controlled trial (RCT) in Nepal, children’s intellectual functioning was 
higher in an iron/folic acid group at 7 – 9 years compared to a placebo group, but not in iron/folic 
acid/zinc or multiple micronutrient groups.[160]  In an Indonesian RCT, no difference in mental 
development was reported among children of mothers taking standard and low dose folic acid and 
iron.[161]  In other RCTs, children of mothers who took iron had similar IQ scores at 4 years as 
children of mothers taking placebo[162] and children of mothers who took folic acid alone or in 
combination with iron scored similarly on mental development at 3, 6, and 12 groups and IQ at 7 
– 10 years.[163, 164]  A prospective cohort of dietary and supplementary iron intake reports no 
relationship with intelligence at mean 7.8 years[165] 
While studies of maternal multivitamin supplementation report null findings with regard 
to mental development through 12 months[163], 18 months[166], and 2 – 6 years[167] and 
intelligence at 7-9 years [160] and 7 – 10 years[164], a recent randomized controlled trial in 
Indonesia reported higher cognitive development at 9 – 12 years of age among children of 
mothers given multiple micronutrients compared to mothers given iron and folic acid.[168]  
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Genes related to folate metabolism and ASD 
MTHFR is perhaps the most examined gene in folate metabolism with respect to ASD.  
There has been an increase in the frequency of the C677T allele and its homozygous genotype in 
individuals born in the last quarter of the 20th century, as compared to the first three 
quarters,[169] with a greater frequency of this polymorphism in individuals with ASD.[170, 171]  
Independent associations between ASD and MTHFR[171, 172] have been replicated in the 
literature, but research indicates that the relationship between the C677T variant and autism does 
not hold under conditions of higher folate nutritional status.[173]  A meta-analysis of studies of 
MTHFR C677T and A1298C through the year 2012 reported the C677T polymorphism being 
associated with increased ASD risk, (T vs C allele: OR = 1.42, 95% confidence interval: [1.09, 
1.85]) while the A1298C polymorphism was only significantly associated with reduced ASD in a 
recessive model (CC vs AA+CC: 0.73 [0.56, 0.97]).  The C677T polymorphism was associated in 
ASD only in children from countries without food fortification.[174]  Other genes in folate 
metabolism have been examined to a limited extent among individuals with ASD.   
Associations with ASD have also been reported between other functional gene variants 
involved in one-carbon metabolism, such as catechol-O-methyltransferase (COMT),[175]  
transcobalamin II (TCN2),[175] 5-methyltetraydrofolate-homocysteine methyltransferase 
(MTRR),[176] and cystathionine-β-synthase (CBS),[172] while associations have not been 
reported between ASD and either betaine-homocysteine S-methyltransferase (BHMT), 5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR), folate receptor 1 (FOL1), or 
folate receptor 2 (FOLR2).[172] 
In the gestational environment, maternal and/or child genes related to folate metabolism 
may influence the risk of ASD, which may interact with maternal intake of nutrients involved in 
folate metabolism (folic acid, vitamin B12). Schmidt et al (2011)[142] explored effect 
modification between nutritional factors and functional genetic variants involved in folate 
metabolism (MTHFR, COMT, MTRR, BHMT, FOLR2, CBS, and TCN2) as carried by the 
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mother or child and risk of ASD.  They found significant interaction effects for maternal MTHFR 
677 TT, CBS rs234715 GT + TT, and child COMT 472 AA genotypes, with greater autism risk 
observed when mothers did not report taking prenatal vitamins periconceptionally.  Another study 
reported that low daily folate intake (< 400 mg/d) was associated with lower mental development 
in the child at 1, 3, 6, and 12 months only among MTHFR677 TT mothers.[126] 
Conclusions 
While maternal nutrition may be related to ASD, evidence is inconsistent regarding 
whether prenatal nutrient supplementation is protective against autism and related traits, and 
whether associations depend on relevant genotypes.  In examination of relationships between 
nutritional supplementation and ASD, few studies have accounted for the possibility that autism-
related traits may have varying etiologies.   
Since investigating related traits in addition to clinically diagnosed ASD would provide 
richer etiological context, we examine these relationships in two prospective population-based 
cohorts.  In the Stockholm Youth Cohort, we investigate maternal nutritional supplementation 
with folic acid, iron, and multivitamins and ASD, stratified by intellectual disability.  In 
ALSPAC, we investigate maternal nutritional supplementation with folic acid, iron, and vitamins, 
and potential interactions with genes involved in folate metabolism as they relate to autism and 
related factors.  Multiple analytic strategies will be utilized to help clarify these relationships.
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Abstract
Emerging evidence from epidemiological studies supports the notion that maternal folate status regulated by dietary and genetic factors early
in pregnancy may inﬂuence the risk of autism spectrum disorders (ASD). In this review, we provide an overview of what is known about the
role of folate in the aetiology of neurodevelopmental disorders; summarise relevant biological, genetic and epigenetic mechanisms; and
synthesise the evidence from human observational studies and randomised controlled trials that have examined the relationship between
maternal folate and ASD or related traits. Much of the existing literature on this topic is subject to limitations such as potential confounding by
healthy behaviours and other dietary factors, and exposure assessed within limited exposure windows. As the existing evidence is
inconclusive, further research remains to be conducted in order to verify this hypothesis. Complete assessment of maternal functional folate
status through the pre- and peri-conceptional periods requires biological measurement of folate, vitamin B12 and homocysteine and genetic
variants involved in one-carbon metabolism and epigenetic mechanisms. In addition to more complete assessment of maternal functional
folate status, careful consideration of potential confounding is warranted.
Key words: Autism: Epigenetics: Folic acid: Neurodevelopment: Pregnancy
Autism spectrum disorders (ASD) are neurodevelopmental
disorders characterised by impaired social function, abnormal
communication and repetitive or unusual behaviour(1).
Although the measured prevalence of ASD was no greater than
ﬁve per 10 000 individuals in the 1980s, estimated rates in US
surveillance populations have increased to one in sixty-eight
children in 2010(2). Recent genetic and epidemiological studies
suggest that the heritability of ASD is approximately 50 %(3,4),
indicating that non-heritable risk factors contribute to a sub-
stantial proportion of ASD risk.
Recent epidemiological studies(5,6) have suggested a possible
link between maternal folate status during pregnancy and risk
of ASD in children. As folate cannot be synthesised by humans
and is entirely derived from dietary sources, folate status can be
modiﬁed through increased intake of folate-rich foods such as
leafy green vegetables, folic acid (FA) supplements or for-
tiﬁcation of the food supply. This raises the intriguing prospect
that, much like with neural tube defects(7,8), the incidence of
ASD may be decreased through interventions that enrich
maternal folate status. This review aims to summarise the bio-
logical, genetic and epidemiological evidence linking folate
status and the risk of ASD. In addition, we discuss the research
challenges that remain to be addressed before any ﬁrm
conclusion can be drawn about the possible link between
maternal folate status and risk of ASD.
Neurodevelopment is inﬂuenced by deoxyribonucleic acid
methylation
Documentation of problems in ASD core areas such as com-
munication, socialisation and attention in children <12 months of
age(9,10) supports the notion that disruption of neurodevelop-
mental processes during the pre- and perinatal period may
contribute to ASD. In particular, epigenetic modiﬁcations during
peri-conception are increasingly recognised as having lasting
developmental implications with regard to ASD(11). One espe-
cially relevant epigenetic process crucial to neurodevelopment is
DNA methylation, which inﬂuences gene expression through the
methylation of cytosine residues in CpG dinucleotides. DNA
methylation depends on the availability of dietary methyl donors
such as folate, choline and methionine, which are interrelated
through one-carbon metabolism. Changes to the availability of
folate or other methyl donors can affect DNA methylation
capacity, with potential downstream neurodevelopmental
consequences.
*Corresponding author: E. A. DeVilbiss, email ead77@drexel.edu
Abbreviations: ASD, autism spectrum disorders; FA, folic acid; MTHFR, methylene tetrahydrofolate reductase.
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During the peri-conceptional period, methylation patterns of
the genome (with the exception of imprinted genes) are ﬁrst
established, beginning with de-methylation of maternal and
paternal DNA, followed by re-methylation of the combined
genome. De-methylation occurs in the pre-implantation
embryo, and it is generally completed by the 16- or 32-cell
morula stage, about 4 d after fertilisation. Methylation levels
then increase markedly through the blastocyst stage, about 5 d
post fertilisation(12,13). Thus, even before a pregnancy can be
conﬁrmed, a high concentration of dietary methyl donors is
required to establish epigenetic patterns in the cells of the
developing embryo(14).
Another critical window occurs during early pregnancy,
in which the brain rapidly begins to develop. In the 1st month
of gestation, the central nervous system begins to form with
neurogenesis and cell migration occurring in the forebrain,
midbrain and hindbrain(15). Neurogenesis in most cortical and
subcortical structures occurs between 5 and 25 weeks of
gestation(15). The development of functional neuron networks(16)
requires high concentrations of methyl donors for cellular
differentiation(17), as DNA methylation is essential for individual
cell viability(18,19). Early modiﬁcations in DNA methylation that
cause developing brain cells to deviate from proper differentiation
can result in irreversible reductions or expansions of neuron
pools(16). Consequently, epigenetic dysregulation during the
period when brain organisation develops could result in
alterations in brain connectivity(20–22).
Dietary and genetic determinants of folate status affect
deoxyribonucleic acid methylation capacity in the brain
Embryonic DNA can become hypomethylated if maternal
plasma does not contain sufﬁcient levels of methyl donors such
as folate and cofactors such as vitamin B12 at critical periods in
development(23). Dietary deﬁciency of methyl donors has been
associated with DNA hypomethylation in the brains(24) of rats
and in genes controlling brain development in rat fetuses(20).
For example, a maternal diet low in choline, another dietary
methyl donor, resulted in global DNA hypomethylation and
increased expression of genes that turn off cell cycling and
promote early differentiation in the hippocampus of fetal
mice(20).
Although environmental exposures (e.g. decreased dietary folate
intake) can result in embryonic hypomethylation, hypomethylation
also can occur via genetic regulation of processes relevant to both
folate metabolism and DNA methylation. For example, functional
hypomethylation can result from polymorphisms in the offspring
gene coding for protein readers of DNA methylation patterns,
namely methyl-CpG-binding protein 2 (MeCP2), a methyl-binding
domain protein. This can have important structural and functional
consequences, as neurons without functional MeCP2 in the cortex
have been found to have signiﬁcantly smaller dendritic arbours in
both humans(21) and mice(22).
Another example of genetic regulation is with 5-
methyltetrahydrofolate (5-MTHF), the functional methyl donor
form of folate, which is synthesised from a folate derivative by the
enzyme methylene tetrahydrofolate reductase (MTHFR). Human
carriers of the MTHFR C677T and A1298C polymorphisms have
lower enzyme activity, reducing the production of 5-MTHF and the
ability of folate to function as a methyl donor in the production of
methionine and subsequent DNA methylation(25). Interestingly, a
meta-analysis of eight studies on the relationship between child
MTHFR polymorphisms and ASD(26) reported that the C677T
polymorphism was only associated with ASD in children living in
countries without food fortiﬁcation. The dependence of a genetic
association on a background of the dietary environment is sug-
gestive evidence that gene–environment interactions are instru-
mental in pathways linking folate status with child ASD.
Collectively, the existing human and animal research on one-
carbon metabolism suggests that maternal folate status could be
a biologically plausible risk factor for ASD through its impact on
DNA methylation.
Other pathways by which folate inﬂuences
neurodevelopment
In addition to the effects on DNA methylation, folate status can
inﬂuence neurodevelopment through multiple other pathways.
Mutations in the folate receptor 1 (FOLR1) gene coding for folate
receptor α (FRα) have been associated with severe hypomyeli-
nation in the brains of affected patients(27). Because cellular
uptake of metabolised folate (MTHF) is mediated by FRα (along
with other proteins), functional mutations in FOLR1 also result in
systemic folate deﬁciency(27). Moreover, the folate cycle is per-
ipherally involved in the creation of essential phospholipids (e.g.
phosphatidylcholine) and neurotransmitters (e.g. serotonin)(28).
Therefore, reduced availability of dietary methyl donors during
key exposure windows could interfere with the production of
these critical neurodevelopmental elements. Children with ASD
have been found to exhibit dysregulated serotonergic function(29),
as well as lower levels of phosphatidylcholine in plasma, in
comparison with typically developing children(30). Finally, as
folate is also involved in DNA synthesis, folate deﬁciency may
result in deﬁcient DNA repair, inducing DNA damage and neu-
ronal death(31). This is consistent with work demonstrating that
dietary maternal FA deﬁciency in mice affects the development of
the neocortex and other regions of the brain by reducing the
number of progenitor cells through its inﬂuence on cell mitosis
and apoptosis(32).
Although a comprehensive review examining folate and
altered neurodevelopment is beyond the scope of this paper,
other authors have reviewed such literature in detail(33,34).
Human studies linking maternal folate and autism
spectrum disorders and related traits
Methods
To identify studies examining maternal folate status and autism or
related traits speciﬁed as such, PubMed was ﬁrst searched for the
terms (folic acid or folate) (autis*) on 21 January 2014, with no
date range speciﬁed. This search was repeated periodically
through 15 April 2015, to ensure inclusion of new relevant stu-
dies. As of 15 April 2015, this search produced 136 citations.
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Criteria for inclusion in the review were original research articles
examining FA or folate exposure during pregnancy, with autism
or related traits as outcomes in the offspring. Studies (or aspects of
manuscripts(35)) examining multivitamins without speciﬁc men-
tion of FA were excluded. Additional exclusion criteria were
biochemical studies and/or those focused on understanding
biological mechanisms, animal studies and ecological studies, the
lattermost because of the lack of rigour and inability to draw
causal inference. Of the search results, four citations remained
after application of inclusion and exclusion criteria (Fig. 1).
Because of the existence of relevant literature on ASD traits not
designated as such, literature for review was also selected from
references of included (ﬁve additional studies) and excluded
search results (one additional study). As many references exam-
ined numerous outcomes, autism outcomes experts were con-
sulted to identify the most ASD-relevant outcomes (executive
function, communication and social competence) within the ten
articles selected for review. Included studies were evaluated
based on quality of measured exposure and outcome, control for
relevant confounders, biases and other analytical issues.
The human evidence linking maternal folate status with ASD
and related traits comes from various studies distinguished by
study design (observational v. randomised), how folate status is
measured (e.g. self-reported folate or supplement intake v.
biomarker measurement) and study outcome (clinical diag-
noses of ASD v. ASD-related traits). We discuss this evidence in
the following sections, organised by these characteristics. All
studies are summarised in Table 1.
Observational studies of maternal folate and autism
spectrum disorders
To date, there are only two published epidemiological studies
examining maternal folate status during pregnancy and diag-
noses of ASD. Despite differences in size, populations and
study designs, an American case–control study by Schmidt
et al.(5) and a Norwegian cohort study by Suren et al.(6) reported
similar protective associations for maternal FA intake in the
peri-conceptional period and early pregnancy, and children’s
risk of ASD. The case–control study featured 429 cases and 278
controls, whereas the cohort study featured 85 176 children, of
whom only 270 had been diagnosed with ASD. The OR for the
case–control study(5) was 0·62 (95 % CI 0·42, 0·92) for a mean
daily FA intake of ≥600 v. <600 μg in the 1st month of preg-
nancy, whereas the cohort study(6) estimated an OR of 0·61
(95 % CI 0·41, 0·90) for FA supplementation in the month before
and ﬁrst 2 months of pregnancy compared with no supple-
mentation. Furthermore, the case–control study found that the
reduced risk for FA intake ≥600 μg was only evident for
mothers and/or children having the MTHFR C677T variant(5).
Although these studies support that maternal folate status may
inﬂuence ASD risk, there are important considerations. For
example, the ASD prevalence in the Norwegian study was 0·3%.
Given that 1 % is the generally accepted ﬁgure for worldwide ASD
prevalence(43), this disparity is a strong indication of case under-
ascertainment that may inﬂuence results. The potential for
ascertainment bias is supported by evidence that mothers of
severely affected children had lower response rates.
Another limitation is that both studies relied on self-reported
maternal intake of FA. Self-reports can introduce recall or
reporting bias, although the concern is less in the prospectively
designed Norwegian study, which assessed peri-conceptional FA
use at 18 weeks of gestation, well before the birth of the child(6).
To what degree such self-reports reﬂect actual folate exposure is
unclear, as no biomarkers were available in these studies. In
addition, social, economic, behavioural and environmental factors
can inﬂuence self-reported vitamin supplementation(44,45). For
instance, in a study of childbearing-age women in the USA,
PubMed search 
(Folic acid or folate) (autis*)  
(n 136) 
Christian et al.
JAMA (2010)(41)
Referenced (n 6) In scope (n 4) 
Suren et al.
JAMA (2013)(6)
Braun et al.
J Autism Dev Disord (2014)(35) 
Ecological 
(n 1)
Animal study 
(n 9)
Biochemical/mechanism 
(n 16)
Not autism or traits 
(n 21)
Not pregnancy 
(n 23)
Not folate 
(n 28)
Not original research 
(n 34)
Out of scope (n 132) 
Dobo & Czeizel
Eur J Pediatr (1998)(42)
Roth et al.
JAMA (2011)(37)
Schmidt et al.
Am J Clin Nutr (2012)(5)
Julvez et al.
Paediatr Perinat Epidemiol (2009)(38)
Wehby & Murray, Matern
Child Health J (2007)(39)
Veena et al.
J Nutr (2010)(40)
Steenweg-de Graaff et al.
Eur J Public Health (2014)(36)
Fig. 1. Derivation of reviewed literature.
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Table 1. Epidemiologic studies assessing maternal folate status and autism spectrum disorders (ASD) or ASD-related traits
Reference (country)
Study design and
number of children Exposure assessment Outcome Results
Self-reported maternal folate status and ASD diagnosis
Suren et al.(6)
(Norway)
Cohort study of
85 176 (114 AD;
56 Asperger;
100 PDD-NOS)
FA supplementation 4 weeks
before to 8 weeks after
conception; questionnaire at
18 weeks of gestation
AD, with or without language
delay at 36 months; Asperger
syndrome; PDD-NOS
Children of FA users v. non-users
had 0·61 (95% CI 0·41, 0·90)
times the odds of AD; protective
association only in AD with
language delay (OR 0·49;
95% CI 0·25, 0·99) but not in
AD without language delay
(OR 0·91; 95% CI 0·46, 1·81);
FA use not associated with
Asperger or PDD-NOS
Schmidt et al.(5)
(USA)
Case–control study of
429 ASD; 278 TD;
130 DD
Dietary and vitamin FA intake
3 months before pregnancy and
in the 1st month of pregnancy;
questionnaire at 2–5 years after
birth
ASD defined by Autism
Diagnostic Interview-Revised
and the Autism Diagnostic
Observation Schedule–Generic
Children of mothers taking ≥600
v. <600 μg FA in the 1st month
of pregnancy had reduced odds
of ASD (OR 0·62; 95% CI 0·42,
0·92). In stratified analyses, the
association was only evident
when the mother and/or child
had the MTHFR C677T variant
genotype
Self-reported maternal folate status and ASD-related traits
Steenweg-de
Graaff et al.(36)
(The Netherlands)
Cohort study of 3893
children
FA supplement use and when
initiated; questionnaire at
<18 weeks of gestation
Autistic traits at 6 years – Social
Responsiveness Scale (SRS)
short form, Pervasive
Developmental Problems
subscale of the Child Behavior
Checklist
Use of FA associated with lower
SRS scores: ‘pre-conception
start’ v. ‘no use’: –0·042,
95% CI –0·068, –0·017
‘Start< 10 week’ v. ‘no use’:
–0·041, 95% CI –0·066, –0·016
‘Start >10 week’ v. ‘no use’:
–0·057, 95% CI –0·089, –0·025
Roth et al.(37)
(Norway)
Cohort study of
38 954 children
(204 severe
language delay)
FA supplementation 4 weeks
before to 8 weeks after
conception; questionnaire at
17 weeks of gestation
Severe language delay at
3 years – MacArthur
Communication Development
Inventory UK short form
Maternal FA only (OR 0·55; 95%
CI 0·35, 0·86) or in combination
with other supplements (OR
0·55; 95% CI 0·39, 0·78)
associated with reduced risk
of severe language delay.
Supplements without FA not
associated with severe
language delay (OR 1·04;
95% CI 0·62, 1·74)
Julvez et al.(38)
(Spain)
Cohort study of
420 children
FA supplementation at the end of
the first trimester; questionnaire
at a median of 12·4 weeks of
gestation
Verbal competence and executive
function at 4 years (McCarthy
Scales of Children’s Abilities)
Social competence at 4 years
(California Preschool Social
Competence Scale)
FA use associated with higher
verbal (3·98 pt, 95% CI 0·66,
7·31) and social competence
(3·97 pt, 95% CI 0·81, 7·14)
scores. Use of vitamins without
FA associated with
improvements in verbal (6·52 pt,
95% CI 0·46, 12·58), but not
social competence scores
(3·73 pt, 95% CI –1·86, 9·32).
FA use not associated with
executive function scores
Wehby & Murray(39)
(USA)
Cohort study of
6774 children
FA supplementation for at least
3 d/week during the 3 months
before becoming aware of
pregnancy through first
trimester; questionnaire at
≥6 months after birth
Personal-social and language
domains at 3 years (Denver
developmental screening)
FA use associated with somewhat
poorer performance within the
personal-social domain,
compared with non-use of FA
(OR 1·78; 95% CI 0·94, 3·38).
No associations observed
between FA use and language
development (OR 0·91; 95% CI
0·55, 1·50)
Biomarker-assessed maternal folate status and ASD-related traits
Braun et al.(35) (USA) Cohort study of
209 children
Maternal whole blood folate at a
mean of 16 weeks of gestation
(range: 11–21 weeks)
SRS scores at 4–5 years Folate concentrations associated
with slightly higher SRS scores
(0·6/SD, 95% CI 0·3, 1·5) and
SRS scores≥ 60 (OR 1·42;
95% CI 0·81, 2·49)
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women of normal weight were more likely to use supplements
with FA, compared with women who were overweight or
obese(46). However, this difference was not statistically signiﬁcant.
In a study of the Kaiser Permanente Medical Care Program in
Northern California, alcohol users were less likely to take multi-
vitamins than non-alcohol users during pregnancy(47). Data from
the National Maternal and Infant Health Survey indicate that
regular multivitamin users before and after pregnancy were more
likely to be older, white, married, have a wanted pregnancy, less
likely to consume six or more drinks per week during pregnancy
and have greater levels of education and income than mothers
not using multivitamins regularly(48). In another study maternal FA
use in the peri-conceptional period was associated with increased
socio-economic status(49). These factors can be difﬁcult to com-
pletely adjust for in observational studies(44).
Exposure assessment in the Norwegian study was of FA as a
single nutrient formulation. Although this study had information
on multivitamin usage available, it did not explicitly account for
this in analyses, indicating that FA content of multivitamins was
<400 μg (the amount in single nutrient formulations) in Norway
at the time of the study. The exclusion of multivitamin usage from
statistical analyses leaves the possibility of confounding by other
dietary factors, as FA and multivitamin use may be positively
correlated. For example, increased maternal intake of iron(50)
or n-3 fatty acids(51) has been associated with a reduced risk of
ASD. In a recent study, FA use in the peri-conceptional period
was associated with a higher intake of other B vitamins(49).
However, the Norwegian study found that ﬁsh oil supple-
mentation was not similarly associated with a reduced risk of
ASD, suggesting that maternal healthy behaviours, such as mul-
tivitamin use, were not responsible for the observed protective
effect observed for FA(6).
The American case–control study considered both supple-
mentary FA and dietary folate from select high concentration
sources, but not total dietary folate intake. This study did
examine potential confounding by other nutrients and found
that adjustment for total amounts of other nutrients from dietary
and supplementary sources actually strengthened the reduction
in risk between FA and ASD in the 1st month of pregnancy(5).
It is important to emphasise the exposure windows assessed by
these two studies. The protective association reported by the
prospective Norwegian study was of FA use in the month before
conception and in the ﬁrst 2 months of pregnancy. This study also
examined FA use at 22 weeks of gestation and found no asso-
ciation. Meanwhile, the American case–control study assessed
exposure in the 1 month of pregnancy only. It is difﬁcult to
ascertain how the use of different exposure windows inﬂuenced
study results because of their other methodological differences.
However, despite their limitations, the studies’ similar OR were
strong and robust to confounder control and sensitivity analyses.
Observational studies of self-reported maternal folate and
autism spectrum disorder traits
In contrast to the limited evidence concerning maternal folate
status and ASD diagnoses, four prospective cohort studies have
linked self-reported maternal folate with traits related to autism,
such as social competence and verbal abilities, but not to
Table 1 Continued
Reference (country)
Study design and
number of children Exposure assessment Outcome Results
Steenweg-de
Graaff et al.(36)
(The Netherlands)
Cohort study of
3893 children
Maternal plasma folate at a
median of 13·2 weeks of
gestation (90% range:
10·5–17·2 weeks)
Autistic traits at 6 years – SRS
short form, Pervasive
Developmental Problems
subscale of the Child Behavior
Checklist
Folate concentrations not
associated with SRS scores
(–0·004 pts/1 SD increase;
95% CI –0·013, 0·004) or
odds of probable ASD
(OR 1·03; 95% CI 0·76, 1·39)
Veena et al.(40)
(India)
Cohort study of
536 children
Maternal plasma folate at a mean
of 30 (SD 2) weeks of gestation
Language production at 9–10
years – A Developmental
Neuropsychological
Assessment
Folate concentrations not
associated with language
production scores
Randomised trials of FA supplementation and ASD-related traits
Christian et al.(41)
(Nepal)
Cohort follow-up of
676 children
Assignment of daily supplement
use at a mean of 11 weeks
(SD 5·1) of gestation:
FA+ iron + vitamin A,
FA+ iron + zinc + vitamin A,
FA+ iron + zinc + vitamin
A+multiple micronutrients,
control of vitamin A only
Executive functioning at 7–9
years: Stroop numbers test,
backward digit span from the
Wechsler memory scale,
go/no-go test
Executive function scores
improved in the FA+ iron group
relative to controls for Stroop
test (failure proportion –0·14,
95% CI –0·23, –0·04) and
backward digit span (0·36,
95% CI 0·01, 0·71), but
not for go/no-go test
Dobo & Czeizel(42)
(Hungary)
Cohort follow-up of
625 children
Assignment of multivitamin with
FA or placebo-like trace
element at least 1 month before
conception through 2 months of
gestation
Speaking, communication and
sociability at 2 years –
Developmental Quotient
Speech and sociability at
6 years – Goodenough man
drawing test
No differences in developmental
scores in children of mothers
assigned to take a multivitamin
with FA compared with trace
element controls
AD, autistic disorder; PDD-NOS, pervasive developmental disorder not otherwise specified; FA, folic acid; TD, typically developing; DD, developmental delay.
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executive function. However, results are not wholly in
agreement.
These cohort studies differ in their selection of FA exposure
windows. Three studies assessed whether FA use had com-
menced before pregnancy (4 weeks before conception(37),
3 months before becoming aware of pregnancy(39) or pre-
conception(36)), whereas the remaining study limited assess-
ment of the exposure window to after pregnancy had been
established – at the end of the ﬁrst trimester(38).
Studies assessing FA use before pregnancy reported a
reduced risk of severe language delay at 3 years(37), lower
autistic trait scores (less autistic traits) at 6 years(36), but also
unfavourable development of the personal-social domain at 3
years of age(39). The research investigating FA use only during
pregnancy reported improved verbal and social competence,
but not executive functioning scores at 4 years(38). Measures
used to assess these outcomes are provided in Table 1.
A concern of many of the studies examining folate and ASD is
that self-report of folate may be a poor surrogate for biological
folate status. To that end, in the Generation R Study, although
FA users had higher plasma folate concentrations at a median of
13 weeks of gestation(36), associations between maternal
plasma folate and ASD traits did not persist as they had for self-
report of FA supplementation. These discordant results could
be related to the timing of biological sampling, given that the
most crucial period for dietary methyl donor availability is likely
in the peri-conceptional period. Therefore, if folate were indeed
protective against ASD, peri-conceptional folate levels would be
more relevant to measure. This also may indicate that residual
confounding may be partly responsible for the observed pro-
tective effect, in that health-related behaviours are more com-
mon among women who take supplements.
In particular, one health-related behaviour that could con-
found observed protective effects of FA on developmental
outcomes is dietary intake of nutrients other than FA(49). This is
a possibility in the study in which improvements in verbal and
social competence scores were noted for children of mothers
using multivitamins both with (n 244) and without FA (n 28)(52).
A second study reported signiﬁcant associations between mul-
tivitamin and/or mineral use and reduced risk on the personal-
social and language scales, but suggested a relationship
between maternal FA use and unfavourable development on
the personal-social scale(39). This may indicate that a compo-
nent of multivitamins other than FA may be responsible for the
observed protective association. Alternatively, as 83 % of indi-
viduals in this latter study reported multivitamin and/or mineral
use and only 3·2 % of the total sample in the study reported
FA use, this is perhaps suggestive of confounding by indication
among the small sample of FA users. Conversely, the
Norwegian study(37) that examined severe language delay
reported results both for mothers taking FA only and those
taking it in combination with other supplements, and reported
similar OR (FA only: OR 0·55; 95 % CI 0·35, 0·86; FA with other
supplements: OR 0·55; 95 % CI 0·39, 0·78). A fourth study did
not consider the use of other vitamins in their analyses(36).
Results from these studies were inconsistent, but overall
tended to support a protective effect. Self-report of FA sup-
plementation in early pregnancy, either alone or in combination
with other vitamins, was associated with reduced risk of ASD-
related traits in three of the four studies, whereas a harmful
association was noted in one of the studies. However, because
of potential confounding by other nutrients, two of the three
studies reporting protective associations cannot speciﬁcally
ascribe this protection to FA. In addition, if health-related
behaviours are incompletely controlled in these studies,
observed associations may be biased because of residual
confounding.
Observational studies of maternal folate biomarker and
autism spectrum disorder traits
Three epidemiological studies of biologically ascertained
maternal FA status and ASD traits were identiﬁed, one of
which(36,52,53) was discussed in the preceding section. This
study reported no association between maternal serum folate
concentrations at a median of 13 weeks of gestation and child
autistic traits(36). Another study of 209 children reported a weak
positive association between maternal whole blood folate
concentrations at a mean of 16 weeks of gestation and Social
Responsiveness Scale scores at 4–5 years(35). Within the domain
of language production, an Indian study of 536 births reported
that signiﬁcant associations with maternal serum folate at
30± 2 weeks of gestation did not persist after adjustment(40).
One advantage of these studies is that use of a biomarker for
folate status mitigates the measurement error associated with
subjective, self-reported measures. However, as previously
described, assessment at different time periods may affect ﬁnd-
ings. As folate concentrations might be expected to be most
similar within short time intervals, folate biomarkers measured
later in pregnancy might be less correlated with peri-conceptional
values than those measured earlier in pregnancy. Studies of FA
usage patterns during pregnancy indicate that FA use is typically
commenced within the ﬁrst trimester(54–56). It is thus not likely that
maternal folate even at 13 weeks of gestation, the earliest of
biomarker measurement of these three studies, is highly corre-
lated with concentrations during the peri-conceptional period.
Results of these studies may therefore not be as meaningful as
those measuring maternal folate by the time of neural tube clo-
sure at 6 weeks of gestation(6,55) or by development of basic brain
structures at 5–10 weeks of gestation(57).
In summary, the studies utilising biomarker measures of
folate status do not consistently support an overall effect. A
weak association was reported in the cohort assessing folate at
16 weeks of gestation, but reduced risks of ASD-related traits
were not shown in the cohorts assessing maternal folate bio-
markers at 13 and 30 weeks of gestation. However, given the
timing of maternal folate biomarker measurement, these
ﬁndings should be interpreted with caution.
Folate supplementation and autism spectrum disorder
characteristics: randomised trials
Only two randomised trials have examined relationships
between maternal FA supplementation and ASD traits. A Nepali
study of 676 mother–child pairs reported higher executive
functioning scores among 7- to 9-year-old children of women
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assigned to take daily iron/FA at a mean of 11 weeks of
gestation, as compared with a control group assigned to take
daily vitamin A supplements(41). Similar ﬁndings were not
reported among children of women assigned to take iron/
FA/zinc or iron/FA/zinc and micronutrients. Conversely,
a Hungarian study of 625 mother–child pairs reported no
meaningful differences in developmental scores assessing
speech, communication and sociability at 2 and 6 years
between children of mothers assigned to take multivitamins
containing FA at least 1 month before conception through
2 months gestation, compared with children of mothers taking
trace elements only(42).
Although both studies were randomised, were of similar size
and had a high rate of follow-up, the potential effect of FA could
not be isolated in either study, as FA was taken with other
vitamins. The multivitamin supplement in the Hungarian
study(42) contained zinc, which may have an inhibitory role,
as evidenced by the Nepali(41) study and as described in the
literature(58,59). As the Hungarian study most likely examined
the most critical exposure window, results produced by this
study may have been more meaningful had this study examined
FA use independent of other vitamins.
Trends in maternal folate status
Although maternal folate status may be a biologically plausible
risk factor for ASD, the collective evidence is not conclusive.
Similar to ASD prevalence, maternal folate status has undergone
a large change in recent decades, especially for countries that
have adopted fortiﬁcation. In the USA, the recommendation of
400 μg of daily supplemental FA for women of childbearing age
was put forth by the Centers for Disease Control and Prevention
(CDC) in 1992(60) and cereal fortiﬁcation with folate began in
1996(61). These actions resulted in an elevation in median serum
folate from 12·6 μg/l in 1994 to 18·7 μg/l in 1998(61). However,
one possible misconception is that if maternal folate status was
indeed causal for ASD, then the introduction of FA fortiﬁcation in
the 1990s should have resulted in a decline in ASD prevalence.
Given the apparent rise in ASD prevalence in the USA over the
past two decades, this would appear to contradict the possible
role of maternal folate status.
Such ecologic thinking can be misleading, as it is more likely
that changes in diagnostic practices, increased awareness and
secular trends in other modiﬁable risk factors (e.g. advanced
parental age) would offset any potentially beneﬁcial effects of
higher folate. In a California study(62), approximately 26 % of the
increase in autism between 1992 and 2005 could be directly
attributed to changes in diagnostic criteria. In particular, a sepa-
rate study noted that higher autism prevalence was signiﬁcantly
associated with corresponding declines in the prevalence of
mental retardation and learning disabilities between 1994 and
2003(63). Within the California sample, it was estimated that 16 %
of the increase in autism prevalence over time was because of
social inﬂuence and increased awareness(64) and that 11% was
attributable to the increase in parental age over time(65,66). Thus,
much of the increase in autism diagnoses within this California
sample could be explained by changes in diagnostic practices,
increased awareness and advanced parental age.
It has been suggested that the coincident timing of FA for-
tiﬁcation with the beginning of the increase in measured autism
prevalence(67) is not random, but rather the reﬂection of altered
natural selection. The natural selection theory is that increased
maternal folate status arising from these FA policy changes
increased survival rates of infants with the MTHFR C677T poly-
morphism, who in the absence of increased FA in uteromay have
been miscarried. For example, there has been an increase in the
frequency of the C677T allele and its homozygous genotype in
individuals born in the last quarter of the twentieth century, as
compared with the ﬁrst three quarters(68), with a greater fre-
quency of this polymorphism in autistic individuals(69,70). Whether
this hypothesis carries weight remains to be examined.
Recommendations for future research
In this review, we examined the evidence that maternal folate
status, especially early in pregnancy, might be involved in the
development of ASD. The evidence to date is inconclusive, and
highlights future research needs.
More complete assessment of maternal functional folate
status
As folate intake is not the single determinant of functional folate
status, studies with more complete assessment of this measure
would allow for improved exposure assessment and clearer
understanding of this aetiology.
With regard to folate measures, much of the epidemiological
data on this topic use self-reported dichotomous data on mul-
tivitamin/FA intake as a surrogate for prenatal folate exposure.
In contrast to self-reported measures, biological measures of
folate status are not subjective, and therefore they are not
subject to recall bias, as self-report may be. The use of serum or
plasma folate as an indicator of folate status enables the
exploration of potential dose–response effects, which is critical
in establishing causality. Furthermore, given that one folate
biomarker measurement is not necessarily indicative of a
mother’s folate status throughout pregnancy, serum folate
measured at multiple time points before conception and
throughout the ﬁrst trimester would provide a more complete
view of maternal folate status during this critical period of
development. Repeated folate measurements may also help
elucidate a critical window for adequate methyl donor avail-
ability, revealing potential mechanisms of ASD development.
It is important to note that only one of the studies reviewed in
this paper measured maternal vitamin B12
(40), and none of the
studies measured plasma homocysteine status in their analyses.
Vitamin B12 and homocysteine are important components in the
functional pathways connecting dietary methyl donors to neuro-
development. Deﬁciency of vitamin B12 results in functional
deﬁciency of folate, as the reaction cannot proceed in the absence
of vitamin B12. For example, peri-conceptional vitamin B12 deﬁ-
ciency is linked with abnormal brain development in children(71).
Homocysteine is a more complete indicator of methyl donor
status and functionality, as folate is only one of three major
dietary methyl donors. Dietary methyl donors are not func-
tionally independent of one another, but rather changes in
Maternal folate status and autism: a review 7
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concentration of one donor result in compensatory changes in
the others. Thus, the folate-ASD hypothesis may be further
substantiated if links between other agents in the folate meta-
bolic pathway are reported. Future studies should incorporate
vitamin B12 and total homocysteine concentration measure-
ments into their exposure assessments in the peri-conceptional
period and in early pregnancy to account for the complex
interdependency between these dietary factors.
Incorporating genetic data
To assess vulnerability to low maternal folate, to examine
interactions between dietary and genetic factors and to under-
stand the potential capability of maternal folate intake to offset
genetic risk factors, further study is needed in which important
genetic factors are sequenced. Most of the previously reviewed
studies found in the literature did not explore associations
between both dietary folate and genetic risk factors. A notable
exception was the case–control study of FA intake and ASD(5).
It is conceivable that if any of the enzymes on the pathway
between folate and 5-MTHF acquire functional mutations, it may
impair the ability of folate and/or FA to be converted to 5-MTHF
and act as an efﬁcient methyl donor. For example, polymorph-
isms in the MTHFR gene, which metabolises folate into a form
capable of methyl donation, can reduce enzymatic activity,
attenuating the ability of folate to function effectively. Other key
enzymes on this pathway include dihydrofolate reductase, which
converts synthetic FA and dihydrofolate into trihydrofolate
(THF)(72), and serine hydroxymethyltransferase, which converts
THF into 5,10-MTHF with vitamin B6 as a co-enzyme
(73).
Functional mutations in enzymes related to the other two dietary
methyl donors, choline and betaine, could also affect the action
of folate because of compensatory changes that may occur
through their interrelated metabolic pathways. Last, mutations in
the MeCP2 gene can prevent the MeCP2 protein product from
binding to and interpreting DNA methylation marks, resulting in
functional hypomethylation by allowing downstream genes to
inappropriately escape repression. Such mutations would also be
worthwhile to assess in study cohorts.
Conclusion
Animal and human data indicate that maternal folate status
could be a biologically plausible risk factor for ASD. Insufﬁcient
folate intake can result in DNA hypomethylation, and hypo-
methylation is associated with neurodevelopment. However,
the weight of evidence regarding the role of maternal folate
status and the development of ASD is far from unequivocal.
Given their limitations in study design, especially with regard to
timing of exposure and potential confounding by other vita-
mins, the randomised trials and studies of maternal folate bio-
markers provide little insight into the potential role of FA as a
protective factor against ASD traits.
Studies of self-reported maternal FA use and ASD and related
traits are inconsistent, providing limited evidence of a protective
effect. Nevertheless, methodological limitations exist, including
potential confounding by other nutrients and residual confound-
ing by health-related behaviours, and thus these results should be
interpreted with caution. However, the two epidemiological stu-
dies of FA intake and ASD diagnoses incorporated various sensi-
tivity analyses or controlled for multivitamin use, thereby
suggesting reduced susceptibility to confounding.
In light of an apparent rising prevalence along with the pro-
found individual, familial and societal burden of ASD, there is an
urgent need to ﬁll in the gaps in what is currently known of
the relationship between folate and ASD. To investigate this
aetiology most effectively and efﬁciently, large historical archives
of existing prospective, population-based cohorts should be
utilised. Complete assessment of maternal functional folate status
requires repeated biological measurement of folate, vitamin B12
and homocysteine through the ﬁrst trimester of pregnancy, as
well as folate-relevant genetic variants involved in one-carbon
metabolism and epigenetic mechanisms. Information on dietary
and supplemental intake ideally would be available to relate
measures of folate status in a large population, and aid in inter-
pretation of existing studies utilising measures of self-report.
Children’s ASD diagnoses should be assessed from a clinical
source, with high levels of case ascertainment.
As ASD is complex, heterogeneous and multi-causal, exploring
environmental inﬂuences in conjunction with functionally rele-
vant genes may help identify an additional subset of causes for
which genetic contributions may be indirect. If one-carbon
metabolism is involved in the aetiology of ASD, this provides a
potential route for prevention through nutritional intervention
in the pre- and peri-conceptional periods, especially for the
subgroup of children having speciﬁc genetic risk factors for ASD.
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ABSTRACT 
Objectives: We evaluated whether nutrient supplementation during pregnancy is associated with 
reduced risk of autism spectrum disorder (ASD) and intellectual disability (ID). 
Design: The Stockholm Youth Cohort is a population-based prospective cohort of individuals 
living in Stockholm County, Sweden.  We identified a population-based sample of 273,107 
mother-child pairs through population registers.  Our study sample was restricted to children who 
were 4 to 15 years of age by December 31, 2011 and were born 1996-2007.  Using multivariable 
logistic regression, sibling controls, and propensity score matching, we estimated adjusted odds 
ratios (ORs) and 95% confidence intervals (CI) between folic acid, iron, and multivitamin 
supplement use reported at the first antenatal visit and child ASD and ID from register data 
through 2011. 
Results: Prevalences of child ASD with ID in the maternal multivitamin use group and the group 
with no use of folic acid/iron/multivitamins were 158 cases/61,934 (0.26%) and 430 cases/90,480 
(0.48%), respectively.  Maternal multivitamin use was associated with lower odds of ASD with 
ID in the child relative to mothers who did not use folic acid, iron, or multivitamins in regression 
(OR: 0.69 [95% CI: 0.57 to 0.84], sibling control (0.77 [0.52 to 1.15]) and propensity score 
matched (0.68 [0.54 to 0.86]) analyses.  Findings were not specific to ASD, as similar estimates 
were found for ID only.  There was no consistent evidence that either iron or folic acid use were 
associated with lower risk of ASD.    
Conclusions: Maternal multivitamin supplementation appeared to be associated with a reduced 
risk of intellectual disability with and without ASD using three different analytic methods with 
different assumptions.  Although making causal inference using observational data is difficult, 
our findings suggest that further scrutiny of maternal nutrition and its role in the etiology of 
intellectual disability is warranted.
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INTRODUCTION 
With the heritability of autism spectrum disorders (ASD) estimated to be between 50 and 
80%,[1, 2] non-heritable risk factors contribute to a substantial proportion of ASD risk.  Research 
suggests that ASD likely develops prenatally.[3-5]  Maternal nutrition influences 
neurodevelopment[6-8] and could influence the risk of ASD.[9]  However, results from 
population-based studies have been inconsistent.  An American case-control study (CHARGE - 
CHildhood Autism Risks from Genetics and Environment)[10] and a Norwegian cohort study[11] 
reported reduced risk of ASD with maternal folic acid supplementation and intake in the peri-
conceptional period and early pregnancy.  Meanwhile, a Danish cohort study reported no 
associations between early folic acid or multivitamin supplementation and ASD risk.[12]  
Maternal iron intake[13] and prenatal vitamin use[14] were both associated with reduced ASD 
risk in CHARGE, while no association between ordinary multivitamin use and ASD was 
reported.[14]  To date, all published studies of maternal folate biomarkers and child ASD or 
autistic traits have found null relationships.[15, 16]  Clarifying the potential role of nutritional 
supplements is a delicate endeavor, given the potential for ASD etiology to differ by presence of 
intellectual disability (ID),[17-19] although this has not been well-studied in the context of 
nutritional supplementation. 
 The body of evidence does not seem to support a protective association between maternal 
multivitamins[20-24], folic acid and/or dietary folate intake[20, 25-27], or supplementary and/or 
dietary iron intake[20-22, 25, 28] and child cognition.  Most biomarker folate studies also have 
not found associations between maternal plasma or blood folate and cognitive function.[26, 29-
32] 
Another critical aspect in considering this association is that it may be confounded by 
maternal characteristics.[9, 33]  Namely, persons who have a given dietary pattern are likely to be 
different from persons who do not have that dietary pattern; potential differences may include 
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socioeconomic characteristics, disease status, healthy behaviors, or pregnancy characteristics.[9, 
33]  If these differences are not properly accounted for, then results may be due to confounding.  
In the present study, three analytic strategies were employed to elucidate potential 
associations between maternal nutrient supplementation with iron, folic acid, and multivitamins 
and risk of offspring ASD and ID.  These included multivariable regression with adjustment for a 
large number of covariates, sibling controls to account for familial environmental and genetic 
confounding, and propensity score matching to ensure balanced comparisons between exposed 
and unexposed individuals.  The authors’ a priori approach was to use the different strengths of 
the three analytic approaches to triangulate on a conclusion.  The multivariable regression 
analysis in the whole sample provides the most generalizable and interpretable estimates, but is 
the most susceptible to limitations such as confounding from observed and unobserved 
characteristics.  The propensity score matched analyses are intended to help determine whether 
confounding from observed characteristics or data from highly dissimilar individuals unduly 
influences results, but are not necessarily generalizable.  The sibling-matched analyses serve as a 
barometer as to whether estimates are confounded by unobserved shared familial confounders but 
suffer from low statistical power.  Thus, no one method is necessarily sufficient to gauge 
causality of any observed association.  Converging results from all three methods, however, 
strengthens causal inference.  
 
METHODS 
Study sample 
Data were drawn from the Stockholm Youth Cohort, a total population register-based 
cohort of children living in Stockholm County, Sweden, for at least four years in 2001 through 
2011.[34]  The study sample was, for the purpose of availability of exposure data, restricted to 
children who were born in Sweden in 1996-2007, and who were thus aged 4 to 15 years at the end 
of follow-up in December 2011.  Children who were not in the Medical Birth Register (MBR) (n 
43 
= 17,029), not linked to birth mother (n = 41), adopted (n = 193), or who had missing data on 
family disposable income (n = 298) or maternal age (n = 5) were excluded (Figure 2).  Children 
may not be recorded in the MBR if birth records are not sent from the delivery hospital to the 
register.[35]  Although an earlier report about the quality of the MBR[35] cited that 1-2% of 
children born in Sweden are not recorded in the register, the report acknowledged that this rate 
has increased in recent years.   
Multivariable regression analyses were based on the whole cohort, propensity score 
analyses were based on a subset of matched groups, and sibling analyses were based on the whole 
cohort with single children removed (Figure 2 and Table 4).  Siblings were restricted to members 
of the study sample born within the study period, and were defined as having the same birth 
mother. 
Ethical approval was given by the Regional Ethical Review Board in Stockholm, 
Sweden. 
 
Patient involvement 
 No patients were involved in setting the research question or the outcome measures, nor 
were they involved in developing plans for design or implementation of the study.  No patients 
were asked to advise on interpretation or writing up of results.  There are no plans to disseminate 
the results of the research to study participants or the relevant patient community. 
 
Case ascertainment 
ASD data were drawn from computerized registers covering all pathways of ASD 
diagnosis and care in Stockholm County.  Case ascertainment is described in detail 
elsewhere.[34]  Pediatric healthcare and habilitation services are available free of charge in 
Sweden.  Developmental screening occurs at regular intervals, whereby children with suspected 
autism are referred for structured diagnostic assessments by specialists.[36]  ASD is recorded via 
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ICD-10 (F84), and DSM-IV (299) codes in registers covering child and adolescent mental health, 
habilitation, and pediatric in-patient and outpatient services.   
Intellectual disability was ascertained through the Clinical Database for Child and 
Adolescent Psychiatry in Stockholm using DSM-IV (317-319) classification and supplemented 
with Habilitation Register data, which categorizes autism by intellectual disability.[18, 37]  For 
any ASD, medical records review indicated that 96.0% of recorded cases were consistent with 
diagnostic criteria.[37]  When assessing the validity of ASD case status by co-occurring ID, ASD 
with ID was confirmed in 68 of 90 (75.6%); 17 of the 22 non-confirmed ASD with ID cases had 
ASD but no documentation of ID.[34] 
 
Maternal supplement use 
Recommendations regarding supplement use for pregnant women during the study period 
are discussed in Methods Supplement 1.  Briefly, pregnant women are advised to take 400 ug/d 
folic acid during the first trimester[38].  Through 2008, 100 mg/d iron was recommended for 
pregnant women during weeks 20-24, but is currently only recommended for pregnant women 
who are anemic (in a 200 mg/d dosage)[39].  There were no guidelines for multivitamin use 
during the study period.  Self-reported supplement and drug use was assessed at first antenatal 
visit.  Gestational week at first antenatal visit was recorded in the MBR from mid-1995 onwards 
(median: 10.7 weeks; interquartile range: 9.0 -12.7 weeks).[35]  Most women attended scheduled 
antenatal care visits, as they are free of charge in Sweden.[40]  Using a standardized form, the 
woman was interviewed by a midwife at the first visit and asked if she had used any drug at any 
point during pregnancy.  Drug information was recorded by the midwife and later transcribed into 
the MBR as Anatomical Therapeutic Chemical (ATC) classification codes (Table A1) or free 
text. 
Exposure variables were individually created based on ATC code and free text matches 
(Methods Supplement 1), and combined in the creation of five non-overlapping exposure groups: 
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multivitamins; folic acid; iron; folic acid and iron; no use of multivitamins, folic acid, or iron.  
For all analyses, this latter group served as the reference category against which other supplement 
use groups were compared.  The multivitamins category included individuals who noted use of 
any multivitamin (MV), regardless of any combined use with additional iron and/or FA.  
Multivitamin formulations in Sweden commonly include multiminerals; these combinations were 
included in the “multivitamins” category.  Multiminerals such as calcium/magnesium 
supplements without evidence of inclusion of folic acid or iron in the formulation were classified 
as “none”.  Since MBR data do not reliably discern between multi- and prenatal vitamins, they 
were combined and are referred to as multivitamins.  Register data also do not contain 
information regarding dosage, timing of initiation, frequency, or duration.  Midwife interview of 
self-reported maternal folic acid use has been reported to correspond well with plasma folate 
levels among Swedish women,[41] so it is not unreasonable that other supplements may 
correspond similarly.   
 
Covariates 
 National identification numbers enabled record linkage between national registers held by 
Statistics Sweden and the National Board of Health and Welfare.  Registers utilized include the 
MBR for child and pregnancy characteristics,[35, 42] the Integrated Database for Labour Market 
Research for socioeconomic factors,[17] and national and regional health registers for inpatient, 
outpatient, prescription drug, and psychiatric data.[34]  All covariates were chosen a priori based 
on published relationships with ASD[43] and/or the use of supplements.   
Child factors were sex, birth year (unordered single year categories), and years resided in 
Stockholm County (continuous) to account for length of follow-up.  Sociodemographic data 
included maternal country of birth  (Sweden, Other Europe, Outside Europe), maternal 
education[44] (pre-secondary, secondary, post-secondary, missing), and disposable family 
income (quintiles).  Family income was calculated after tax deductions, was adjusted for family 
46 
size, and based on birth year to account for inflation. 
Maternal covariates included age in years (< 25, 25 - < 30, 30 - < 35, 35+), parity (1, 2, 
3+), smoking at first antenatal visit (yes, no, missing), and body mass index (BMI) at first 
antenatal visit in kg/m2 (underweight: < 18.5, normal: 18.5 - < 25, overweight: 25 - < 30, obese: 
≥30, and missing). 
Lifetime history of maternal neurologic or psychiatric conditions before the child’s birth 
(anxiety disorders, ASD, bipolar disorder, depression, intellectual disability, non-affective 
psychoses, stress-related disorders, and epilepsy - yes/no for each (Table A2) were ascertained 
from the National Patient Register (NPR) and the Stockholm County Adult Outpatient Psychiatric 
Register.  Both registers have high validity.[45] 
Medication use (antiepileptics and antidepressants - yes/no for each) was ascertained via 
the MBR (self-report at first antenatal visit by interview, available for the entire study period) and 
the Prescription Drug Register (records of prescribed dispensed drugs, available for births 2006-
2007).  Some validation work has been conducted examining the concordance of maternal drug 
use during pregnancy in the Prescription Drug Register and the MBR.  For example, 69% of 
mothers with antiepileptic use recorded in the Prescription Drug Register also had corresponding 
information in the MBR.[46] 
 
Primary analyses 
Regression analyses used generalized estimating equation (GEE) models with logit link, 
clustered by mother, to calculate odds ratios (ORs) with 95% confidence intervals (CI) between 
supplement intake and each outcome (any ASD, ASD with ID, and ASD without ID).  An 
exchangeable correlation matrix was assumed.  
After removal of covariates imparting < 5% change to the estimates for the autism with 
ID multivariate regression GEE analysis, only maternal birth country and birth year remained 
(Table A3).  Removing these covariates only minimally increases precision, reducing confidence 
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interval width only by 0.01 – 0.02.  Minimally adjusted models were therefore adjusted for birth 
year and maternal birth country and fully adjusted models included all covariates described 
above. 
Sibling-matched analyses were performed using conditional logistic models matched on 
mother and adjusted for sex, parity, and birth year.  Propensity score analyses were conducted 
separately for each exposure and were compared against non-users of folic acid, iron and 
multivitamins.  Propensity scores were estimated using logistic regression including all covariates 
with observed or hypothesized associations with supplementation and/or ASD described above.  
Odds ratios were calculated for matched samples using GEE models with logit link, clustered by 
mother.  Details of propensity score matching are described in the Methods Supplement 1.  
Analyses were conducted using SAS software, version 9.3 (SAS Institute Inc., Cary, North 
Carolina) and R. 
 
Sensitivity analyses 
Maternal hospitalizations: We hypothesized that underlying, possibly unobserved health 
factors might influence an apparent increase in risk associated with use of only folic acid.  To 
investigate, a post-hoc sensitivity analysis was conducted, stratifying by number of maternal 
hospitalizations during pregnancy excluding the delivery (0 vs. 1 or more, in a ~45:55 split).  
Although other health factors were considered as stratification factors (e.g., maternal epilepsy), 
these analyses were not possible due to the small number of folic acid users with children with 
ASD with (n = 15) or without ID (n = 63). 
Unmeasured confounding: The method of Lin et al[47] was used to examine robustness 
of an observed association to unmeasured confounding.  The goal of this analysis was to assess 
whether an observed association between multivitamin use and risk of ASD with ID was likely to 
be qualitatively changed under reasonable assumptions about unmeasured confounding.  A 
hypothetical binary confounder that reduced the risk of ASD was assumed to be more prevalent 
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among multivitamin users than in non-users across a range of plausible parameters.  Because the 
association from the propensity score analysis is theoretically the most robust to measured 
confounding, this association was the basis of this test of unmeasured confounding. 
Intellectual disability: As a means to evaluate specificity of multivitamin findings for 
ASD with ID, additional post-hoc sensitivity analyses examined ID only as an outcome.  
Individuals with known congenital or metabolic causes of intellectual disability were excluded 
from these analyses. 
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RESULTS 
Study sample 
The study sample consisted of 273,107 mother-child pairs, categorized into groups: 
multivitamins (n = 62,840, 23.0%), iron only (n = 90,138, 33.0%), iron + folic acid (n = 25,445, 
9.3%), folic acid only (n = 2789, 1.0%), and none of the above (n = 91,895, 33.7%) (Table 2).  
The multivitamin group included MV only (n = 17,539, 6.4%), MV + Iron (n = 37,046, 13.6%), 
MV + folic acid (FA) (n = 1602, 0.6%), and MV + Iron + FA (n = 6653, 2.4%). 
Event rates (ASD, ASD with ID, ASD without ID) were as follows for the groups: 
multivitamin (1.7%, 0.3%, 1.4%), iron (2.1%, 0.5%, 1.6%), iron + folic acid (2.0%, 0.5%, 1.5%), 
folic acid (2.8%, 0.5%, 2.3%), and none (2.2%, 0.5%, 1.8%). 
In the cohort, supplement user groups differed from one another across multiple health 
and socioeconomic characteristics (Table 2).  Multivitamin users tended to be older, primiparous, 
more educated, higher-income, less likely to smoke, and more likely to be born in Sweden than 
non-users.  Folic acid users were similar to multivitamin users but were more likely to be 
immigrants than non-users and have epilepsy or taking antiepileptics.  Conversely, mothers taking 
iron only or in combination with folic acid tended to be younger, multiparous, less educated, 
lower-income, and more likely to be immigrants and smokers than non-users.  Depression and 
antidepressant use were more prevalent among all categories of supplement users vs. non-users. 
 
Primary analyses 
Multivitamin use: Regression analysis indicated that multivitamin use was associated 
with lower likelihood of ASD with ID relative to non-use of folic acid, iron, or multivitamins in 
all analyses (multivariate regression OR and 95% CI: 0.69 [0.57 to 0.84]).  Point estimates from 
the sibling control (0.77 [0.52 to 1.15]), and propensity score analyses (0.68 [0.54 to 0.86]) were 
similar, although the sibling control estimate had a wider CI that included 1 (Table 3).  
Multivitamin use was not associated with ASD without ID in any analysis. 
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Folic acid and iron: Although imprecision due to small numbers of folic acid only users 
was evident, there was a suggestion of an elevated association between folic acid and ASD 
without ID in the regression (1.29 [0.99 to 1.67]) and sibling control (1.70 [0.94 to 3.10]) 
analyses, that was attenuated in the propensity score analysis (1.10 [0.83 to 1.48]).  Iron use was 
not associated with ASD with or without ID in any analysis. 
 
Sensitivity analyses 
  Maternal hospitalizations: Evidence of an elevated risk of child ASD with folic acid use 
was limited to mothers with at least one hospitalization during pregnancy (1.59 [1.21 to 2.10] for 
any ASD; Table 4).  No evidence of elevated risk with folic acid use was seen in mothers with 
zero hospitalizations (0.84 [0.54, 1.30] for any ASD).  Importantly, the associations of 
multivitamin use with lower risk of ASD with ID persisted in this sensitivity analysis (no 
hospitalizations: 0.64 [0.47 to 0.87], any hospitalizations: 0.75 [0.58 to 0.97]). 
Unmeasured confounding: Sensitivity analysis of the multivitamin propensity score 
finding did not provide support for the presence of unmeasured confounding (Table 5).  
Intellectual disability: After excluding children with known congenital (n = 897) or 
metabolic (n = 194) causes of intellectual disability, 1048 of 272,018 children had ID without 
ASD (0.4%).  Regression analysis indicated that multivitamin use was associated with lower 
likelihood of ID only relative to non-use of folic acid, iron, or multivitamins in all analyses 
(multivariate regression OR and 95% CI: 0.67 [0.54 to 0.81]).  Point estimates from the 
propensity score (0.73 [0.56 to 0.93]) and sibling control (0.74 [0.48 to 1.14]) analyses were 
similar, although the wider CI for the sibling analysis included 1 (Table A4). 
There was a suggestion of an elevated association between folic acid and ID only in the 
regression (1.47 [0.90 to 2.39]) and propensity score analyses (1.56 [0.90 to 2.69]) that was 
attenuated in the sibling control (1.15 [0.33 to 4.00]) analysis.  The sibling analysis showed a 
suggestion of a lower likelihood of ID only associated with iron (0.76 [0.56 to 1.02]), while 
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regression (0.98 [0.85 to 1.13]) and propensity score estimates (0.93 [0.79 to 1.09]) did not.  All 
analyses indicated that iron + folic acid was associated with lower likelihood of ID only 
(regression: 0.69 [0.54 to 0.88], sibling control: 0.51 [0.31 to 0.83], and propensity score: 0.64 
[0.50 to 0.82]).   
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DISCUSSION 
Principal findings 
The present population-based study used multivariable regression, sibling controls and 
propensity score matching to examine associations of nutritional supplementation during 
pregnancy and risk of child ASD and intellectual disability.  With their different analytic 
strengths, limitations, and sample compositions, all three analyses appeared to converge in 
suggesting that maternal multivitamin use was associated with reduced risk of ID with and 
without ASD in the child.  Given the absence of associations between multivitamins and ASD 
without ID, this seems to suggest that associations observed for ASD with ID may be related to 
ID, rather than being linked to ASD. 
There was no consistent evidence that either iron or folic acid use were associated with 
lower risk of ASD or ID.  Although there was a possible association of folic acid use with higher 
risk of ASD, this was limited to women with hospitalization during pregnancy.  Moreover, there 
was no association of the iron + folic acid group with ASD risk.  This suggests that rather than 
use of folic acid, problems associated with hospitalization that may have led to folic acid use 
were underlying this result.  There was also a possible association of folic acid use with higher 
risk of ID only, though the three analytic methods converged in suggesting a reduced risk of ID 
with folic acid + iron, which was specific to ID.  
Strengths and limitations 
The main strengths of the present study include the relatively large, population-based 
sample in which advanced analytic methods were used to provide a more solid base for inference. 
The case-finding approach covered all pathways to ASD care and services in Stockholm County 
in the context of a universal healthcare system, thus increasing the likelihood that ASD cases 
were identified.  In addition, the availability of intellectual disability diagnoses helped discern 
specificity of observed associations. 
Propensity score matching[48] and sibling control[49] analyses were used to examine 
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whether results obtained using conventional regression were likely to be influenced by either 
observed or unobserved confounding.  Such confounding is possible, given that nutritional 
supplement users were different from non-users in ways that may influence ASD and ID risk.  As 
shown in Figure A1, propensity score matching was effective in balancing covariate distributions 
between exposed and unexposed persons.  Because propensity score estimates were similar to the 
regression estimates, this suggested that neither confounding from observed covariates nor undue 
influence from non-comparable individuals affected results. 
By comparing within sibling-matched sets, sibling analyses neutralize potential shared 
observed and unobserved confounders such as maternal genetics that might predict both 
supplement use and child ASD or ID risk.  This control comes at a cost, since sibling studies have 
lower sample sizes, leading to imprecise estimates and high type II error, among other 
limitations.[50]  In the present study, point estimates for associations between multivitamins and 
ID with and without ASD were similar across regression, propensity score, and sibling analyses.  
Although the sibling estimates’ CI included 1, the point estimates were similar to the regression 
estimates, supporting the possibility that familial confounding was not driving these associations.  
Together, the three analyses appeared to triangulate to point toward associations between 
multivitamin use and ID with and without ASD. 
Calculations of the potential impact of unmeasured confounding suggest that an 
unmeasured confounder would have to be a strong protective factor, exerting an effect above and 
beyond the covariates matched in propensity score analyses, in order to nullify the potential 
associations between multivitamin use and ID with and without ASD.  Because a maternal trait 
that predicts multivitamin use (higher intelligence) may decrease risk of ID, analyses controlled 
for maternal education level, ID, and ASD.  Since healthy lifestyle is a well-known confounder in 
studies of nutritional supplement use,[33] our analyses also controlled for maternal BMI but were 
unable to assess the contribution of diet or other nutritional supplements.  However, the sibling 
control analyses, which would be expected to control for such cognitive and behavioral 
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confounders similar across pregnancies, produced point estimates consistent with the regression 
analyses. 
The observation that folic acid use was associated with higher risk of ASD with ID only 
in women with a hospitalization during pregnancy suggests confounding by causes of 
hospitalization such as chronic somatic or psychiatric conditions, acute illness, pregnancy-related 
disorders, or psychosocial distress.[51-53]  Whether this occurs through structural pathways (e.g., 
folic acid being prescribed at higher rates among women hospitalized during pregnancy) or 
through biological pathways (e.g., folate insufficiency due to a chronic condition or medication) 
remains to be seen.  Potential exposure to anti-folates through either maternal history of 
epilepsy[54] and use of an anti-epileptic medication[55] during pregnancy have both been 
associated with increased risk of child ASD and were more prevalent in the folic acid group, 
making confounding by indication possible.  
Exposure assessment was limited, since type, timing, and dose of supplements could not 
be determined.  Changes to nutritional status or supplement use after the first antenatal visit could 
not be assessed.  It is possible that the reported supplement was not taken, or a supplement was 
taken but not reported.  Prevalences of supplement use observed here are in the range of estimates 
from other studies in the Swedish population during the same time period.[56, 57]  The extent of 
misclassification is unknown; however, because supplement use was prospectively ascertained, it 
may be less likely that such misclassification could wholly explain the present findings.  
Even if causal associations could be established between multivitamins and ID with and 
without ASD, it cannot be determined from the data whether there is a critical window for 
exposure or what dosage levels are required.  For ASD with ID, it cannot be determined from the 
data what specific nutrients or combinations thereof may be responsible.  However, converging 
associations between folic acid + iron and reduced risk of intellectual disability may indicate that 
these two nutrients in combination may have etiological relevance for ID without ASD.  
External validity is also not assured, since different populations have different 
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backgrounds of supplement use, fortification, dietary patterns, and health risks.  Lastly, although 
the study featured a relatively large sample size, small cells made it difficult to obtain precise 
estimates from lower-powered analyses, particularly the sibling control analyses. 
Comparison with other studies 
The findings are in mixed alignment with the existing literature.  The three case-control 
studies reporting reduced ASD risk with prenatal vitamins,[14] folic acid,[58] and iron[13] were 
from the CHARGE study in the U.S.  Interestingly, lower mean folic acid intake in CHARGE 
was found for children with ASD with a lower cognitive function but not for ASD with higher 
functioning, suggesting that nutrients may differentially affect ASD risk depending on co-
occurrence with intellectual disability.  In the prospective Norwegian Mother and Child Cohort 
study (MoBa), maternal folic acid intake, but not other vitamins and minerals, in the peri-
conceptional period and early pregnancy, was associated with lower risk of autistic disorder.[11]  
The Danish National Birth Cohort (DNBC) study reported null associations between folic acid 
and multivitamin intake and ASD or any of its subtypes.[12]  To date, all published studies of 
maternal folate biomarkers and child ASD or autistic traits have found null relationships.[15, 16]  
However, these biomarker studies also evaluated nutrient intake and reported associations with 
reduced ASD symptoms.  The body of evidence does not seem to support a protective association 
between maternal multivitamins[20-24], folic acid and/or dietary folate intake[20, 25-27], or 
supplementary and/or dietary iron intake[20-22, 25, 28] and child cognition.  Most biomarker 
folate studies also have not found associations between maternal plasma or blood folate and 
cognitive function.[26, 29-32] 
Exposure timing could have played a role in differences among findings for iron and folic 
acid.  In the current study, supplementation was assessed at median 10.7 weeks pregnancy.  The 
observed association for folic acid intake in CHARGE was for exposure through the first month 
of pregnancy, and findings were null after the second month of pregnancy.  In MoBa, the 
protective association pertained to exposure through the first trimester, while the DNBC study 
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examined exposure through 8 weeks gestation.  Conversely, biomarker studies with positive 
findings had assessed maternal folate after the first trimester. 
Another possibility that may contribute to differences between studies is that the 
background nutritional contexts of the countries where the studies conducted differ.  For example, 
while the U.S. engages in folic acid fortification, Sweden, Norway, and Denmark do not.  Fish oil 
supplements are routinely taken in Norway by nearly 60% of pregnant women[59] but are rarely 
used in Sweden.  Similarly, serum 25-hydroxyvitamin D levels in pregnant women are lower in 
Sweden[60] than in Denmark,[61] corresponding with the difference in latitude. 
Such differences may be illustrative in explaining why a reduced risk of ASD with folic 
acid or iron was not observed.  Data suggest that nutritional intake may differ between 
cohorts.[62]  MoBa participants reported combined daily dietary and supplementary folic acid 
(615 µg) and iron (40.4 mg)[59] concentrations similar to levels associated with protection 
against ASD in the CHARGE study (600 ug folic acid,[58] 57.1 mg iron[13]).  DNBC 
participants reported 575 ug combined dietary and supplementary folic acid.[63]  In contrast, 
combined dietary folate and supplementary folic acid (430 µg) and iron intake (15.0 mg) among 
Swedish pregnant women[62] were less than in CHARGE or MoBa. Taken together, it is not 
unreasonable to conclude that effects of supplements taken in one country may differ from those 
in another country, depending on whether combined dietary and supplement levels of nutrients 
reach a threshold necessary to elicit protection. 
Conclusions and policy implications 
We observed associations between gestational multivitamin supplement use and lower 
risk of intellectual disability with and without autism.  There does not yet exist a sufficient body 
of mechanistic evidence supporting these findings.  Verification in independent epidemiologic 
investigations with improved exposure assessment, perhaps in randomized studies, is necessary 
before a level of evidence suggesting practice change could be reached.   
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Table 2. Selected characteristics of the SYC study sample born 1996-2007 by maternal supplement use 
 Multivitamin Iron Iron + Folic Acid Folic Acid None 
Characteristics 62840 (23.0) 90138 (33.0) 25445 (9.3) 2789 (1.0) 91895 (33.7) 
ASD 
   ASD + ID 
   ASD – ID 
1064 (1.7) 
158 (0.3) 
906 (1.4) 
1872 (2.1) 
422 (0.5) 
1450 (1.6) 
516 (2.0) 
138 (0.5) 
378 (1.5) 
78 (2.8) 
15 (0.5) 
63 (2.3) 
2045 (2.2) 
430 (0.5) 
1615 (1.8) 
Sex of child – male 31990 (50.9) 45933 (51.0) 12855 (50.5) 1451 (52.0) 47683 (51.9) 
Parity 
  First child 
  Second child 
  Third child and higher 
 
32488 (51.7) 
21927 (34.9) 
8425 (13.4) 
 
38780 (43.0) 
33258 (36.9) 
18100 (20.1) 
 
10628 (41.8) 
9161 (36.0) 
5656 (22.2) 
 
1335 (47.9) 
995 (35.7) 
459 (16.5) 
 
41679 (45.4) 
33509 (36.5) 
16707 (18.2) 
Maternal education  
  ≥ 12 yrs 
  Missing data 
 
34633 (55.1) 
242 (0.4) 
 
36613 (40.6) 
611 (0.7) 
 
10281 (40.4) 
258 (1.0) 
 
1365 (48.9) 
17 (0.6) 
 
43019 (46.8) 
499 (0.5) 
Maternal country of origin, Sweden 51571 (82.1) 62296 (69.1) 16399 (64.5) 2164 (77.6) 70698 (76.9) 
Highest quintile family income 27051 (43.1) 25012 (27.8) 6978 (27.4) 1078 (38.7) 33122 (36.0) 
Maternal age, mean (SD) 31.3 (4.7) 30.2 (5.2) 30.5 (5.3) 31.4 (5.0) 30.9 (5.0) 
Maternal smoking 
   Yes 
   No 
   Missing data 
 
3434 (5.5) 
57080 (90.8) 
2326 (3.7)  
 
8229 (9.1) 
78636 (87.2) 
3273 (3.6) 
 
2080 (8.2) 
22393 (88.0) 
972 (3.8) 
 
200 (7.2) 
2502 (89.7) 
87 (3.1) 
 
6523 (7.1) 
55576 (60.5) 
 29796 (32.4) 
Maternal body mass index 
   Underweight (BMI < 18.5) 
   Normal (18.5 ≤ BMI < 25)` 
   Overweight (25 ≤ BMI < 30)  
   Obese (BMI ≥30) 
   Missing data 
 
1715 (2.7) 
40593 (64.6) 
10287 (16.4) 
3207 (5.1) 
7038 (11.2) 
 
2435 (2.7) 
53299 (59.1)  
17637 (19.6)  
6131 (6.8) 
10636 (11.8)  
 
729 (2.9)  
14960 (58.8)  
5065 (19.9)  
1884 (7.4)  
2807 (11.0) 
 
49 (1.8)  
1655 (59.3)  
526 (18.9)  
205 (7.4)  
354 (12.7) 
 
1503 (1.6)  
36995 (40.3)  
12675 (13.8)  
4991 (5.4)  
35731 (38.9) 
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Table 2 (continued). Selected characteristics of the SYC study sample born 1996-2007 by maternal supplement use 
 Multivitamin Iron Iron + Folic Acid Folic Acid None 
Characteristics 62840 (23.0) 90138 (33.0) 25445 (9.3) 2789 (1.0) 91895 (33.7) 
Maternal medications 
   Antidepressant use 
   Antiepileptic use 
 
1017 (1.6) 
118 (0.2) 
 
1368 (1.5)  
119 (0.1) 
 
367 (1.4)  
215 (0.8) 
 
38 (1.4)  
65 (2.3) 
 
916 (1.0)  
125 (0.1) 
Maternal neuropsychiatric conditions 
   Anxiety disorders 
   Autism 
   Bipolar disorder 
   Depression 
   Epilepsy 
   Intellectual disability 
   Non-affective psychotic disorders 
   Stress disorders    
 
870 (1.4) 
64 (0.1) 
115 (0.2) 
2036 (3.2)  
347 (0.6)  
19 (0.0) 
140 (0.2) 
1210 (1.9) 
 
1209 (1.3) 
127 (0.1) 
159 (0.2) 
2571 (2.9) 
391 (0.4) 
68 (0.1) 
258 (0.3) 
1668 (1.9) 
 
347 (1.4) 
34 (0.1) 
56 (0.2) 
695 (2.7) 
282 (1.1) 
20 (0.1) 
83 (0.3) 
475 (1.9) 
 
35 (1.3) 
5 (0.2) 
9 (0.3) 
82 (2.9) 
69 (2.5) 
2 (0.1) 
11 (0.4) 
70 (2.5) 
 
1176 (1.3) 
120 (0.1) 
176 (0.2) 
2434 (2.7) 
470 (0.5) 
67 (0.1) 
281 (0.3) 
1648 (1.8) 
 
66 
 
 
 
 
 
Table 3. Crude and adjusted odds ratios and 95% confidence intervals for supplement use and ASD with and without intellectual disability, and 
any ASD 
Sample Sibling Sibling Propensity score Multivariate Multivariate 
Adjustment Unadjusted Adjusteda PS matched Unadjusted Adjustedb 
Model CLRc CLRc OLR and GEEd GEEe GEEe 
ASD with ID      
Folic acid 0.81 (0.28 to 2.36) 0.94 (0.29 to 3.04) 1.14 (0.64 to 2.04) 1.16 (0.69 to 1.94) 1.20 (0.71 to 2.01) 
Iron 0.84 (0.64 to 1.10) 0.90 (0.67 to 1.21) 0.96 (0.82 to 1.13) 0.99 (0.87 to 1.14) 0.95 (0.83 to 1.11) 
Folic acid and Iron 0.81 (0.54 to 1.22) 0.99 (0.63 to 1.57) 1.06 (0.86 to 1.30) 1.14 (0.93 to 1.38) 1.03 (0.84 to 1.26) 
Multivitamin 0.60 (0.42 to 0.86) 0.77 (0.52 to 1.15) 0.68 (0.54 to 0.86) 0.54 (0.45 to 0.65) 0.69 (0.57 to 0.84) 
ASD without ID      
Folic acid 1.46 (0.87 to 2.45) 1.70 (0.94 to 3.10) 1.10 (0.83 to 1.48) 1.30 (1.00 to 1.68) 1.29 (0.99 to 1.67)  
Iron 0.93 (0.81 to 1.07) 0.96 (0.81 to 1.12) 0.95 (0.88 to 1.04) 0.92 (0.85 to 0.98) 0.96 (0.89 to 1.04) 
Folic acid and Iron 0.91 (0.73 to 1.13) 1.00 (0.78 to 1.29) 0.84 (0.74 to 0.94) 0.85 (0.76 to 0.95) 0.89 (0.79 to 1.00) 
Multivitamin 0.93 (0.79 to 1.10) 1.00 (0.83 to 1.20) 0.95 (0.85 to 1.06) 0.82 (0.75 to 0.89) 0.94 (0.85 to 1.03) 
Any ASD      
Folic acid 1.30 (0.82 to 2.06) 1.48 (0.87 to 2.51) 1.17 (0.89 to 1.51) 1.27 (1.01 to 1.60) 1.27 (1.01 to 1.60) 
Iron 0.91 (0.80 to 1.03) 0.95 (0.83 to 1.09) 0.93 (0.87 to 1.01) 0.93 (0.87 to 0.99) 0.96 (0.90 to 1.03) 
Folic acid and Iron 0.89 (0.73 to 1.07) 1.01 (0.81 to 1.25) 0.89 (0.81 to 0.99) 0.91 (0.82 to 1.00) 0.92 (0.83 to 1.02) 
Multivitamin 0.86 (0.74 to 1.00) 0.95 (0.81 to 1.13) 0.86 (0.78 to 0.95) 0.76 (0.71 to 0.82) 0.89 (0.82 to 0.97) 
Analytic sample sizes are documented in Table A5, ranging from 15,575 mothers and 16,086 children (Folic acid ASD with ID propensity score analysis) to 
178,083 mothers and 273,107 children (any ASD multivariate sample analyses). 
a Adjusted for child sex, parity, and birth year 
b Adjusted for child characteristics (sex, birth year, and years resided in Stockholm County), socioeconomic indicators (education, family income, and maternal 
birth country), maternal characteristics (age, BMI, parity, smoking status), medication use during pregnancy (anti-depressants or anti-epileptics), and specific 
neuropsychiatric diagnoses before birth (anxiety disorders, autism, bipolar disorder, depression, epilepsy, intellectual disability, non-affective psychotic disorder, 
and stress disorder) 
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Table 3 (continued). Crude and adjusted odds ratios and 95% confidence intervals for supplement use and ASD with and without intellectual 
disability, and any ASD 
c Conditional logistic regression, matched on birth mother 
d Propensity scores were calculated with covariates in b as predictors of supplement use in ordinary logistic regression models (maternal age was a continuous 
covariate); in the matched sample, propensity scores were used as predictors of ASD in generalized estimating equation logistic regression models grouped by 
birth mother 
e Generalized estimating equation logistic regression, grouped by birth mother
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Table 4. Adjusted odds ratios and 95% confidence intervals for multivariate analysisa stratified 
by hospitalizations during pregnancy 
Hospitalizations Sample None 
n = 121,689 
1 or more 
n = 148,324 Model GEEb GEEb 
ASD with ID   
Folic acid 0.70 (0.25 to 2.00) 1.58 (0.86 to 2.89) 
Iron 1.05 (0.85 to 1.31) 0.87 (0.72 to 1.06) 
Folic acid and Iron 1.17 (0.87 to 1.57) 0.96 (0.73 to 1.26) 
Multivitamin 0.64 (0.47 to 0.87) 0.75 (0.58 to 0.97) 
ASD without ID   
Folic acid 0.88 (0.55 to 1.43) 1.59 (1.16 to 2.16) 
Iron 1.04 (0.92 to 1.17) 0.92 (0.83 to 1.02) 
Folic acid and Iron 0.94 (0.78 to 1.13) 0.87 (0.74 to 1.01) 
Multivitamin 1.01 (0.88 to 1.17) 0.89 (0.79 to 1.01) 
Any ASD   
Folic acid 0.84 (0.54 to 1.30) 1.59 (1.21 to 2.10) 
Iron 1.04 (0.93 to 1.16) 0.91 (0.83 to 1.00) 
Folic acid and Iron 0.99 (0.85 to 1.17) 0.89 (0.78 to 1.02) 
Multivitamin 0.94 (0.82 to 1.07) 0.87 (0.78 to 0.97) 
a Adjusted for child characteristics (sex, birth year, and years resided in 
Stockholm County), socioeconomic indicators (education, family 
income, and maternal birth country), maternal characteristics (age, BMI, 
parity, smoking status), medication use during pregnancy (anti-
depressants or anti-epileptics), and specific neuropsychiatric diagnoses 
before birth (anxiety disorders, autism, bipolar disorder, depression, 
epilepsy, intellectual disability, non-affective psychotic disorder, and 
stress disorder) 
 b Generalized estimating equation logistic regression, grouped by birth 
mother  
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Table 5. Potential impact of unmeasured confounding on the propensity score estimate for 
maternal multivitamin supplementation and risk of ASD with ID 
Prevalence of confounder Reduced risk of 
ASD with ID due 
to confoundera 
Multivitamin 
users Non-users 
Adjusted OR 
(95% CI) 
- 0% 0% 0.69 (0.57 to 0.84)b  
25% 20% 10% 0.71 (0.59 to 0.86) 
25% 40% 20% 0.73 (0.60 to 0.89) 
25% 60% 30% 0.75 (0.62 to 0.91) 
25% 80% 40% 0.78 (0.64 to 0.95) 
50% 20% 10% 0.73 (0.60 to 0.89) 
50% 40% 20% 0.78 (0.64 to 0.95) 
50% 60% 30% 0.84 (0.69 to 1.02) 
50% 80% 40% 0.92 (0.76 to 1.12) 
a Assumes that the elevated risk of ASD with ID due to the unmeasured 
confounder is the same in both multivitamin users and non-users 
b The original reported estimate in Table 2 
Sensitivity analysis of our propensity score finding did not provide support for 
the presence of unmeasured confounding.  For example, even if there were an 
unmeasured confounder that reduced the risk of ASD with ID by 50%, and had 
40% prevalence among multivitamin users and 20% prevalence in non-users, 
the corrected PS estimate would remain protective (OR: 0.78 [0.64 to 0.95]).  
The unmeasured confounder would have to exert such an effect above and 
beyond the covariates matched in propensity score analyses.   
We believe the ranges of the parameters represent a realistic range of plausible 
values.  While stronger influences, such as having an affected first-degree 
family member, are in theory plausible, shared genetic familial factors are 
controlled for in the sibling analyses, which produced a similar adjusted OR 
among matched siblings. 
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Figure 2. Derivation of Stockholm Youth Cohort study samples 
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Methods Supplement 1 
Supplement recommendations and use 
The official recommendation from the National Board of Health and Welfare since 1996 
is to take a folic acid supplement with 400 µg per day, beginning one month prior to conception 
and continuing through the end of the first trimester.[1]  Regarding iron supplementation, 
guidelines from the Swedish Society of Obstetrics and Gynecology from 1991 through the study 
period recommended initiation of iron supplementation of 100 mg per day in weeks 20-24 (this 
recommendation was removed in 2008), while women with anemia should start iron 
supplementation immediately at 200 mg daily.[2]  We were unable to find any guidelines 
regarding multivitamin supplement use in Sweden during the study period.  As the reviewer 
points out, use of multivitamins in pregnant Swedish women may vary by time and place.  A 
large study in southeast Sweden for children born 1997-1999 found that 18% of pregnant women 
take multivitamins,[3] supporting that estimates of use of multivitamins in the present study do 
not appear to be unreasonably low. 
 Actual recommendations regarding diet and nutrition vary depending on the health 
practitioner seen.  For example, a 2003 study in Sweden found that 41% of midwives who were 
responsible for individual counseling provided recommendations regarding use of iron 
supplements that were consistent with the policy.[4]  Prenatal supplements are purchased at the 
pharmacy and this purchase is subsidized by the universal health care system.  Because of 
repeated antenatal visits, it is possible that a woman’s intake might change after this point.  We 
acknowledge that timing, among other aspects of supplement use such as dose, are necessary to 
investigate in further studies. 
 While there is no tradition of using omega 3 fatty acid (e.g., cod liver oil) supplements 
in Sweden,[3] women in Sweden reported a wide variety of supplement use during pregnancy.  
For example, in a study of >15,000 women in Sweden giving birth during the timeframe of our 
study, 89% of women used some sort of supplement during pregnancy.[5]  Thus, we are careful 
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to clarify that the ‘no MV/FA/iron’ group is likely to be taking other supplements at some point 
during pregnancy. Because of the prior studies on folic acid, iron, and multivitamins and ASD, 
we restricted our study to these exposures a priori.  
 
Free text coding of nutritional supplementation 
Free text coding of supplements and other drugs was performed in R.  Manual coding 
was performed on the most common 1,002 (2.4%) of 41,020 free text responses.  Since the 1,002 
manually coded values occurred 338,555 times from a total of 414,907 free text responses, 
manual examination of these values represented 81.6% of the free text data. 
Manual coding informed an automated exact and fuzzy pattern matching process.  Exact 
matching was used to account for known generic, Swedish, and international brand names, 
abbreviations, and non-standard terms, whereas fuzzy matching was integrated to account for 
punctuation and spacing differences, and misspellings.[6]  Automated matches were reviewed, 
false positives were removed as necessary, and coding was optimized accordingly.  R code for 
pattern matching is included in Methods Supplement II. 
 
Propensity score analyses 
Propensity score (PS) matching can create a sample matched on all observed covariates, 
including maternal health indicators.  The goal of matching is to make exposed and unexposed 
groups more comparable, or balanced, on these characteristics.  PS matching aims to reduce bias 
due to confounding by comparing the outcomes of matched groups that primarily differ in their 
exposure.  As such, PS matching reduces dependence on model-based assumptions and increases 
robustness of resulting statistical models.[7] 
PS analyses were conducted separately for each exposure and were compared against 
non-users of folic acid, iron and multivitamins.  k:1 nearest neighbor greedy matching was 
implemented with a caliper of 0.05 - 0.1 standardized difference using the MatchIt package in 
74 
 
 
74 
R.[8]  Exact matching on birth year was specified for multivitamin models to improve balance.  
Unexposed to exposed matching ratios were a function of size of the exposed group, with ratios 
ranging from 1:1 to 5:1.  Balance was assessed through comparison of standardized mean 
difference of covariates before and after matching.  PS matching resulted in well-balanced 
comparison groups (eFigure 1). 
 
Population preventive fraction 
Given the low prevalence of ID only, the estimated unadjusted odds ratio (uOR) of 0.51 
should approximate a relative risk.  The estimated prevalence of ID only among mothers not 
taking multivitamin supplements (908/209,416 = 0.43%) and uOR suggest that if the association 
between multivitamins and ASD with ID could be assumed to be causal, absolute risk among 
children of mothers not taking supplements could be reduced from 434 to 212 per 100,000 with 
supplementation[9].  Similarly, the prevalence of ASD with ID among mothers not taking 
multivitamin supplements (963/207,193 = 0.46%) and uOR (0.54) suggest that absolute risk 
among children of mothers not taking supplements could be reduced from 465 to 214 per 100,000 
with supplementation.  This translates to a combined reduction for intellectual disability with and 
without ASD from 899 to 426 per 100,000 with multivitamin supplementation. 
Assumptions that may be unsupported are implicit in this calculation and given that 
underlying mechanisms are unknown, this estimate must be cautiously interpreted.[10]  
Moreover, assuming a causal link could be established between multivitamin use and ID, it is 
uncertain how this magnitude of absolute effect would translate to other populations that have 
different backgrounds of nutritional supplement use, fortification, dietary patterns, and health 
risks.  
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Appendix 2: R code for exposure derivation 
 
 
 
#~~~~~ Pattern matching in free text of old MBR~~~~~# 
# Find patterns that indicate usage of a drug 
#~~ IRON ~~~# 
# fuzzy matching 
ironmatches <- NULL 
patterns <- c("NIFEREX","HEMOFER","BLUTSAFT","DUROFERON","JÄRN","JÄRNTILLSKOTT", 
"JÄRNTABL","FERRONOL","ERCOFER","FE TABL", "GLOBIFER", "FE 100 MG", 
"VENOFER","FERRO","HEMIRON") 
for (i in patterns){ 
temp <- agrep(i, drugs$drugs) 
ironmatches[[i]] <- as.character(drugs$drugs[temp]) 
} 
# exact matching 
patterns <- c("FE","IRON","FE KOMB FOLACID","FE M FOLACIN","FE, FOLACIN", 
"IRON-FOLLIC PLU,","FE & VITAMINER","FE-SAFT", 
"VITAMINER +FE","VIT/MINERAL/FE","FE-VITAMINER", 
"FE & ACO VITAMINER","FE + VITAMINER","FE MED VITAMINER", 
"FE OCH C-VITAMINER","FE VITAMINER","VITAMINER/FE","FLYTANDE FE", 
"T. FE","FE+","FLYT FE") 
ironmatches[["EXACT"]] <- patterns 
# exact matching for specifc part 
patterns <- c("JÄRN") 
for (i in patterns){ 
temp <- grep(i, drugs$drugs) 
ironmatches[[i]] <- c(ironmatches[[i]], as.character(drugs$drugs[temp])) 
} 
# manual cleaning of incorrect matches 
incorrect <- c(# from JÄRN # 
"PUMPAKÄRNE-EXTRAKT","SE JORNAL ANTECKNING","PUMPAKÄRNE-EXTRAKT", 
# from FE TABL # 
"DEXOFEN TABL","TRANDATE TABLETT 100","TRIOBE TABLETT","ALVEDON FORTE TABLET", 
"POSTAFEN TABL","POSTAFEN TABL","LUGNANDE TABL.","TRANDATE TABLETT 200","ALVEDON FORTE 
TABL 1", 
"BLTR HÖJANDE TABL","DEXOFEN TABL 50","DEXOFEN TABL 50 MG","DEXOFEN TABL.","DEXOFEN 
TABLETT", 
"DEXOFEN TABLETT 100","DIANE TABLETT 2 MG/","FOLSYRE TABL","POSTAFEN TABL 25", 
"POSTAFEN TABL.V","ILLAMÅENDE TABL","ILLAMÅNENDE TABL","ILLLAMÅENDE TABL I T", 
"POSTAFEN TABL 25 MG", 
# from FE 100 MG # 
"TRANDATE 100 MG","DEXOFEN 100 MG","ZOLOFT 100 MG","DOLOXENE 100 MG","T TRANDATE 100 MG", 
"T. TRANDATE 100 MG","T.DEXOFEN 100 MG","T.TRANDATE 100 MG"," TRAMDATE 100 MG", 
"T TRANDATE 100 MG","T .TRANDATE 100 MG","T.SOLOFT 100 MG","TANDATE 100 MG","TRAMDATE 100 
MG", 
# from FERRO # 
"BETAFERON","CAFERGOT","INJ BETAFERON","TOCOFEROL","BETAFERONINJ","BEFERON","BERROCCA 
BRUS", 
"CEFERGOT","CHOLECALCIFEROL","ERRONL","FERRHYD","FEROMYN S","FERRACODIL", 
"EFEROX","ERGOKALCIFEROL","ERGOKALICIFEROL APL","FERMONEST","FEROMFOL","FEROMOL","FEROMOL 
15 ML", 
"T BERROCA","SERRODETTE","SERROVENT DISKUS","OMEPRAZOL ERRO","PROGESTERRON VAG", 
"INJ. INTERFERON","INTERFERON","FERRATI", 
# from HEMIRON # 
"REMIRON","REMIRON 15 MG","T REMIRON","T.REMIRON-S") 
for (i in 1:length(ironmatches)) { 
ironmatches[[i]] <- setdiff(ironmatches[[i]], incorrect) 
} 
#~~~ FOLIC ACID ~~~# 
folicmatches <- NULL 
# fuzzy matching 
patterns <- c("FOLSYRA","FOLACIN","FEMIBION","HEMOPLETT","TRIOBE","FOLIC", 
"FERRONOL","HEMOFER PLUS","BIOFOLIN") 
for (i in patterns){ 
temp <- agrep(i, drugs$drugs) 
folicmatches[[i]] <- as.character(drugs$drugs[temp]) 
} 
# exact matching 
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patterns <- c("HEMOFER +","HEMOFER+","HEMOPLUS", 
"T.HEMOFER+","T HEMOFER +","HEMOFER MED FOL","T HEMOFER M FOL", 
"HEMOFER M FOLS","T HEMOFER FOLS","HEMOFER+FOL","T.HEMOFER M FOL", 
"THEMOFER+",".HEMOFER+","HEMOFER M. FOLS","T HEMOFER MED F", 
"HEMOFER M FOL","HAEMOFER +","HEMOFER+BVIT","TABL HEMOFER MED FOL", 
"THEMOFER M FOL","THEMOFER M. FOL","VITAMINER + FOL", 
"T VITAMINERAL M. FOL","VITAMINER MED F","VITAMINER/ FOLS", 
"HÄMO-FER+") 
folicmatches[["EXACT"]] <- patterns 
# exact matching for specifc part 
patterns <- c("FOLS","FOLAC","FEMIBIO","FOLIC") 
for (i in patterns){ 
temp <- grep(i, drugs$drugs) 
folicmatches[[i]] <- c(folicmatches[[i]], as.character(drugs$drugs[temp])) 
} 
# manual cleaning of incorrect matches 
incorrect <- c(# from TRIOBE# 
"TRIOMEGA","TRIONETTA","T TRIOMEGA","T TRIONETTA","TRIONETTA 28","TRIODERON","TRIOMEGA F 
KVINNA", 
"TRIOMEGALL", 
# from FOLIC# 
"KYOLIC","DIFLICAN","DUFLICAN","PROCYANIDOLIC","SOLICO","SYMFONIC","T METABOLIC PRE","T 
KOLICIN", 
"KRYOLIC (VITLÖK)","FOLIO", 
# from HEMOFER PLUS# 
"HEMOFER BLUTSAFT") 
for (i in 1:length(folicmatches)) { 
folicmatches[[i]] <- setdiff(folicmatches[[i]], incorrect) 
} 
#~~~ MULTIVITAMIN ~~~# 
# fuzzy matching 
mvmatches <- NULL 
patterns <- c("MITT VAL KVINNA", "MULTIVITAMIN","MITT VAL", 
"VITAMIN KVINNA","MAMMAVITAL","KVINNA VITAMIN", "VITAMAX","KVINNA", 
"APOTEKET KVINNA", "MULTIPLEX","ENOMDAN", "BEROCCA","GRAVITAMIN", 
"MULTI KVINNA","MIVITOTAL","KVINNA VITAL","VIT FÖR GRAVIDA","MULTIVIT GRAVID", 
"PREGNACARE","MULTIVIT","KVINNA GRAVID", 
"ACO KVINNA","ACO FAMIL","ACO FERTIL","ACO MULT","ACO GRAV", 
"KVINNAMITTVAL","VITAMIN FÖR GRAVIDA") 
for (i in patterns){ 
temp <- agrep(i, drugs$drugs) 
mvmatches[[i]] <- as.character(drugs$drugs[temp]) 
} 
# fuzzy matching with lower tolerance 
patterns <- c("ACO VITAMIN") 
for (i in patterns){ 
temp <- agrep(i, drugs$drugs, max.distance=0.001) 
mvmatches[[i]] <- as.character(drugs$drugs[temp]) 
} 
# exact matching 
patterns <- c("MATERNA") 
mvmatches[["EXACT"]] <- patterns 
# exact matching for specifc part 
patterns <- c("VITAMINERAL","VITAPLEX","ACO Q") 
for (i in patterns){ 
temp <- grep(i, drugs$drugs) 
mvmatches[[i]] <- c(mvmatches[[i]], as.character(drugs$drugs[temp])) 
} 
# manual cleaning of incorrect matches 
incorrect <- c(# from MULTIPLEX# 
"MULTIPLEX OMEGA","MULTIPLEX OMEGA3","MULTIPLEX C","MULTIPLEX C-VITAMIN", 
"OMEGA 3 MULTIPLEX","OMEGA3 MULTIPLEX", 
# from ACO VITAMIN # 
"FOLSYRA O VITAMIN","FOLSYRA O VITAMINER") 
for (i in 1:length(mvmatches)) { 
mvmatches[[i]] <- setdiff(mvmatches[[i]], incorrect) 
} 
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Table A1. Derivation of SYC supplement user groups from ATC codes 
Supplement use Logic 
Folic acid onlya Contains B03BB  
(B03BB, B03BB01, 
B03BB51) 
AND Does not contain B03A OR A11A OR A11B 
Iron onlyb Contains B03A  
(B03A, B03AA, B03AB, 
B03AC, B03AD, 
B03AE) 
AND Does not contain B03BB OR A11A OR A11B 
Iron and Folic acid Contains B03BB  AND Contains B03A  AND  Does not contain 
B03BB OR A11A 
OR A11B 
Multivitaminsc Contains A11A  
(A11A, A11AA, 
A11AB)  
OR Contains A11B (A11B, A11BA) 
Non-use (ref) Does not contain B03BB, B03A, A11A, or A11B 
a Folic acid use is recorded as B03BB, “Folic acid and derivatives”, including ATC codes B03BB, B03BB01, and 
B03BB51.   
b Iron use is recorded as B03A, “Iron preparations”, which includes B03A, B03AA, B03AB, B03AC, B03AD, and 
B03AE.   
c Multivitamin use is recorded as A11A, “Multivitamins, combinations” or A11B, “Multivitamins, plain”.  This 
includes ATC codes A11A, A11AA, A11AB, A11B, and A11BA. 
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Table A2. ICD-8, ICD-9, and ICD-10 codes used to identify history of specific neuropsychiatric conditions before birth 
ICD version Nordic ICD-8 Nordic ICD-9 ICD-10 
Neuropsychiatric condition    
Anxiety disorders (any) 300 [0,2,9] 300 [00,01,02] 
300 [2,9] 
F40-41 (all) 
Autism  299 (all) F84 
Bipolar disorder 296 (all) 296 [.0, .1, .4, .5, .6, .7, .8, .9] F30-31 
Depression/ mood disorder 300.4 296 [2,3] 
300.4 
311  
F32-39 
Epilepsy 345 (all) 345 (all) G40 (all) 
G41 
Intellectual disability 310-315 317 
318 
319 
F70-79 
Non-affective psychotic disorder 
(schizophrenia) 
F20-29 295 
298 
295 (all) 
298 [3,9] 
299 
Stress related disorders 298 [0,1,2,9] 308 (all) 
309 (all) 
F43 (all) 
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Table A3. Minimally adjusted odds ratios and 95% confidence 
intervals for supplement use and ASD with and without 
intellectual disability, and any ASD 
Sample Full 
Adjustment Minimala 
Model GEEb 
ASD with ID  
Folic acid 1.21 (0.72, 2.03) 
Iron 0.97 (0.84, 1.11) 
Folic acid and Iron 1.06 (0.87, 1.30) 
Multivitamin 0.66 (0.55, 0.80) 
ASD without ID  
Folic acid 1.28 (0.99, 1.66) 
Iron 0.95 (0.88, 1.02) 
Folic acid and Iron 0.88 (0.78, 0.99) 
Multivitamin 0.89 (0.81, 0.97) 
Any ASD  
Folic acid 1.27 (1.01, 1.60) 
Iron 0.95 (0.89, 1.01) 
Folic acid and Iron 0.92 (0.83, 1.02) 
Multivitamin 0.85 (0.78, 0.91) 
a Adjusted for birth year and maternal birth country 
b Generalized estimating equation logistic regression, grouped by birth 
mother 
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Table A4. Crude and adjusted odds ratios and 95% confidence intervals for supplement use and ID only 
Sample Sibling Sibling Propensity score Full Full 
Adjustment Unadjusted Adjusteda PS matched Unadjusted Minimalb 
Model CLRc CLRc OLR and GEEd GEEe GEEe 
ASD with ID      
Folic acid 0.81 (0.28 to 2.36) 0.94 (0.29 to 3.04) 1.14 (0.64 to 2.04) 1.16 (0.69 to 1.94) 1.21 (0.72 to 2.03) 
Iron 0.84 (0.64 to 1.10) 0.90 (0.67 to 1.21) 0.96 (0.82 to 1.13) 0.99 (0.87 to 1.14) 0.97 (0.84 to 1.11) 
Folic acid and Iron 0.81 (0.54 to 1.22) 0.99 (0.63 to 1.57) 1.06 (0.86 to 1.30) 1.14 (0.93 to 1.38) 1.06 (0.87 to 1.30) 
Multivitamin 0.60 (0.42 to 0.86) 0.77 (0.52 to 1.15) 0.68 (0.54 to 0.86) 0.54 (0.45 to 0.65) 0.66 (0.55 to 0.80) 
ID only      
Folic acid 0.93 (0.27 to 3.24) 1.15 (0.33 to 4.00) 1.56 (0.90 to 2.69) 1.38 (0.85 to 2.23) 1.47 (0.90 to 2.39) 
Iron 0.71 (0.53 to 0.94) 0.76 (0.56 to 1.02) 0.93 (0.79 to 1.09) 0.99 (0.88 to 1.14) 0.98 (0.85 to 1.13) 
Folic acid and Iron 0.45 (0.24 to 0.72) 0.51 (0.31 to 0.83) 0.64 (0.50 to 0.82) 0.70 (0.55 to 0.90) 0.69 (0.54 to 0.88) 
Multivitamin 0.62 (0.41 to 0.95) 0.74 (0.48 to 1.14) 0.73 (0.56 to 0.93) 0.51 (0.42 to 0.61) 0.67 (0.54 to 0.81) 
Analytic sample sizes are documented in Table A5, ranging from 15,787 mothers and 16,376 children (folic acid propensity score analysis) 
to 177,682 mothers and 272,018 children (full sample analyses). 
a Adjusted for child sex, parity, and birth year (continuous) 
b Adjusted for birth year and maternal birth country 
c Conditional logistic regression, matched on birth mother 
d Propensity scores were calculated with covariates in b as predictors of supplement use in ordinary logistic regression models (maternal age 
was a continuous covariate); in the matched sample, propensity scores were used as predictors of ASD in generalized estimating equation 
logistic regression models grouped by birth mother 
e Generalized estimating equation logistic regression, grouped by birth mother 
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Table A5. SYC analytic sample sizes 
 Sibling1 Propensity score Full 
 Mothers Children Mothers Children Mothers Children 
ASD with ID       
Folic acid 15,575 16,086 
Iron 102,974 127,860 
Folic acid and Iron 71,645 84,473 
Multivitamin 
77,395 
 
Discordant: 
642 
169,760 
 
Discordant: 
1536 72,696 85,568 
173,839 268,695 
ASD without ID       
Folic acid 15,810 16,353 
Iron 103,994 129,582 
Folic acid and Iron 72,373 85,495 
Multivitamin 
78,903 
 
Discordant: 
2447 
173,209 
 
Discordant: 
5615 73,533 86,686 
176,952 271,944 
Any ASD       
Folic acid 15,892 16,432 
Iron 104,280 130,230 
Folic acid and Iron 72,695 85,871 
Multivitamin 
79,404 
 
Discordant: 
3066 
174,428 
 
Discordant: 
7122 73,730 86,994 
178,083 273,107 
ID only       
Folic acid 15,787 16,376 
Iron 103,914 129,682 
Folic acid and Iron 72,352 85,516 
Multivitamin 
78,902 
 
Discordant: 
593 
173,238 
 
Discordant: 
1460 73,428 86,626 
177,682 272,018 
1 While the larger figures represent the samples utilized in sibling analyses, only strata (mothers) 
having discordant supplement usage contribute to the analyses mathematically. The N’s in the Mothers 
column thus represents the number of sets of siblings with discordant exposures. The N’s in the 
Children column represents the number of siblings total in the discordant sets. 
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Table A6. Selected characteristics of the SYC study sample born 1996-2007 by child ASD  
 ASD with ID ASD without ID No ASD 
Characteristics 1163 (0.4) 4412 (1.6) 267,532 (98.4) 
Nutrient supplementation 
   Folic acid 
   Iron 
   Iron + FA 
   Multivitamins 
   None 
 
15 (1.3) 
422 (36.3) 
138 (11.9) 
158 (13.6) 
430 (37.0) 
 
63 (1.4) 
1450 (32.9) 
378 (8.6) 
906 (20.5) 
1615 (36.6) 
 
2711 (1.0) 
88,266 (33.0) 
24,929 (9.3) 
61,776 (23.1) 
89,850 (33.6) 
Sex of child – male 848 (72.9) 3298 (74.8) 135,766 (50.8) 
Parity 
  First child 
  Second child 
  Third child and higher 
 
490 (42.1) 
419 (36.0) 
254 (21.8) 
 
2280 (51.7) 
1396 (31.6) 
736 (16.7) 
 
122,140 (45.7) 
97,035 (36.3) 
48,357 (18.1) 
Maternal education  
  ≥ 12 yrs 
  Missing data 
 
413 (35.5) 
11 (1.0) 
 
1773 (40.2) 
11 (0.3) 
 
123,725 (46.3) 
1605 (0.6) 
Maternal country of origin, Sweden 665 (57.2) 3497 (79.3) 198,966 (74.4) 
Highest quintile family income 264 (22.7) 1309 (29.7) 91,668 (34.3) 
Maternal age, mean (SD) 30.4 (5.5) 30.3 (5.3) 30.7 (5.0) 
Maternal smoking 
   Yes 
   No 
   Missing data 
 
116 (10.0) 
905 (77.8) 
142 (12.2) 
 
525 (11.9) 
3316 (75.2) 
571 (12.9) 
 
19,825 (7.4) 
211,966 (79.2) 
35,741 (13.4) 
Maternal body mass index 
   Underweight (BMI < 18.5) 
   Normal (18.5 ≤ BMI < 25)` 
   Overweight (25 ≤ BMI < 30)  
   Obese (BMI ≥30) 
   Missing data 
 
30 (2.6) 
561 (48.2) 
226 (19.4) 
113 (9.7) 
233 (20.0) 
 
93 (2.1) 
2101 (47.6) 
868 (19.7) 
395 (9.0)  
955 (21.7) 
 
6308 (2.4) 
144,840 (54.1) 
45,096 (16.9) 
15,910 (6.0) 
55,378 (20.7) 
Maternal medications 
   Antidepressant use 
   Antiepileptic use 
 
15 (1.3) 
7 (0.6) 
 
131 (3.0) 
27 (0.6) 
 
3560 (1.3) 
608 (0.2) 
Maternal neuropsychiatric conditions 
   Anxiety disorders 
   Autism 
   Bipolar disorder 
   Depression 
   Epilepsy 
   Intellectual disability 
   Non-affective psychotic disorders 
   Stress disorders    
 
22 (1.9) 
11 (1.0) 
3 (0.3) 
35 (3.0) 
11 (1.0) 
6 (0.5) 
9 (0.8) 
24 (2.1) 
 
76 (1.7) 
80 (1.8) 
13 (0.3) 
195 (4.4) 
45 (1.0) 
8 (0.2) 
15 (0.3) 
134 (3.0) 
 
3539 (1.3) 
259 (0.1) 
499 (0.2) 
7588 (2.8) 
1503 (0.6) 
162 (0.1) 
749 (0.3) 
4913 (1.8) 
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Figure A1. Absolute standard biasesa for covariates in ASD 
propensity score modelsb 
Each graph incorporates data from propensity score models for any ASD; graphs for 
ASD with ID and ASD without ID were largely similar 
a The purpose of these plots is to indicate the relative improvement in covariate balance 
after matching. Absolute standardized bias is the absolute value of the weighted 
difference in covariate means between the treatment (supplement users) and control 
group (non-supplement users) divided by the standard deviation in the exposed group.  
If treated and control groups were perfectly balanced on all measured covariates, 
absolute standard bias would be equal to zero, indicating perfect matching.  Absolute 
standard biases were calculated for all covariates used to calculate the propensity score.   
b Propensity scores were calculated using logistic regression. 
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Figure A2. ASD prevalence in the Stockholm Youth Cohort by birth year 
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Figure A3. Maternal nutrient supplementation by birth year 
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CHAPTER 4. Study II: Prenatal nutritional supplementation, folate-related genes, and 
autism-related traits in the ALSPAC birth cohort 
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ABSTRACT 
Background: Evidence is inconsistent regarding whether prenatal supplementation with folic 
acid, iron, or multivitamins is protective against autism and its sub-components, and whether 
associations depend upon relevant genotypes. 
Methods: The Avon Longitudinal Study of Parents and their Children (ALSPAC) is a 
population-based prospective birth cohort of mothers residing in Avon, England who had 
expected dates of delivery between 1st April 1991 and 31st December 1992.  Folic acid, iron, and 
vitamin use during pregnancy were reported at 18 weeks gestation.  Seven factor scores related to 
autism and 1 combined score were derived from factor analysis.  IQ scores were derived from all 
verbal and performance subtests of WISC-III 
UK
administered at 8.5 years of age.  Linear 
regression was used to calculate β estimates with 95% confidence intervals (CI) between 
supplementation and factor scores and IQ.  Supplementation was also examined in interaction 
models with maternal and child genetic variants involved in folate metabolism (MTHFR C677T, 
MTHFR1298, MTR, MTRR, BHMT, FOLR1, CBS, COMT, and TCN2). 
Results: Vitamin supplementation was associated with higher language acquisition skills, while 
folic acid use were associated with lower articulation scores; both of these relationships were also 
observed for higher dietary folate.  Vitamin and folic acid supplementation were associated with 
higher IQ scores in the child; associations between folic acid supplementation and IQ appeared to 
depend upon child MTHFR677 genotype.  There was no strong evidence of relationships between 
iron and ASD sub-components. 
Conclusions:  These findings suggest that maternal nutrition may be related to sub-components 
of autism such as language development and cognition, and may depend upon genes involved in 
folate metabolism, specifically child MTHFR677.  Further investigation is warranted to 
disentangle these complex relationships.
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INTRODUCTION 
Approximately 1.5% - 2.0% of children in the US[1, 2] and UK[3] are estimated to have 
autism spectrum disorder (ASD).  While reported prevalence has increased in dramatically in 
recent decades,[4] ASD etiology remains largely unknown.  Research suggests that ASD 
develops prenatally, and generally involves both heritable and non-heritable risk factors.[5-9] 
Maternal nutrition and ASD 
Maternal nutrition has been shown to influence neurodevelopment.[10-12]  In particular, 
maternal folate status regulated by dietary and genetic factors early in pregnancy may influence 
risk of ASD.[13]  Two population-based studies[14, 15] reported reduced risk of ASD with 
maternal folic acid supplementation and intake in the peri-conceptional period and early 
pregnancy, while another reported no associations between early folate supplementation and ASD 
risk.[16]  The evidence for multivitamins is mixed.  One study reported a protective association 
between prenatal vitamins, but not ordinary multivitamins,[17] while another study also reported 
no associations between early multivitamin supplementation and ASD risk.[16]  A protective 
association has also been reported between prenatal iron supplementation[18] and ASD. 
Maternal nutrition and autism-related traits 
There is a need to examine not just clinical ASD diagnosis but also quantitative ASD 
sub-components, or traits, because individuals with ASD may have behaviors at the extremes of 
normally distributed continuums[19, 20] and traits may have distinct etiologies.[21]  Studies have 
linked self-reported folic acid supplementation or dietary folate during pregnancy with both 
reductions and increases in ASD traits as measured by quantitative scores.[22-27]  Discrepancies 
may be due to dissimilarities in trait etiology[21, 28] differences in timing of folic acid initiation, 
dose, frequency, or duration, and/or methodological inconsistencies including timing of outcome 
assessment and outcome definition or assessment instruments.[13, 28]  The majority of biomarker 
folate studies have not found associations between maternal plasma or blood folate and cognitive 
function (null: [29-32], protective:[33]) and no association was observed between maternal blood 
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folate and social responsiveness at 4-5 years.[34]  
Genes related to folate metabolism 
Gene variants in folate metabolism confer less efficient metabolism and higher 
homocysteine levels (Table A7).  A meta-analysis of studies of MTHFR C677T and A1298C 
reported the C677T polymorphism being associated with increased ASD risk, (T vs C allele: OR 
= 1.42, 95% confidence interval: [1.09, 1.85]) while the A1298C polymorphism was only 
associated with reduced ASD in a recessive model (CC vs AA+CC: 0.73 [0.56, 0.97]).  The 
C677T polymorphism was associated in ASD only in children from countries without food 
fortification.[35] 
Schmidt et al (2011)[17] explored effect modification between prenatal vitamin use and 
functional genetic variants involved in folate metabolism (MTHFR, COMT, MTRR, BHMT, 
FOLR2, CBS, and TCN2) as carried by the mother or child and risk of ASD.  They found 
interactions between periconceptional prenatal vitamin use and maternal MTHFR 677 TT, CBS 
rs234715 GT + TT, and child COMT 472 AA genotypes, with greater autism risk observed for 
variant genotypes and among mothers not taking prenatal vitamins.  Another study reported that 
low daily folate intake (< 400 mg/d) was associated with lower mental development in the child 
at 1, 3, 6, and 12 months only among MTHFR677 TT mothers.[36] 
In order to address prior inconsistencies and remaining questions in the associations 
between folate and other nutrients and ASD, in a population-based prospective birth cohort, we 
investigated maternal nutritional supplementation with folic acid, iron, and vitamins, and 
potential interactions with genes involved in folate metabolism as they relate to ASD sub-
components.  In alignment with the NIMH Research Domain Criteria (RDoC) initiative[37], this 
research is focused on exploring risk factors that may differentially impact sub-components of 
autism.  In addition, since all individuals are on quantitative trait spectra, this research involves 
examination of the underlying drivers of traits in a population more broadly, rather than limiting 
investigation to clinically diagnosed autism.
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METHODS 
Sample description 
Data were obtained from the Avon Longitudinal Study of Parents and their Children 
(ALSPAC), a population-based prospective birth cohort study designed to investigate factors 
impacting children’s health and development.  Study methods are described in detail elsewhere 
(http://www.alspac.bris.ac.uk).[38, 39]  Briefly, expectant mothers living around Bristol, England 
and due to deliver between 1st April 1991 and 31st December 1992 were eligible for inclusion.  
Mothers who were resident in the area but left shortly after enrolment were omitted from further 
follow-up.  Eligible families were defined as one-year surviving singleton children and their 
mothers (Figure 3).  The supplementation sample was restricted to children with non-missing 
autism and factor score data and mothers with folic acid, iron, and multivitamin supplementation 
data.  The genetic sample further excluded mothers and children without genotype data. 
 
Ethics statement 
Ethical approval was obtained from the ALSPAC Law and Ethics Committee and the 
Local Research Ethics Committees (Bristol and Weston, Southmead, and Frenchay Health 
Authorities).  All research was within the guidelines set out by these bodies.  Participating 
mothers provided written informed consent to the use of anonymized linked data for research at 
enrolment. 
 
Exposure definition 
Self-reported supplement use of folic acid, iron and vitamins was assessed through 
mailed questionnaire at 18 weeks gestation: “During this pregnancy have you been taking any of 
the following?: iron (yes/no), folic acid/folate (yes/no), vitamins (yes/no)”.  Due to substantial 
overlap between the folic acid and other two categories (only 99 mothers in the vitamin sample 
were taking folic acid alone), the variables were examined in their original forms, and are 
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therefore not mutually exclusive. 
 
Outcome definition 
Quantitative ASD sub-components 
Steer et al (2010)[28] utilized factor analysis to analyze 93 individual measures assessed 
in ALSPAC between 6 months and 9 years related to the social/communication, and repetitive 
behavior domains of ASD (Table A8).  Forty-six of the 93 individual measures related to 12 
standard assessment tests.[40-51]  Repeat measures were used so that enduring traits could be 
identified.  Seven factors were found to be independently predictive of ASD (p < 0.001) and 
collectively explained 85% of the variance in ASD diagnoses, and were chosen on the basis of 
interpretability and parsimony.[28]  The factors were labeled verbal ability (VA), social 
understanding (SU), repetitive-stereotyped behavior (RSB), social inhibition (SI), language 
acquisition (LA), semantic-pragmatic skills (SPS), and articulation (A).  Four factors (VA, SU, 
RSB, SI) were most specific to ASD, while the other factors (LA, SPS, A) were more specific to 
learning and language disabilities.  Factor loadings are reported in the original report.[28]  A 
combined score was derived (factor mean score - FM) to provide insights not discernable among 
individual factors.  The factor scores are continuous, with higher scores representative of stronger 
abilities.  Continuous factor scores were originally derived to have a mean of 0 and a standard 
deviation of 1. 
IQ 
The WISC-III 
UK
[52] was used to assess cognitive function at 8.5 years old.  Raw scores from 
5 verbal subtests and 5 performance subtests were age-scaled.  Total IQ scores were derived from 
the sum of the scaled total for all verbal and performance subtests.  All tests were administered by 
members of the ALSPAC psychology team, who were trained in these methods. 
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Measurement of potential confounders 
Potential confounders were identified through published literature.  Information on 
potential confounders was ascertained at various points during and after pregnancy through 
questionnaire, unless otherwise stated.  Maternal body mass index (BMI) in kg/m2 was derived 
from height and pre-pregnancy weight reported at 12 weeks gestation (correlation between 
reported pre-pregnancy weight and weight measured at the first antenatal visit at 10-12 weeks 
gestation was 0.96.[53]), and was classified in categories (underweight: < 18.5, normal: 18.5 - < 
25, overweight: 25 - < 30, obese: ≥30, missing).  Maternal history of severe depression, 
schizophrenia, and other psychiatric problems (self-reported psychiatric problem other than 
schizophrenia, anorexia nervosa, or severe depression) were assessed at 12 weeks gestation (yes, 
no, missing).  Covariates assessed at 18 weeks included parity (1, 2, 3+, missing), tobacco 
smoked (yes, no) during the first three months of pregnancy, and antidepressant use during 
pregnancy (yes, no, missing).  Maternal education was assessed at 32 weeks gestation (Below O-
level, O-level, Above O-level, missing; O-levels are UK school-leaving qualifications taken at 
age 16).  Child biological sex was obtained from the birth notification and maternal age at 
delivery was derived from the mother’s and child’s birth dates.  For covariates with missing data, 
categorical variables were utilized with “Missing” as a category. 
For further information, the ALSPAC study website contains a searchable data 
dictionary: (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). 
 
Genotyping 
ALSPAC mothers (n = 10,015) were genotyped using the Illumina 660K quad chip at 
Centre National de Génotypage, Paris.  Quality control measures were performed using PLINK 
software[54] (v1.07).  Subjects were excluded based on incorrect sex assignments, unusual 
autosomal or X-chromosome heterozygosity, >5% individual missingness, evidence of cryptic 
relatedness (>12.5% identity-by-descent [IBD]), and evidence of non-European ancestry 
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determined from multidimensional scaling analysis.  The resulting dataset consisted of 8340 
mothers.[55]   
ALSPAC children (n = 9912) were genotyped using the Illumina HumanHap550 quad 
genome-wide SNP genotyping platform by the Wellcome Trust Sanger Institute (Cambridge, UK) 
and the Laboratory Corporation of America (Burlington, NC, USA) supported by 23andMe.  
Subject exclusion was based on incorrect sex assignments, extreme heterozygosity (<0.320 and 
>0.345 for Wellcome Trust Sanger Institute data and <0.310 and >0.330 for LabCorp data), >3% 
individual missingness, evidence of cryptic relatedness (>10% IDB), or non-European ancestry.  
The resulting dataset consisted of 8365 children.[56, 57] 
From a total of 557,124 SNP markers,[55] SNPs were removed based on a minor allele 
frequency of <1%, a call rate of <95%, or deviation from Hardy-Weinberg equilibrium (mothers: 
p<1.0×10−6, children: p<5×10-7),[55-57] leaving 526,688 maternal[55] and 500,527 child SNPs in 
the genome-wide data set.[57]  Imputation of genotyped data was conducted with Markov Chain 
Haplotyping software (v1.0.16)[58, 59] (autosomal reference set: CEU HapMap phase 2 [release 
22] individuals).[60]  
For this study, maternal and child genotypes for nine SNPs on eight genes were selected 
for evaluation of interaction effects based on previous literature[17] and availability in the 
ALSPAC database: MTHFR C677T (rs1801133), MTHFR A1298C (rs1801131), COMT G472A 
(rs4680), MTRR A66G (rs1801394), BHMT G716A (rs3733890), TCN2 G776C (rs1801198), CBS 
T (rs234715), MTR A2756G (rs1805087), and FOLR1 A (rs2071010).  
 
Statistical methods 
All statistical analyses were run using SAS software, version 9.3 (SAS Institute Inc., 
Cary, North Carolina). 
Linear regression was used to calculate β parameter estimates and p-values for 
continuous factor scores and IQ.  Continuous factor scores were rescaled to 100-point ranges in 
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regression analyses so β parameter estimates can be interpreted as percent change in outcome. 
Folic acid, iron, and vitamins were all included as exposures in all models so were therefore 
adjusted for one another.  Supplement main effect and models also incorporating folic acid- and 
vitamin-genetic interaction were considered. 
An additive inheritance model was assumed for SNPs in interaction models.  Due to 
small numbers of homozygous FOLR1 AA individuals in the genetic sample (n = 20 mothers and 
20 children, 0.4%), this SNP was coded assuming a dominant model.  Multiplicative interaction 
models were run separately for each SNP examined and included terms for supplement use (yes 
[ref], no), an ordinal genotype term coded by number of risk variants (0 [ref], 1, or 2), a 
supplement-gene interaction term for each folic acid and vitamins, and adjustment for potential 
confounders of maternal supplement use.  Comparisons with cell counts less than 5 were not 
calculated.  Epistatic interaction was not considered, and risk variants were defined based upon 
previously published literature.[17, 61] 
Adjusted models included the following potential confounders: maternal age at child’s 
birth, education, and parity.  We also examined, in main effects models, further adjustment for 
child’s sex, pre-pregnancy body mass index (BMI) category, smoking status, anti-depressant use 
during pregnancy, severe depression, and other psychiatric conditions.  However, as these 
changed supplementation estimates less than 0.2% for factor scores (mean: 0.04%) and less than 
0.1 points for IQ (mean: 0.04 pt), they were not included in final adjusted models. 
To examine whether supplement findings were specific to supplement use, dietary folate 
was included in supplement main effects models and examined in interaction models.  Dietary 
folate intake was estimated based on a food frequency questionnaire administered at 32 weeks 
gestation, and excluded supplementary nutrient intake.  Dietary folate was classified into 
categories based on distributional characteristics and the Reference Nutrient Intake of 300 µg 
folic acid per day for pregnant women set forth by the British Nutrition Foundation[62] (< 200 
[27.6%], 200 - < 300 [52.0%] and ≥ 300 µg / day [20.5%]).  To address multiple testing, main 
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findings replicated for dietary folate are emphasized, as well as findings with magnitude of at 
least 1.0% or 1 IQ point. 
In an alternate parameterization, logistic regression was used to calculate odds ratios 
(ORs) with 95% confidence intervals (CI) for the lowest 10th percentile of outcomes relative to 
the upper 90th percentile.
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RESULTS 
Sample description 
Among 15,445 fetuses and 15,243 mothers, there were 14,309 one-year surviving 
singleton children (Figure 3).  The supplementation sample consisted of 11,741 children and their 
mothers with autism data, all factor score data, and all supplementation data (folic acid, iron, and 
vitamins [82.1% eligible children and mothers]).  The genetic sample was further restricted to 
4897 mother-child pairs (34.2% eligible children and mothers) with maternal and child genotype 
data. Allele frequencies were similar to those reported in other Caucasian populations (Table 6). 
Supplementation and genetic sample sizes for IQ analyses were 6633 and 3726, 
respectively, due to substantial levels of IQ missingness (46.0% did not participate).  Mothers of 
children with missing IQ data were not representative of the full supplementation sample; they 
were less likely to use vitamins and more likely to have children with lower factor scores (factor 
mean score, repetitive stereotyped behavior, verbal ability, and semantic pragmatic skills).  
Mothers of children with missing IQ were also more likely to be multiparous, have less than 12 
years education, were younger, more likely to smoke, and less likely to have normal BMI than 
mothers of children with IQ data available (Table A10).   
In the supplementation sample, prevalence of supplement use was 32.4% overall 
(3800/11,741), consisting of overlapping groups of folic acid (n = 1021, 8.7%), iron (n = 2540, 
21.6%), and vitamin (n = 1936, 16.5%) users.  Prevalence of supplement use was similar in the 
genotype sample.  In both samples, supplement users tended to be more educated, have lower 
BMI, and were more likely to be taking anti-depressants and have depression than non-users 
(Table 7).  Continuous factor scores are displayed in Table 7 on their original scale (mean = 0, 
SD = 1 in full ALSPAC sample). 
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Maternal prenatal supplementation 
Relative to non-use of folic acid, iron, or vitamins, folic acid use was associated with 
higher child IQ scores (2.0 pt [0.01]), but poorer articulation scores (-1.1% [0.01]).  Vitamins 
were associated with higher language acquisition scores and IQ (1.0% [0.1] and 1.2 pt [0.02], 
respectively - Table 9).  Crude associations between folic acid and vitamins and higher semantic 
pragmatic skills attenuated after adjustment (Tables 8 and 9).  A crude elevated association 
between iron and and IQ attenuated following adjustment; there was no strong evidence of 
relationships between iron and ASD sub-components.   
There was evidence of a potential dose-response relationship between dietary folate 
intake and higher language acquisition skills (0.7 pt [0.04] and 2.9 pt [< 0.0001] for 200 – < 300 
µg and ≥ 300 µg, respectively).  Unadjusted relationships between higher dietary folate and higher 
semantic pragmatic skills and IQ attenuated following adjustment.  Folic acid and vitamin 
supplementation estimates were similar in models with dietary folate as in models without dietary 
folate (Tables A11 and A12).  
In cut-point models, directionality resembled that of continuous models (Table A20).  
 
Interaction between relevant genotypes and maternal prenatal supplementation 
For each interaction assessment, the reference group is mothers taking supplements and 
the homozygous non-risk variant genotype. 
Continuous models 
Of 180 each folic acid and vitamin-SNP continuous interaction comparisons, 14 had folic 
acid interactions and four had vitamin interactions (p < 0.05 - Tables A14 and A15).  Only the 
interaction between folic acid, child MTHFR677A and IQ was replicated for dietary folate. 
Associations between folic acid supplementation or higher dietary folate and increased IQ were 
limited to MTHFR677 GG (non-variant) children.  Among MTHFR677 GG children, the 
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difference in means between folic acid users and non-users was 3.8 IQ points (95% CI: 1.0, 6.6) 
and the difference in means between the highest and lowest categories of dietary folate intake 
(300+ vs. <200 µg/d) was 3.1 IQ points (95% CI: 0.9, 5.3).  There were no meaningful 
differences in IQ among heterozygous and homozygous variant children. 
Overall differences in means between MTHFR677 GG and AA children was 5.4 IQ 
points (95% CI: 3.0, 7.8) for folic acid use and 2.8 IQ points (95% CI: 0.9, 4.8) for higher 
compared to lower dietary folate (300+ vs. <200 µg/d).  These values are the differences in slopes 
between homozygous non-variant and homozygous variant children, which can be interpreted as 
the interaction “effect”. 
Cut-point models 
Of 180 each folic acid and vitamin-SNP cut-point interaction comparisons, nine had folic 
acid interactions and seven had vitamin interactions (p < 0.05 - Tables A23 and A24).  No cut-
point interactions were replicated for dietary folate intake. 
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DISCUSSION 
Summary of findings 
 In this prospective birth cohort, we examined relationships between maternal folic acid, 
iron, and vitamin supplement use and ASD sub-components, while accounting for heterogeneity 
in genes involved in folate metabolism.  Findings tended to be more specific to language and 
learning disabilities than they were to sub-components more specific to autism.  Vitamin use was 
associated with higher language acquisition skills, while folic acid use was associated with poorer 
articulation scores; both of these relationships were also observed for higher dietary folate.  
Vitamin and folic acid supplementation were both associated with higher IQ scores in the child; 
associations between folic acid supplementation and IQ appeared to depend upon child 
MTHFR677 genotype.  There was no strong evidence of relationships between iron and ASD 
sub-components. 
Strengths and limitations 
Despite the size of the ALSPAC cohort, the low prevalence of autism made it difficult to 
examine in main effects models (n = 141, 1.2%) and precluded investigation of interactions with 
nutrient supplementation, dietary intake, and relevant genetic variants (n = 65, 1.3%).  However, 
an averaged trait score correlated (ρ = 0.16, p < 0.0001) with autism diagnoses and the use of 
multiple characteristics associated with autism provided a richer, and perhaps more informative, 
context for exploring this etiology.  While 88 of 93 of the individual measures used to derive 
factor scores were obtained through self-completed questionnaires, there is research to suggest 
that maternal reporting has a high sensitivity for detecting developmental differences.[63]  In 
addition, while many standard measures used were abbreviated or adapted, short forms have 
acceptable reliability.[64] 
Findings for IQ should be cautiously interpreted since compared to mothers of children 
with IQ data, mothers of children with missing IQ were less likely to be highly educated and were 
more likely to have children with lower factor scores (lower abilities).  Both of these factors are 
103 
associated with lower child IQ.  Since mothers of children with missing IQ were also less likely 
to use vitamins, this could have biased findings toward an apparent protective association. 
We examined a subset of genes involved in folate metabolism, though other folate-
relevant genes warrant investigation into potential B vitamin interactions, such as dihydrofolate 
reductase (DHFR[65]) and reduced folate carriers 1 and 2(RFC-1[66, 67] RFC-2[68]) that have 
previously shown to be associated with autism.  While we restricted interaction assessment to 
comparisons in which all cell counts were greater than or equal to 5, small strata limited our 
ability to detect interactions, and some findings may be due to chance.  Focusing on findings 
replicated for dietary folate and having at least magnitude of 1% or 1 IQ point helped identify 
associations more likely to be of etiological importance and worthy of further investigation.  
Since these relationships were primarily examined in Caucasian individuals, this work has limited 
generalizability to non-white populations.  The consideration of genetic heterogeneity is an 
important one, given that previous studies have reported different associations between prenatal 
nutrition and autism[17] and mental development[36] as a function of maternal and child folate-
related genotypes. 
Lastly, we did not have biological samples, and cannot rule out measurement error in 
exposures, which were self-reported through mailed survey. 
Existing literature 
Maternal nutrition has previously been reported to relate to child language development.  
In the U.S. National Maternal and Infant Health Survey, prenatal multivitamin/mineral use was 
associated with reduced odds for moderate risk on the language scale,[25] and in a Norwegian 
cohort, maternal use of folic acid supplements in early pregnancy were associated with a reduced 
risk of severe language delay,[24] both at 3 years of age.  The Norwegian study reported similar 
odds ratios for mothers taking folic acid only and mothers taking it in combination with other 
supplements.   
Our study reports protective associations between both vitamin use and higher dietary 
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folate and higher language acquisition scores, which is in alignment with these findings.  A 
contradictory finding is our report of associations between folic acid use, higher dietary folate, 
and lower articulation scores, another aspect of language development.  Differences in these 
findings could reflect the loadings of individual measures on these factors (Table A9).  Language 
acquisition was derived primarily from elements of standard assessment instruments, albeit in 
some cases abbreviated or adapted.  The articulation measure is largely based on a single question 
from ALSPAC questionnaires (relating to certain sounds such as th, sss or t .), which may have 
implications on its validity.   
We report associations between vitamin and folic acid supplementation and higher IQ 
scores in the child.  Folic acid and vitamin supplementation was associated with 2.0 and 1.2 point 
increases in IQ in the full sample.  For folic acid, this association was only apparent among 
homozygous non-variant MTHFR677 children, whereby supplementation was associated with a 
3.8 point (95% CI: 1.0, 6.6) increase in IQ.  Comparatively, a 5 point IQ difference is associated 
with IQ differences in children who were exposed to high lead concentrations,[69] or were 
breastfed rather than formula fed as infants.[70]  However, the body of evidence does not seem to 
support a protective association between maternal folic acid and/or dietary folate and child 
cognition (null:[26, 32, 71], protective:[72]) or multivitamins and child cognition (null: [72-75], 
protective:[76]).  The majority of biomarker folate studies have also not found associations 
between maternal plasma or blood folate and cognitive function - Table A31 (null: [29-32], 
protective:[33]).  The two studies reporting protective relationships were randomized controlled 
trials assessing iron and folic acid and child intelligence at 7-9 years in Nepal[72] and multiple 
micronutrients and intellectual ability at 9-12 years in Indonesia.[76]  Protection in the latter 
study was limited to children of anemic mothers, but was not observed in the full sample or 
among children of undernourished mothers.  This study indicates that discrepancies could be 
partially due to the underlying nutritional status of studied populations, specifically of iron in that 
study.   
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Dietary nutrient intake in populations with null findings could be higher than in studies 
with positive findings.  One of the studies with null findings was a prospective cohort conducted 
in the United States.  A separate U.S. cohort of 1777 pregnant women between 1999 and 2002 
reported mean dietary intakes of 365 µg folate and 16.7 mg iron.[77]  Another study with null 
findings was a randomized controlled trial conducted in Hungary, Spain, and Germany.[32]  A 
separate study reported the following dietary folate intakes among women in the 2nd and 3rd 
trimesters of pregnancy, respectively: Hungary – 429 and 396 µg, Spain – 324 and 304 µg, and 
Germany – 271 and 254 µg.[78]  In our supplementation sample, mothers had mean daily dietary 
intakes of 245 µg folate and 10.3 mg iron.  In the event of a causal relationship between maternal 
folic acid or vitamins and child cognition, a threshold-level effect could be partially responsible 
for the observed discrepancies.  This possibility could be supported by a study in Indonesia 
reporting no difference in mental development between infants whose mothers took low and high 
doses of iron and folic acid (60 mg iron with 250 µg folic acid and 120 mg iron with 500 µg folic 
acid, respectively),[79] but since there was no placebo group, it is not possible to determine 
whether the low dose was protective.  Other potential contributors could be differences in 
assessment instruments, age at assessment, and/or differences in timing of initiation, dose, 
frequency, or duration of nutrient exposure. 
In the current study, relationships between folic acid supplementation and dietary folate 
and IQ were dependent upon child MTHFR677 genotype, with positive associations only 
apparent among homozygous non-variant MTHFR677 children.  A previous study of mental 
development reported that low daily folate intake (< 400 mg/d) was associated with lower mental 
development in the child at 1, 3, 6, and 12 months only among MTHFR677 TT mothers.[36]  A 
previous study of autism reported an interaction between maternal, but not child MTHFR677, and 
prenatal vitamin use. [17]  Non-use of prenatal vitamins and the A variant allele were associated 
with higher risk.  The prior study also reported interactions for maternal CBS and child COMT 
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variants.  MTHFR677 interactions reported in these previous studies were for maternal rather 
than child genotypes, which we did not observe for either folic acid or vitamin supplementation, 
or dietary folate (Tables A14, A15, and A17).  Differences in interactions between our and 
previous studies could be partially due to differences in outcome constructs, variations in the 
genetics of studied populations, or a reflection of relatively small strata. 
Possible mechanisms 
It has been shown that some children with autism have reduced methylation capacity.[80]  
Dietary nutritional supplementation could influence autism traits through one-carbon metabolism, 
whereby the methyl groups necessary for DNA methylation are derived from dietary methyl 
group intake; folate is the predominant dietary methyl donor.[81, 82]  DNA methylation 
influences gene expression by restricting gene transcription machinery from associating with the 
DNA.[83]  DNA methylation patterns are dependent upon methyl donor availability and the 
proper functioning of one-carbon metabolism, with the latter affected by functional 
polymorphisms in genes involved in folate metabolism.  For instance, carriers of the MTHFR 
C677T and A1298C polymorphisms have lower enzyme activity, reducing the ability of folate to 
function as a methyl donor[84]. 
Future work 
Our findings suggest that maternal folic acid and vitamin supplementation may be related 
to sub-components of autism such as language development and cognition, and may depend upon 
genes involved in folate metabolism, specifically child MTHFR677.  Further investigation is 
warranted to disentangle these complex relationships in large population-based samples and 
randomized controlled trials.   This requires careful consideration of multiple determinants of 
maternal nutritional status including supplementary and dietary intake, biological measurement of 
folate and homocysteine (a marker of functional folate status) in the peri-conceptional period and 
throughout pregnancy, and robust interaction assessment of genes involved in one-carbon 
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metabolism.
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Figure 3. ALSPAC sample derivation 
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Table 6. Selected gene characteristics and allelic frequencies of the ALSPAC genetic sample by child autism status 
Maternal frequency (%) Child frequency (%) 
Gene SNP Chromosome Position Allele 
Autism 
N = 65 
No autism 
N = 4832 
Autism 
N = 65 
No autism 
N = 4832 
Published allele 
frequency in 
Caucasian 
populations 
MTHFR 677 rs1801133 1 11796321 T 26 34 31 33 31-35[17, 66, 85, 86] 
MTHFR 1298 rs1801131 1 11794419 C 32 32 34 31 34[86] 
MTR rs1805087 1 236885200 G 25 19 22 19 16[86] 
MTRR rs1801394 5 7870860 G 55 54 55 56 45-52[17, 86] 
BHMT rs3733890 5 79126136 A 19 29 25 29 28-32[17, 86] 
FOLR1 rs2071010 11 72189920 A 9 6 6 6 9[86] 
CBS rs234715 21 43068285 T 27 25 31 25 22-24[17, 86] 
COMT rs4680 22 19963748 A 46 51 52 52 43-48[17, 86] 
TCN2 rs1801198 22 30615623 G 42 45 49 45 43-47[17, 86] 
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Table 7. Selected characteristics of the ALSPAC samples by maternal supplementation 
 
Supplementation 
(n = 11,741) 
Genotype  
(n = 4897) 
Supplement use Any  None Any  None 
Characteristics 3800 (32.4) 7941 (67.6) 1501 (30.6) 3396 (69.4) 
Supplement use     
   Folic acid 1021 (8.7) 0 (0.0) 416 (8.5) 0 (0.0) 
   Iron 2540 (21.6) 0 (0.0) 944 (19.3) 0 (0.0) 
   Vitamins 1936 (16.5) 0 (0.0) 838 (17.1) 0 (0.0) 
Sex of child – male 1919 (50.5) 4124 (51.9) 706 (47.0) 1698 (50.0) 
Parity     
First child 1691 (44.5) 3502 (44.1) 697 (46.4) 1555 (45.8) 
Second child 1272 (33.5) 2778 (35.0) 517 (34.4) 1212 (35.7) 
Third child and higher 763 (20.1) 1535 (19.3) 264 (17.6) 597 (17.6) 
Missing 74 (2.0) 126 (1.6) 23 (1.5) 32 (0.9) 
Maternal education      
≥ 12 yrs 1447 (38.1) 2648 (33.4) 738 (49.2) 1384 (40.8) 
Missing 209 (5.5) 333 (4.2) 46 (3.1) 84 (2.5) 
Maternal age, mean (SD) 28.3 (5.0) 28.3 (4.8) 29.1 (4.8) 29.0 (4.5) 
Maternal smoking - yes 930 (24.5) 1862 (23.5) 302 (20.1) 631 (18.6) 
Maternal body mass index     
Underweight (BMI < 18.5) 201 (5.3) 307 (3.9) 76 (5.1) 114 (3.4) 
Normal (18.5 ≤ BMI < 25) 2553 (67.2) 5208 (65.6) 1061 (70.7) 2340 (68.9) 
Overweight (25 ≤ BMI < 30) 413 (10.9) 1172 (14.8) 159 (10.6) 487 (14.3) 
Obese (BMI ≥30) 151 (4.0) 419 (5.3) 64 (4.3) 170 (5.0) 
Missing 482 (12.7) 835 (10.5) 141 (9.4) 285 (9.4) 
Maternal antidepressant use     
Yes 46 (1.2) 60 (0.8) 15 (1.0) 14 (0.4) 
Missing 31 (0.8) 26 (0.3) 6 (0.4) 8 (0.2) 
Depression     
Yes 383 (10.1) 607 (7.6) 129 (8.6) 223 (6.6) 
Missing 199 (5.2) 317 (4.0) 45 (3.0) 86 (2.5) 
Other psych disorders     
Yes 83 (2.2) 178 (2.2) 29 (1.9) 68 (2.0) 
Missing 199 (5.2) 317 (4.0) 45 (3.0) 86 (2.5) 
 
 
119 
 
 
119 
 
 
 
Table 7 (continued). Selected characteristics of the ALSPAC samples by maternal 
supplementation 
 
Supplementation 
(n = 11,741) 
Genotype  
(n = 4897) 
Supplement use Any  None Any  None 
Characteristics 3800 (32.4) 7941 (67.6) 1501 (30.6) 3396 (69.4) 
Autism 53 (1.4) 88 (1.1) 21 (1.4) 44 (1.3) 
Continuous outcomes, mean (SD)     
   Factor mean score -0.0003 (0.38) 0.011 (0.37) 0.044 (0.34) 0.035 (0.35) 
   Repetitive stereotyped behavior -0.037 (0.96) 0.029 (0.92) 0.0073 (0.90) 0.039 (0.86) 
   Social understanding -0.024 (0.95) 0.012 (0.94) -0.0006 (0.97) 0.039 (0.96) 
   Verbal ability 0.027 (0.96) 0.0096 (0.95) 0.12 (0.71) 0.077 (0.84) 
   Social inhibition 0.0066 (0.93) 0.0038 (0.91) 0.027 (0.99) 0.015 (0.94) 
   Semantic pragmatic skills 0.041 (0.92) 0.0061 (0.93) 0.18 (0.94) 0.10 (0.95) 
   Articulation -0.043 (0.92) 0.021 (0.90) -0.076 (0.96) -0.0029 (0.94) 
   Language acquisition 0.027 (0.96) -0.0056 (0.98) 0.047 (0.94) -0.023 (0.96) 
   IQ 105 (16) 104 (16) 107 (16) 105 (16) 
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Table 8.  Unadjusted relationshipsa between nutrient supplementation and dietary folate for factor scoresb and IQd 
 Supplementation Dietary folate intake 
Outcome Folic acid Vitamins Iron 200 - < 300 µg ≥ 300 µg 
FM 0.1 (0.76) 0.2 (0.34) -0.6 (0.01) 0.8 (<.0001) 0.9 (0.0001) 
RSB -0.1 (0.48) -0.5 (<.0001) -0.1 (0.39) 0.0 (0.64) -0.3 (0.02) 
SU -0.5 (0.20) -0.7 (0.01) 0.1 (0.60) 0.5 (0.02) 0.7 (0.02) 
VA 0.4 (0.08) 0.5 (0.0003) -0.4 (0.004) 0.3 (0.02) 0.2 (0.19) 
SI 0.3 (0.50) 0.2 (0.39) -0.2 (0.46) 0.1 (0.74) -0.5 (0.08) 
SPS 1.6 (<.0001) 1.3 (<.0001) -0.8 (0.005) 1.9 (<.0001) 2.3 (<.0001) 
A -1.3 (0.001) -0.9 (0.001) 0.0 (0.91) -0.8 (0.0004) -1.3 (<.0001) 
LA -0.3 (0.64) 1.0 (0.01) -0.1 (0.71) 0.4 (0.19) 2.5 (<.0001) 
IQ 4.0 <(.0001) 3.0 (<.0001) -2.1 (0.001) 2.8 (<.0001) 3.6 (<.0001) 
a β (p-value); Models include supplements (iron, folic acid, and vitamins) and dietary folate intake; associations p < 0.05 are 
bolded 
b β estimate indicates percentage change in factor score (higher scores reflect higher abilities); RSB – repetitive stereotyped 
behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic 
pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
d β estimate indicates change in IQ points 
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Table 9. Adjusted relationshipsa between nutrient supplementation and dietary folate for factor scoresb and IQd 
 Supplementation Dietary folate intake 
Outcome Folic acid Vitamins Iron 200 - < 300 µg ≥ 300 µg 
FM -0.2 (0.49) -0.1 (0.61) -0.4 (0.10) 0.4 (0.03) 0.4 (0.10) 
RSB -0.1 (0.53) -0.4 (0.0002) -0.1 (0.31) 0.0 (0.69) -0.3 (0.03) 
SU -0.5 (0.24) -0.6 (0.04) 0.1 (0.83) 0.5 (0.03) 0.7 (0.02) 
VA 0.2 (0.45) 0.3 (0.04) -0.3 (0.07) 0.1 (0.47) -0.1 (0.54) 
SI 0.3 (0.44) 0.2 (0.50) -0.3 (0.39) 0.1 (0.67) -0.5 (0.09) 
SPS 0.4 (0.31) 0.3 (0.17) -0.1 (0.82) 0.6 (0.002) 0.5 (0.03) 
A -1.1 (0.01) -0.7 (0.01) 0.0 (0.98) -0.5 (0.04) -0.8 (0.01) 
LA 0.1 (0.93) 1.0 (0.01) -0.3 (0.47) 0.7 (0.04) 2.9 (<.0001) 
IQ 2.0 (0.01) 1.2 (0.02) -0.9 (0.14) 0.8 (0.10) 0.8 (0.15) 
a β (p-value); Models include supplements (iron, folic acid, and vitamins), dietary folate intake, maternal age, parity, and 
education; associations p < 0.05 are bolded 
b β estimate indicates percentage change in factor score (higher scores reflect higher abilities); RSB – repetitive stereotyped 
behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic 
pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
d β estimate indicates change in IQ points 
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Table 10. Mean IQ by maternal folic acid supplementation and child MTHFR677 genotype 
Vitamin use 
Genotype 
FA+ FA- 
MTHFR677 GG 105.5 (ref) 101.6 (0.007) 
MTHFR677 AG 102.9 (ref) 102.2 (0.67) 
MTHFR677 AA 99.5 (ref) 101.1 (0.55) 
a Model includes iron, folic acid, vitamins, child MTHFR677 genotype, vitamin-SNP interaction, folic acid-
SNP interaction, maternal age, parity, and education 
 
Figure 4. Mean IQ by maternal folic acid supplementation and child MTHFR677 genotype 
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Table 11. Mean IQ by maternal dietary folate intake and child MTHFR677 genotype 
Daily intake 
Genotype 
> 300 µg 200-<300 µg < 200 µg 
MTHFR677 GG 102.3 (ref) 101.0 (0.17) 99.1 (0.006) 
MTHFR677 AG 100.8 (ref) 100.7 (0.94) 101.5 (0.51) 
MTHFR677 AA 99.8 (ref) 100.2 (0.85) 99.6 (0.91) 
a Model includes iron, folic acid, vitamins, dietary folate, child MTHFR677 genotype, dietary folate-
maternal CBS interaction, maternal age, parity, and education 
 
Figure 5. Mean IQ by maternal dietary folate intake and child MTHFR677 genotype 
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APPENDIX 4: Supplementary Tables and Figures
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Table A7. Enzyme functions of genes in folate metabolism  
Abbreviation Gene Enzyme function 
MTHFR Methylene tetrahydrofolate reductase 
 
Regulates folate availability 
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate 
MTR  5-Methyltetrahydrofolate-Homocysteine 
Methyltransferase  
Converts homocysteine to methionine 
MTRR 5-Methyltetrahydrofolate-Homocysteine 
Methyltransferase Reductase 
Regenerates methionine synthase to convert S-adenosylhomocysteine 
(SAH) into S-adenosylmethionine (SAM) with B12 
BHMT Betaine-Homocysteine S-
Methyltransferase 
Catalyzes the conversion of betaine and homocysteine to 
dimethylglycine and methionine, respectively 
FOLR1 
 
Folate receptor 1 
 
Transports 5-methyltetrahydrofolate into cells 
CBS Cystathionine B synthase Catalyzes the conversion of homocysteine (with B6) to cystathionine, 
permanently removing homocysteine from the methionine pathway 
COMT Catechol-O-Methyltransferase Catalyzes the transfer of a methyl group from SAM to catecholamines, 
and thereby the inactivation, of catecholamine neurotransmitters and 
catechol hormones 
TCN2  Transcobalamin II  Binds cobalamin in the portal circulation and mediates the transport of 
cobalamin into cells 
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Table A8. Individual measures used to derive factor scores in ALSPAC  
Age1 Measure Age1 Measure 
6, 18 DDST - Communication Combines words 
6, 18, 30, 42 Pretend play Empathy 
CDI - gestures Musical 
CDI - imitates words 
57, 69, 81 
Pronouncing certain sounds 
CDI - objects 81 Nonverbal communication 
CDI - response to language DAWBA - Compulsions score 
15 
CDI - understand score DAWBA - Number compulsions 
15, 24, 38 CDI - vocabulary DAWBA - Social fears 
18, 30, 42, 57, 69, 77 Repetitive behavior DAWBA - Tics or twitches 
CDI - combines words 
91 
SCDC 
CDI - grammar (irregular) Nonword repetition 24, 38 
CDI - grammar (regular) WISC - verbal IQ 
38 CDI - complexity WOLD - comprehension 
38, 57, 69 EAS - Sociability 
8y 
WOLD - oral expression 
Avoids eye contact CCC - coherence 
Communication CCC - conversational context 
Echoes what said CCC - conversational rapport 
Intelligibility CCC - inappropriate initiation 
Prefers gestures CCC - intelligibility & fluency 
Stays mainly silent CCC - stereotyped conversation 
38, 57, 69, 81 
Stumbles on words CCC - syntax score 
42 Rutter Prosocial 
9y 
DANVA - faces 
47, 81, 97, 9y SDQ Prosocial   
1 Age is designated in months unless otherwise indicated (y: years) 
DDST: Denver Developmental Screening test, CDI: MacArthur Infant Communicative development 
inventories (words and gestures), EAS: Emotionality Activity Sociability, SDQ: Strengths and Difficulties 
Questionnaire, DAWBA: Development and Well-Being Assessment, WISC: Wechsler Intelligence Scale 
for Children, WOLD: Wold sentence copying test, WISC: Wechsler Intelligence Scale for Children, CCC: 
Children’s communication checklist, DANVA: Diagnostic Analysis of Nonverbal Accuracy 
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Table A9. Language factors: individual measures with factor loadings ≥ 0.50 
Language acquisition Articulation 
DDST – Communication (18m) Pronouncing certain sounds  
CDI – understand score (15m)    (57, 69, 81m) 
CDI – imitates words (15m)  
CDI – gestures (15m)  
CDI – objects (15m)  
CDI – vocabulary (15, 24m)  
CDI – grammar (regular) (24m)  
CDI – grammar (irregular) 
(24m) 
 
CDI – combines words (24m)  
DDST: Denver Developmental Screening test, CDI: MacArthur Infant Communicative development 
inventories (words and gestures), WOLD: Wold sentence copying test, WISC: Wechsler Intelligence Scale 
for Children, CCC: Children’s communication checklist, 
 
Language acquisition was derived most heavily from the Denver Developmental Screening Test (DDST) 
communication score and multiple elements of the MacArthur Infant Communicative Development 
Inventory (CDI).  Articulation was predominantly based on the “pronouncing certain sounds” measure.  
This was a question that related to certain sounds such as th, sss or t .{Steer, 2010 #186} Of the individual 
measures indicated here, Wold oral expression and WISC verbal IQ were assessed by trained personnel or 
involved computerized data entry, while the others were based on mailed questionnaires completed by the 
primary caregiver.
128 
 
 
 
 
 
Table A10. Selected characteristics of the ALSPAC 
supplementation sample (n = 11,741) by IQ availability 
IQ data Yes No 
Characteristics 6633 (56.5) 5108 (43.5) 
Supplement use   
   Folic acid 600 (9.1) 421 (8.2) 
   Iron* 1335 (20.1) 1205 (23.6) 
   Vitamins* 1157 (17.4) 779 (15.3) 
Sex of child – male* 3300 (49.8) 2742 (53.7) 
Parity*   
First child 3051 (46.0) 2142 (41.9) 
Second child 2322 (35.0) 1728 (33.8) 
Third child and higher 1164 (17.6) 1134 (22.2) 
Missing 96 (1.5) 104 (2.0) 
Maternal education*   
≥ 12 yrs 2828 (42.6) 1267 (24.8) 
Missing 172 (2.6) 370 (7.2) 
Maternal age, mean (SD)* 29.2 (4.5) 27.2 (5.0) 
Maternal smoking – yes* 1187 (17.9) 1605 (31.4) 
Maternal body mass index*   
Underweight (BMI < 18.5) 264 (4.0) 244 (4.8) 
Normal (18.5 ≤ BMI < 25) 4597 (69.3) 3164 (61.9) 
Overweight (25 ≤ BMI < 30) 900 (13.6) 685 (13.4) 
Obese (BMI ≥30) 311 (4.7) 259 (5.1) 
Missing 561 (8.5) 756 (14.8) 
Maternal antidepressant use*   
Yes 31 (0.5) 72 (1.4) 
Missing 27 (0.4) 30 (0.6) 
Depression   
Yes 460 (6.9) 530 (10.4) 
Missing 149 (2.3) 367 (7.2) 
Other psych disorders - yes 152 (2.3) 109 (2.3) 
Autism 69 (1.0) 72 (1.4) 
Continuous outcomes, mean (SD)   
   Factor mean score* 0.040 (0.33) -0.036 (0.41) 
   Repetitive stereotyped behavior* 0.036 (0.88) -0.029 (1.0) 
   Social understanding 0.0065 (0.99) -0.0072 (0.88) 
   Verbal ability* 0.11 (0.69) -0.11 (1.20) 
   Social inhibition 0.011 (0.96) -0.0037 (0.86) 
   Semantic pragmatic skills* 0.13 (0.96) -0.13 (0.85) 
   Articulation -0.0087 (0.96) 0.011 (0.82) 
   Language acquisition -0.0091 (0.97) 0.023 (0.98) 
* Chi-square test produced p < 0.05
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Table A11. Relationshipsa between dietary folate intake and nutrient supplementation for factor scoresb and IQc 
Daily folate intake FM RSB SU VA SI SPS A LA IQ 
 < 200 µg  (Ref)          
 200 - < 300 µg 0.41 -0.04 0.52 0.08 0.10 0.63 -0.48 0.66 0.77 
 ≥ 300 µg 0.39 -0.26 0.68 -0.09 -0.51 0.54 -0.78 2.85 0.82 
Supplement          
 Folic acid -0.23 -0.11 -0.48 0.15 0.33 0.36 -1.09 0.05 2.03 
 Vitamins -0.11 -0.43 -0.55 0.28 0.19 0.33 -0.67 1.04 1.21 
 Iron -0.38 -0.12 0.06 -0.26 -0.26 -0.06 -0.01 -0.29 -0.86 
a Models include supplements (iron, folic acid, and vitamins), dietary folate intake, maternal age, parity, and education; associations p 
< 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk 
b β estimate indicates percentage change in factor score associated with each risk allele (higher scores reflect higher abilities); RSB – 
repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – 
semantic pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
c β estimate indicates change in IQ points associated with each risk allele
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Table A12. Relationshipsa between nutrient supplementation for autismb, factor scoresc, and IQd 
Supplement FM RSB SU VA SI SPS A LA IQ 
Folic acid -0.10 -0.08 -0.55 0.23 0.40 0.50 -0.99 0.05 1.91 
Vitamins 0.07 -0.41 -0.46 0.31 0.21 0.48 -0.57 1.22 1.26 
Iron -0.47 -0.13 0.08 -0.28 -0.37 -0.11 0.00 -0.44 -0.61 
a Models include supplements (iron, folic acid, and vitamins), dietary folate intake, maternal age, parity, and 
education; associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk 
b Odds ratio estimate 
c β estimate indicates percentage change in factor score associated with supplement use (higher scores reflect 
higher abilities); RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, 
VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – 
intellectual quotient, LA- language acquisition 
d β estimate indicates change in IQ points associated with supplement use 
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Table A13. Relationshipsa between variant alleles in folate metabolism and factor scoresb and IQc 
 
a Unadjusted associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; blank cells have at least one 
cell count < 5 
b β estimate indicates percentage change in factor score associated with each risk allele (higher scores reflect higher abilities); 
RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social 
inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
c β estimate indicates change in IQ points associated with each risk allele
Person Variant FM RSB SU VA SI SPS A LA IQ 
BHMT A -0.14 -0.06 0.16 -0.12 -0.01 0.16 -0.03 -0.55 0.87 
CBS T 0.04 -0.11 0.34 -0.11 -0.13 0.03 0.12 0.32 -0.19 
COMT A 0.12 -0.09 -0.28 0.21 0.39 -0.05 0.21 -0.07 0.60 
FOLR1 
AG+AA 
0.29 0.34 0.49 0.11 -1.11 1.18 0.49 -1.61 1.12 
MTHFR1298 
G 
-0.17 0.10 -0.13 -0.06 -0.30 0.00 -0.11 -0.21 0.02 
MTHFR677 A 0.06 -0.08 0.04 -0.12 0.26 0.09 -0.14 0.51 0.02 
MTR G 0.19 0.06 0.17 -0.13 -0.02 0.26 0.70 -0.48 0.04 
MTRR G 0.29 0.12 0.11 0.08 0.43 0.33 -0.29 -0.05 -0.27 
Child 
TCN2 C 0.26 0.02 -0.08 0.05 0.12 0.23 0.21 0.34 0.05 
BHMT A 0.17 0.08 0.04 -0.17 0.54 0.23 0.03 -0.13 0.44 
CBS T -0.03 -0.09 0.14 -0.07 0.23 -0.41 -0.05 0.50 -0.54 
COMT A 0.03 0.02 0.15 0.02 0.46 -0.17 -0.25 -0.19 -0.11 
FOLR1 
AG+AA 
0.26 0.40 -0.29 0.07 -0.39 0.54 0.07 -0.26 0.91 
MTHFR1298 
G 
-0.16 0.03 0.06 -0.11 -0.27 0.13 -0.28 -0.04 -0.18 
MTHFR677 A 0.33 0.08 -0.05 0.01 0.37 0.13 0.20 0.39 0.41 
MTR G 0.24 0.05 0.25 -0.21 -0.04 0.21 0.58 0.10 0.50 
MTRR G 0.17 0.06 -0.07 0.00 0.01 0.29 -0.04 0.28 0.09 
Mother 
TCN2 C 0.08 -0.07 -0.24 0.00 -0.08 0.20 0.09 0.61 0.27 
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Table A14.  Interactionsa between folic acid supplementation and genetic variants in folate metabolism for factor scoresb and IQc 
Person Variant FM RSB SU VA SI SPS A LA IQ 
BHMT A -0.94 -0.46 0.54 -0.11 -2.24 0.94 -0.33 -1.28 2.83 
CBS T 1.39 0.08 1.75 -0.57 1.85 0.63 0.63 1.16 -0.66 
COMT A -1.13 -0.56 -0.94 0.15 0.30 -0.71 0.26 -2.25 -1.36 
FOLR1 AG+AAd 0.91 0.11 -0.11 -0.22 2.41 -0.64 3.76 -2.63 -0.81 
MTHFR1298 G -0.10 -0.11 0.49 -0.05 -0.84 0.54 0.13 -0.50 -0.70 
MTHFR677 A 0.33 -0.21 -1.34 0.55 -1.02 1.72 0.38 0.88 2.74 
MTR G -0.24 0.23 -1.43 -0.63 -0.65 0.19 1.31 0.67 -0.96 
MTRR G -0.92 0.19 -0.56 -0.13 -1.59 -0.33 -0.62 -0.37 -0.71 
Child 
TCN2 C -1.02 -0.28 0.80 -0.41 -1.52 -0.97 -0.82 0.64 -0.66 
BHMT A 0.01 -0.81 1.13 0.17 -0.08 1.61 -1.09 -0.13 3.12 
CBS T 1.09 0.02 1.51 -0.59 0.16 0.21 1.48 1.99 0.53 
COMT A -0.54 -0.55 0.33 0.12 -0.39 0.29 -0.37 -0.91 -0.31 
FOLR1 AG+AAd 0.24 0.30 -0.36 -0.15 1.55 -0.18 2.18 -3.60 0.24 
MTHFR1298 G -0.34 0.20 0.46 -0.28 -1.00 0.38 -0.08 -1.25 1.87 
MTHFR677 A -0.26 -0.29 -1.86 0.32 -0.62 0.98 -0.69 1.73 1.20 
MTR G -0.30 0.01 -0.23 -0.76 -0.78 1.13 1.13 -1.10 0.69 
MTRR G -0.96 0.34 -0.68 -0.40 -1.47 0.74 -1.22 -0.94 0.75 
Mother 
TCN2 C -0.44 0.10 0.02 -0.09 -1.36 0.03 -0.66 0.47 0.50 
a Associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include iron, folic acid, vitamins, SNP, folic acid-SNP 
interaction, vitamin-SNP interaction, maternal age, parity, and education 
b β estimate indicates the difference in the percentage change in the average factor score per variant allele whose mothers did not supplement compared to those 
whose mothers did supplement (based on a common contrast to the average factor score for maternal non-supplementers with wild-type alleles); RSB – repetitive 
stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – 
articulation, IQ – intellectual quotient, LA- language acquisition (higher scores reflect higher abilities) 
c β estimate indicates the difference in the average IQ per variant allele whose mothers did not supplement compared to those whose mothers did supplement 
(based on a common contrast to the average IQ for maternal non-supplementers with wild-type alleles) 
d FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous individuals.
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Table A15. Interactionsa between vitamin supplementation and genetic variants in folate metabolism for factor scoresb and IQc 
Person Variant FM RSB SU VA SI SPS A LA IQ 
BHMT A -0.24 -0.18 -0.47 -0.05 0.64 0.24 0.45 -1.49 -1.94 
CBS T -0.26 0.29 -0.95 0.33 0.37 -0.65 -0.15 -1.04 -1.78 
COMT A 1.18 0.16 0.80 -0.03 0.85 0.78 1.04 0.28 1.43 
FOLR1 AG+AAd -0.34 -0.19 1.19 0.36 0.09 0.34 -1.06 -2.76 -0.15 
MTHFR1298 G -0.92 0.00 -0.96 0.10 0.33 -0.73 -1.09 -1.07 -0.65 
MTHFR677 A 0.56 -0.13 -0.43 -0.15 0.20 0.26 1.39 1.49 0.70 
MTR G 0.58 -0.21 0.61 0.18 0.51 0.26 -0.10 1.10 0.25 
MTRR G 0.67 -0.01 0.82 0.30 -0.11 -0.04 0.63 0.48 1.17 
Child 
TCN2 C -0.33 -0.10 -0.93 -0.04 0.67 -0.56 0.48 -0.52 -1.43 
BHMT A -0.89 -0.10 -0.88 -0.03 0.10 -0.63 -0.62 -0.88 -2.32 
CBS T -0.90 -0.02 -1.00 0.27 -0.52 -1.03 0.03 -1.34 -1.78 
COMT A 0.53 -0.09 0.28 -0.13 0.26 0.27 0.98 0.66 0.47 
FOLR1 AG+AAd 0.12 -0.38 1.23 0.02 1.25 -0.23 0.12 -1.43 -1.89 
MTHFR1298 G -0.32 0.00 -0.83 -0.13 0.62 -0.11 -1.00 0.70 0.11 
MTHFR677 A 0.59 0.21 0.86 0.09 0.10 0.53 0.01 -0.28 0.15 
MTR G 0.51 -0.14 1.00 0.32 0.35 0.28 -0.43 0.24 -0.74 
MTRR G -0.52 -0.44 -0.07 -0.13 -0.20 -0.69 0.04 0.62 -1.25 
Mother 
TCN2 C -0.25 -0.04 -0.62 -0.10 0.36 0.01 -0.01 -0.32 -0.82 
a Associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include iron, folic acid, vitamins, SNP, folic acid-SNP 
interaction, vitamin-SNP interaction, maternal age, parity, and education 
b β estimate indicates the difference in the percentage change in the average factor score per variant allele whose mothers did not supplement compared to those 
whose mothers did supplement (based on a common contrast to the average factor score for maternal non-supplementers with wild-type alleles); RSB – repetitive 
stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – 
articulation, IQ – intellectual quotient, LA- language acquisition (higher scores reflect higher abilities) 
c β estimate indicates the difference in the average IQ per variant allele whose mothers did not supplement compared to those whose mothers did supplement 
(based on a common contrast to the average IQ for maternal non-supplementers with wild-type alleles) 
d FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous individuals.
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Table A16. Interactionsa between dietary folate and child genetic variants in folate metabolism and factor scoresb and IQc 
Person SNP Variable FM RSB SU VA SI SPS A LA IQ 
< 200 µg 0.67 0.46 0.51 -0.15 0.52 0.62 0.39 -0.77 0.71 BHMT A 200 -<300 µg 0.80 0.20 0.77 -0.22 0.82 0.78 0.63 -0.39 -0.32 
< 200 µg -0.14 -0.39 -0.53 0.89 0.23 0.22 -1.44 0.23 2.28 CBS T 200 -<300 µg -0.04 -0.11 -0.05 0.03 -0.75 0.37 -0.40 1.15 0.52 
< 200 µg -0.48 -0.19 -0.13 0.11 0.72 0.06 -0.98 -1.43 0.77 COMT A 200 -<300 µg -0.46 -0.10 -0.25 -0.10 -0.70 0.47 -0.69 0.01 1.21 
< 200 µg -0.65 -0.26 -0.58 -0.72 0.51 -1.65 0.53 1.58 -0.77 FOLR1 AG+AAd 200 -<300 µg 0.37 -0.51 -0.11 -0.20 1.75 -1.07 1.54 1.19 1.58 
< 200 µg 0.17 -0.16 -0.25 -0.16 1.22 0.43 -1.53 1.94 -0.10 MTHFR1298 G 200 -<300 µg -0.13 -0.06 -0.36 -0.32 0.62 0.31 -0.86 0.89 0.86 
< 200 µg 0.00 0.03 -0.98 0.29 0.66 -0.12 0.85 -1.30 2.16 MTHFR677 A 200 -<300 µg 0.01 -0.25 -0.60 0.50 0.75 0.01 0.26 -1.00 0.94 
< 200 µg -0.52 -0.45 -0.95 -0.09 -1.21 -0.46 0.55 2.08 -1.16 MTR G 200 -<300 µg -0.41 -0.13 -1.14 -0.46 -0.28 0.07 0.39 1.12 -0.48 
< 200 µg -0.25 -0.29 -0.67 0.28 0.20 -0.76 0.39 0.24 0.56 MTRR G 200 -<300 µg -0.48 -0.27 -0.19 0.23 -1.00 -0.58 0.33 -0.03 0.67 
< 200 µg 0.42 0.25 -1.08 -0.32 0.93 0.65 0.38 0.82 1.26 
Child 
TCN2 C 200 -<300 µg 0.11 0.01 -0.68 -0.34 -0.12 0.67 0.42 0.99 0.10 
a Associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include supplements (iron, folic acid, vitamins), 
dietary folate (ref: ≥ 300 µg/d), SNP (ref: 0 risk variants), dietary folate-SNP interactions, maternal age, parity, and education 
b β estimate indicates the difference in the percentage change in the average factor score per variant allele whose mothers did not supplement compared to those 
whose mothers did supplement (based on a common contrast to the average factor score for maternal non-supplementers with wild-type alleles); RSB – repetitive 
stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – 
articulation, IQ – intellectual quotient, LA- language acquisition (higher scores reflect higher abilities) 
c β estimate indicates the difference in the average IQ per variant allele whose mothers did not supplement compared to those whose mothers did supplement 
(based on a common contrast to the average IQ for maternal non-supplementers with wild-type alleles) 
d FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous individuals 
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Table A17. Interactionsa between dietary folate and maternal genetic variants in folate metabolism and factor scoresc and IQd 
Person SNP Variable FM RSB SU VA SI SPS A LA IQ 
< 200 µg -0.30 0.36 -1.36 0.16 0.40 -0.56 -0.19 -0.54 1.62 BHMT A 200 -<300 µg -0.73 0.10 -0.95 -0.03 0.23 -0.41 -0.29 -1.60 0.57 
< 200 µg 0.32 -0.12 -0.35 0.18 0.92 0.77 -1.08 0.99 0.86 CBS T 200 -<300 µg -0.23 0.11 -0.27 -0.33 -0.72 0.62 -1.34 1.67 -0.69 
< 200 µg 0.16 0.13 0.08 0.08 1.09 -0.21 -0.62 -0.27 0.38 COMT A 200 -<300 µg -0.12 0.12 0.32 0.05 -0.17 -0.10 -0.75 -0.13 -0.10 
< 200 µg -0.39 -0.21 1.76 -0.61 0.45 0.05 -0.79 -1.44 -3.41 FOLR1 AG+AAd 200 -<300 µg 0.53 -0.14 0.88 -0.42 -0.04 0.07 0.44 2.16 -1.11 
< 200 µg 0.45 -0.17 -0.49 -0.16 1.70 1.34 -0.22 -0.11 0.74 MTHFR1298 G 200 -<300 µg -0.13 -0.26 0.00 0.13 0.44 0.43 -0.47 -0.68 0.66 
< 200 µg -0.03 -0.04 0.10 0.20 0.17 -1.13 0.28 0.33 0.01 MTHFR677 A 200 -<300 µg -0.41 -0.29 -0.52 0.00 0.92 -0.75 0.16 -0.59 -0.32 
< 200 µg 0.27 -0.11 -0.91 0.14 0.55 -1.10 1.18 1.74 -0.26 MTR G 200 -<300 µg 0.06 0.34 -0.97 -0.48 0.65 -1.08 1.73 0.23 -1.32 
< 200 µg -0.51 0.14 -1.04 0.04 -0.44 -0.07 0.29 -1.15 1.59 MTRR G 200 -<300 µg -0.69 -0.06 -0.62 0.22 -0.57 -0.34 -0.78 -0.48 1.19 
< 200 µg 0.64 0.57 -0.89 -0.01 1.27 -0.14 0.12 0.77 -0.45 
Mother 
TCN2 C 200 -<300 µg 0.16 0.43 -0.53 -0.46 0.38 0.04 -0.41 1.35 0.34 
a Associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include supplements (iron, folic acid, 
vitamins), dietary folate (ref: ≥ 300 µg/d), SNP (ref: 0 risk variants), dietary folate-SNP interactions, maternal age, parity, and education 
b β estimate indicates the difference in the percentage change in the average factor score per variant allele whose mothers did not supplement compared to those 
whose mothers did supplement (based on a common contrast to the average factor score for maternal non-supplementers with wild-type alleles); RSB – repetitive 
stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – 
articulation, IQ – intellectual quotient, LA- language acquisition (higher scores reflect higher abilities) 
c β estimate indicates the difference in the average IQ per variant allele whose mothers did not supplement compared to those whose mothers did supplement 
(based on a common contrast to the average IQ for maternal non-supplementers with wild-type alleles) 
d FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous individuals 
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Table A18.  Unadjusted relationshipsa between nutrient supplementation and dietary folate for factor scoresb and IQd 
 Supplementation Dietary folate intake 
Outcome Folic acid Vitamins Iron 200 - < 300 µg ≥ 300 µg 
FM 1.07 (0.83, 1.38) 0.97 (0.81, 1.15) 1.06 (0.89, 1.28) 0.75 (0.65, 0.87) 0.79 (0.66, 0.95) 
RSB 0.95 (0.74, 1.22) 1.22 (1.03, 1.43) 1.09 (0.91, 1.30) 0.98 (0.84, 1.14) 1.16 (0.97, 1.39) 
SU 1.15 (0.90, 1.47) 1.28 (1.09, 1.51) 0.91 (0.76, 1.09) 0.93 (0.81, 1.08) 0.98 (0.82, 1.17) 
VA 0.83 (0.63, 1.09) 0.64 (0.52, 0.77) 1.20 (1.00, 1.44) 0.79 (0.68, 0.91) 0.78 (0.64, 0.93) 
SI 1.22 (0.96, 1.55) 1.05 (0.89, 1.24) 0.94 (0.79, 1.13) 1.04 (0.90, 1.21) 1.27 (1.07, 1.51) 
SPS 0.70 (0.52, 0.93) 0.82 (0.68, 0.99) 1.13 (0.94, 1.35) 0.79  (0.68, 0.91) 0.70 (0.58, 0.85) 
A 1.44 (1.14, 1.81) 1.30 (1.11, 1.52) 0.92 (0.77, 1.10) 1.12 (0.97, 1.30) 1.31 (1.10, 1.56) 
LA 1.18 (0.92, 1.51) 0.85 (0.71, 1.01) 0.92 (0.77, 1.11) 0.99 (0.86, 1.14) 0.64 (0.53, 0.78) 
IQ 0.50 (0.33, 0.74) 0.72 (0.56, 0.92) 1.32 (1.04, 1.68) 0.82 (0.67, 0.99) 0.80 (0.63, 1.02) 
a Odds ratio (95% confidence interval); Models include supplements (iron, folic acid, and vitamins) and dietary folate intake; 
associations p < 0.05 are bolded 
b β estimate indicates percentage change in factor score (higher scores reflect higher abilities); RSB – repetitive stereotyped 
behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic 
pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
d β estimate indicates change in IQ points 
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Table A19. Adjusted relationshipsa between nutrient supplementation and dietary folate for factor scoresb and IQd 
 Supplementation Dietary folate intake 
Outcome Folic acid Vitamins Iron 200 - < 300 µg ≥ 300 µg 
FM 1.16 (0.90, 1.50) 1.05 (0.88, 1.25) 1.00 (0.84, 1.20) 0.82 (0.71, 0.95) 0.89 (0.74, 1.07) 
RSB 0.94 (0.73, 1.21) 1.19 (1.01, 1.40) 1.11 (0.93, 1.33) 0.98 (0.84, 1.14) 1.16 (0.97, 1.39) 
SU 1.11 (0.87, 1.43) 1.24 (1.05, 1.45) 0.94 (0.78, 1.12) 0.91 (0.79, 1.06) 0.94 (0.79, 1.13) 
VA 0.96 (0.73, 1.26) 0.74 (0.60, 0.90) 1.08 (0.90, 1.29) 0.90 (0.78, 1.04) 0.94 (0.78, 1.14) 
SI 1.16 (0.91, 1.48) 1.03 (0.87, 1.22) 0.97 (0.81, 1.17) 0.99 (0.86, 1.15) 1.20 (1.00, 1.43) 
SPS 0.87 (0.65, 1.16) 0.98 (0.81, 1.19) 0.99 (0.82, 1.19) 0.99 (0.85, 1.14) 0.97 (0.80, 1.18) 
A 1.34 (1.06, 1.69) 1.24 (1.06, 1.46) 0.94 (0.79, 1.13) 1.02 (0.87, 1.18) 1.14 (0.96, 1.37) 
LA 1.13 (0.88, 1.45) 0.85 (0.71, 1.02) 0.94 (0.78, 1.13) 0.96 (0.84, 1.11) 0.61 (0.50, 0.75) 
IQ 0.61 (0.41, 0.92) 0.87 (0.68, 1.12) 1.14 (0.89, 1.45) 1.01 (0.83, 1.24) 1.08 (0.84, 1.38) 
a Odds ratio (95% confidence interval); Models include supplements (iron, folic acid, and 
vitamins), dietary folate intake, maternal age, parity, and education; associations p < 0.05 are 
bolded 
b β estimate indicates percentage change in factor score (higher scores reflect higher abilities); 
RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, 
VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – articulation, 
IQ – intellectual quotient, LA- language acquisition 
d β estimate indicates change in IQ points 
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Table A20. Odds ratiosa between dietary folate intake and nutrient supplementation for factor scoresb, and IQb 
Daily folate intake FM RSB SU VA SI SPS A LA IQ 
 < 200 µg  (Ref)          
 200 - < 300 µg 0.82 0.98 0.91 0.90 0.99 0.99 1.02 0.96 1.01 
 ≥ 300 µg 0.89 1.16 0.94 0.94 1.20 0.97 1.14 0.61 1.08 
Supplement          
 Folic acid 1.16 0.94 1.11 0.96 1.16 0.87 1.34 1.13 0.61 
 Vitamins 1.05 1.19 1.24 0.74 1.03 0.98 1.24 0.85 0.87 
 Iron 1.00 1.11 0.94 1.08 0.97 0.99 0.94 0.94 1.14 
a Models include supplements (iron, folic acid, and vitamins), dietary folate intake, maternal age, parity, and education; 
associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk 
b RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social 
inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition
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Table A21. Odds ratiosa between supplementationb, factor scoresc, and IQe 
Supplement FM RSB SU VA SI SPS A LA IQ 
Folic acid 1.10 0.97 1.11 0.96 1.10 0.82 1.29 1.11 0.66 
Vitamins 1.00 1.18 1.25 0.71 1.03 0.90 1.21 0.85 0.88 
Iron 1.02 1.12 0.91 1.12 1.02 1.00 0.96 0.96 1.10 
a Odds ratio associated with supplementation compared to no supplementation of having a child 
with autism, low factor scores, or low IQ (higher scores reflect higher abilities); associations p < 
0.05 are color-coded and bolded; Red = higher risk, blue = lower risk 
b Supplementation models include iron, folic acid, vitamins, maternal age, parity, and education. 
c RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA 
– verbal ability, SI – social inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – 
intellectual quotient, LA- language acquisition 
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Table A22. Odds ratiosa between variant alleles in folate metabolism and factor scoresb and IQb 
Person Variant FM RSB SU VA SI SPS A LA IQ 
BHMT A 0.95 0.98 0.85 1.07 1.04 1.00 1.00 1.10 1.02 
CBS T 1.10 1.14 0.99 0.95 0.99 0.92 1.04 0.94 0.92 
COMT A 0.94 1.07 1.08 0.91 0.91 0.94 1.01 1.02 1.08 
FOLR1 AG+AA 0.86 0.89 0.77 1.05 1.28 0.66 1.01 1.00 0.99 
MTHFR1298 G 1.06 1.05 1.05 1.05 1.08 0.96 1.02 1.03 1.12 
MTHFR677 A 1.03 1.00 0.98 1.11 0.91 1.06 1.04 0.91 0.91 
MTR G 1.08 0.99 0.97 1.19 1.00 0.97 0.89 1.00 0.97 
MTRR G 0.88 0.91 1.00 0.91 0.90 0.95 1.08 1.04 1.17 
Child 
TCN2 C 0.85 0.95 1.03 0.91 1.04 1.00 0.90 1.06 1.03 
BHMT A 0.88 0.98 0.86 1.05 0.83 1.10 1.02 1.06 1.00 
CBS T 1.12 1.09 1.04 1.01 0.95 1.14 1.06 0.86 0.95 
COMT A 0.95 0.95 0.99 1.02 0.90 1.03 1.09 0.98 1.18 
FOLR1 AG+AA 1.01 0.84 0.91 1.07 1.17 0.80 0.98 1.01 0.88 
MTHFR1298 G 1.12 1.11 1.00 1.11 1.13 0.81 1.07 1.01 1.08 
MTHFR677 A 0.90 0.88 1.06 1.01 0.83 1.08 0.97 0.88 0.86 
MTR G 0.97 0.89 0.95 1.16 0.98 0.94 0.94 0.86 0.91 
MTRR G 0.97 0.95 0.99 0.97 0.94 1.03 1.02 1.08 1.13 
Mother 
TCN2 C 1.01 1.00 1.04 1.00 1.05 1.07 0.94 1.00 1.09 
a Odds ratio associated with a single variant allele (compared to individuals with no variant alleles) of having a child with low 
factor scores or low IQ (higher scores reflect higher abilities); unadjusted associations p < 0.05 are color-coded and bolded; Red 
= higher risk, blue = lower risk; blank cells had at least one cell count < 5 
b RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social 
inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
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Table A23. Odds ratios for interactionsa between folic acid supplementation and genetic variants in folate 
metabolism for factor scoresb and IQb 
Person Variant FM RSB SU VA SI SPS A LA IQ 
BHMT A 1.11 1.37 0.88 0.94 1.20 0.72 1.15 0.66 0.57 
CBS T 0.80 0.83 0.58 1.15 0.68 0.82 0.90 0.59 1.85 
COMT A 1.72 1.95 1.40 1.03 0.91 1.41 0.96 1.66 0.77 
FOLR1 AG+AAc 0.69 0.91 0.47 1.32 0.64 2.41 0.56 1.37 - 
MTHFR1298 G 1.05 1.24 1.28 1.11 1.10 0.95 0.92 1.01 0.79 
MTHFR677 A 1.04 1.25 1.09 1.00 1.37 0.69 1.01 1.15 1.05 
MTR G 0.98 0.90 1.36 1.59 1.61 0.46 0.70 1.18 4.92 
MTRR G 1.60 0.99 0.99 1.20 1.22 1.10 1.14 1.06 0.62 
Child 
TCN2 C 1.27 1.56 0.60 0.95 1.25 1.41 1.00 1.08 1.91 
BHMT A 0.80 1.86 0.78 0.49 0.95 0.79 1.42 0.59 0.75 
CBS T 0.67 1.01 0.67 1.32 0.70 0.54 0.86 0.46 1.18 
COMT A 1.68 1.47 1.13 1.27 1.14 1.02 0.95 0.84 1.09 
FOLR1 AG+AAc 0.87 0.60 0.60 1.51 0.92 0.66 0.77 2.69 0.33 
MTHFR1298 G 1.08 0.97 0.98 1.53 1.17 0.99 0.91 0.88 0.65 
MTHFR677 A 1.25 1.07 1.03 0.72 1.46 0.79 1.17 0.98 3.57 
MTR G 0.80 1.02 1.14 1.29 1.40 0.52 0.70 2.25 2.16 
MTRR G 1.34 0.88 0.92 1.46 1.04 0.56 0.74 0.99 0.34 
Mother 
TCN2 C 1.13 1.04 0.77 0.84 1.41 0.92 1.00 1.00 1.46 
a Odds ratio associated with maternal non-supplementation per single variant allele (compared to individuals with no variant 
alleles whose mothers used supplements) of having a child low factor scores or IQ (higher scores reflect higher abilities); 
associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include iron, folic acid, vitamins, 
SNP, folic acid-SNP interaction, vitamin-SNP interaction, maternal age, parity, and education  
b RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social 
inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
c FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous 
individuals. 
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Table A24. Odds ratios for interactionsa between vitamin supplementation and genetic variants in folate 
metabolism for factor scoresb and IQb 
Person Variant FM RSB SU VA SI SPS A LA IQ 
BHMT A 1.14 1.27 1.01 1.19 1.06 0.85 0.85 1.53 1.55 
CBS T 1.17 0.96 1.46 0.94 0.78 1.19 0.85 1.15 1.15 
COMT A 0.58 0.86 0.82 0.85 0.67 0.73 0.75 1.02 0.98 
FOLR1 AG+AAc 2.23 0.64 0.63 0.44 0.99 0.94 1.28 1.36 0.55 
MTHFR1298 G 1.40 1.25 1.11 0.77 1.05 1.04 1.21 1.24 1.50 
MTHFR677 A 0.85 0.86 1.09 1.29 0.80 0.84 0.80 0.77 0.89 
MTR G 0.81 1.16 0.81 0.78 1.00 0.87 1.09 1.05 0.61 
MTRR G 0.74 0.83 0.77 0.66 0.95 1.25 0.83 0.69 0.69 
Child 
TCN2 C 0.90 0.84 1.27 1.43 0.83 1.06 0.87 1.02 1.30 
BHMT A 1.34 1.21 1.33 1.16 1.06 1.09 1.14 1.56 1.86 
CBS T 1.47 1.05 1.54 1.22 1.00 1.36 0.78 1.10 1.23 
COMT A 0.79 1.11 0.83 0.75 0.83 0.71 0.72 1.15 1.09 
FOLR1 AG+AAc 2.26 1.02 0.67 0.73 0.80 0.69 0.82 0.77 1.48 
MTHFR1298 G 1.17 1.04 1.02 1.00 0.88 1.39 1.18 0.94 0.94 
MTHFR677 A 0.73 0.74 0.87 0.93 0.73 0.83 1.27 1.07 1.15 
MTR G 0.64 1.03 0.76 0.70 1.23 0.68 1.60 1.22 1.00 
MTRR G 1.22 1.30 1.33 1.01 0.96 1.21 0.86 0.83 1.11 
Mother 
TCN2 C 0.83 0.91 1.26 1.63 0.92 0.93 1.08 0.86 1.07 
a Odds ratio associated with maternal non-supplementation per single variant allele (compared to individuals with no 
variant alleles whose mothers used supplements) of having a child low factor scores or IQ (higher scores reflect higher 
abilities); associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include iron, 
folic acid, vitamins, SNP, folic acid-SNP interaction, vitamin-SNP interaction, maternal age, parity, and education 
b RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – 
social inhibition, SPS – semantic pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
c FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of 
homozygous individuals.
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Table A25. Odds ratios for interactionsa between dietary folate and child genetic variants in folate metabolism and factor scoresb and IQb 
Person Variant Dietary folate FM RSB SU VA SI SPS A LA IQ 
< 200 µg 1.03 0.63 0.78 1.02 0.86 0.96 0.74 1.01 0.84 BHMT A 
200 -<300 µg 1.11 0.93 0.75 0.93 0.83 0.93 0.79 1.04 0.84 
< 200 µg 1.20 1.11 1.09 0.50 0.71 1.33 1.03 0.87 0.57 CBS T 
200 -<300 µg 1.10 0.96 0.88 0.83 1.01 1.26 0.92 0.77 0.71 
< 200 µg 1.18 0.76 0.83 1.39 0.92 1.20 1.14 1.40 0.76 COMT A 
200 -<300 µg 1.14 0.75 1.01 1.40 1.20 0.94 1.26 1.03 0.89 
< 200 µg 3.75 1.58 1.09 1.97 1.37 1.22 0.88 0.64 0.34 FOLR1 AG+AA 
200 -<300 µg 2.10 1.28 0.81 1.30 0.96 1.60 0.59 0.59 0.28 
< 200 µg 1.30 0.94 0.96 1.03 1.02 1.01 1.29 0.70 1.07 MTHFR1298 G 
200 -<300 µg 1.11 1.14 0.98 1.13 0.96 1.13 1.25 0.94 1.05 
< 200 µg 0.96 1.15 1.73 1.16 0.67 0.98 0.82 1.38 0.86 MTHFR677 A 
200 -<300 µg 0.99 1.17 1.48 0.97 0.79 0.76 1.03 1.42 0.89 
< 200 µg 1.53 1.28 1.32 1.15 1.53 1.19 0.81 0.56 0.79 MTR G 
200 -<300 µg 1.12 1.06 1.31 1.30 1.15 1.26 1.00 0.58 0.93 
< 200 µg 1.19 1.30 1.00 0.77 1.15 1.18 1.07 0.76 1.41 MTRR G 
200 -<300 µg 1.19 1.41 1.00 0.83 1.22 1.33 0.87 1.00 0.91 
< 200 µg 0.75 0.87 1.45 1.00 0.85 0.93 0.74 0.62 0.88 
Child 
TCN2 C 
200 -<300 µg 0.82 0.94 1.27 0.81 1.02 0.79 0.82 0.57 1.07 
a Odds ratio associated with a single variant allele (compared to individuals with no variant alleles) of having a child with autism, low factor scores, or low IQ 
(higher scores reflect higher abilities); associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include iron, folic acid, 
vitamins, dietary folate (ref: ≥ 300 µg/d), SNP (ref: 0 risk variants), dietary folate-SNP interactions, maternal age, parity, and education 
b RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic 
pragmatic skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
c FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous individuals.
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Table A26. Odds ratios for interactionsa between dietary folate and maternal genetic variants in folate metabolism and factor scoresb and IQb 
Person Variant Dietary folate FM RSB SU VA SI SPS A LA IQ 
< 200 µg 1.27 0.79 1.28 0.67 0.73 1.28 0.89 0.93 0.97 BHMT A 
200 -<300 µg 1.68 1.22 1.21 0.87 0.85 1.16 1.07 1.17 0.96 
< 200 µg 0.96 1.10 1.05 0.76 0.71 0.71 0.97 0.77 0.48 CBS T 
200 -<300 µg 1.30 0.97 0.97 1.11 1.14 0.93 1.23 0.78 0.68 
< 200 µg 0.96 0.74 0.96 1.28 0.74 1.19 0.95 1.08 0.74 COMT A 
200 -<300 µg 1.00 0.67 0.94 1.16 0.98 1.05 1.12 1.04 0.99 
< 200 µg 2.37 1.88 0.48 1.50 1.20 1.16 1.07 1.25 0.71 FOLR1 AG+AA 
200 -<300 µg 1.86 1.47 0.79 1.37 1.58 1.80 0.98 0.82 0.65 
< 200 µg 1.03 0.90 0.88 0.89 0.74 0.70 1.02 0.74 0.69 MTHFR1298 G 
200 -<300 µg 1.04 1.09 1.08 0.78 0.87 1.02 1.08 1.01 0.78 
< 200 µg 1.02 0.89 1.31 0.92 0.77 1.29 0.96 1.28 1.02 MTHFR677 A 
200 -<300 µg 1.28 1.02 1.33 1.09 0.87 1.05 1.06 1.36 1.01 
< 200 µg 0.92 1.06 1.30 1.06 0.95 1.18 0.74 0.73 0.79 MTR G 
200 -<300 µg 0.88 0.76 1.63 1.33 0.85 1.27 0.83 0.91 1.33 
< 200 µg 1.51 0.93 1.22 0.99 1.17 1.14 0.81 1.23 0.99 MTRR G 
200 -<300 µg 1.42 1.20 1.17 0.93 1.06 1.26 1.15 1.01 0.89 
< 200 µg 0.71 0.76 1.40 0.91 0.85 0.78 0.88 0.90 1.01 
Mother 
TCN2 C 
200 -<300 µg 0.86 0.80 1.37 1.12 0.94 0.88 1.27 0.77 1.11 
a Odds ratio associated with a single variant allele (compared to individuals with no variant alleles) of having a child with autism, low factor scores, or low IQ 
(higher scores reflect higher abilities); associations p < 0.05 are color-coded and bolded; Red = higher risk, blue = lower risk; models include iron, folic acid, 
vitamins, dietary folate (ref: ≥ 300 µg/d), SNP (ref: 0 risk variants), dietary folate-SNP interactions, maternal age, parity, and education 
b RSB – repetitive stereotyped behavior, FM – factor mean score, SU – social understanding, VA – verbal ability, SI – social inhibition, SPS – semantic pragmatic 
skills, A – articulation, IQ – intellectual quotient, LA- language acquisition 
c FOLR1 estimates are calculated for homozygous AA and heterozygous AG combined due to small numbers of homozygous individuals.  
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APPENDIX 5: Autism supplement 
148 
 
 
148 
Outcome definition 
Autism 
Several sources were combined to identify individuals with autism in the ALSPAC 
cohort.  The Bristol Child Health computer system data was searched for individuals who had 
special education needs.  With parental permission, medical and community child-health records 
were searched to identify autism cases.  A consultant pediatrician confirmed that diagnostic 
information from medical records was consistent with ICD-10 criteria (World Health 
Organization’s International Statistical Classification of Diseases and Related Health Problems, 
Tenth Revision).  Additional sources included text responses to any question on diagnoses given 
to the child in questionnaires (6 months – 11 years), the mother’s answer to the question “Have 
you ever been told that your child has autism, Asperger’s syndrome or autistic spectrum 
disorder?” (9 years), classification by the educational system as requiring special educational 
needs due to ASD (16 years), and ad hoc letters from parents to the Study Director. A validation 
exercise was carried out using maternal responses to the ALSPAC questionnaire at 91 months,[1] 
with screening questions designed to identify an autism spectrum disorder.  All individuals 
identified had been previously identified.  
 
Statistical methods 
Statistical methods were similar to those detailed for cut-point models in the main text.  
Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CI) 
for autism.  Comparisons with cell counts less than 5 were not calculated; this excluded all autism 
interaction comparisons. 
Adjusted models included the following potential confounders: maternal age at child’s 
birth, education, and parity.  Further adjustment for child’s sex, pre-pregnancy body mass index 
(BMI) category, smoking status, anti-depressant use during pregnancy, severe depression, and 
other psychiatric conditions in main effects models changed supplementation estimates less than 
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1% of autism odds ratios, so they were not included in final adjusted models. 
 
Results 
Prevalences of child autism were 161 cases/11,741 in the supplementation sample and 65 
cases/4897 in the genetic sample.  There was no strong evidence of relationships between folic 
acid, vitamins, or iron and autism. 
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Table A27. Selected characteristics of the ALSPAC samples by autism 
 
Supplementation  
(n = 11,741) 
Genotype  
(n = 4897) 
 autism No autism autism No autism 
Characteristics 141 (1.2) 11600 (98.8) 65 (1.3) 4832 (98.7) 
Supplement use     
   Folic acid 18 (12.8) 1003 (8.7) 9 (13.9) 407 (8.4) 
   Iron 36 (25.5) 2504 (21.6) 16 (24.6) 928 (19.2) 
   Vitamins 28 (19.9) 1908 (16.5) 11 (16.9) 827 (17.1) 
Sex of child – male 115 (81.6) 5928 (51.1) 52 (80.0) 2352 (48.7) 
Parity     
First child 62 (44.0) 5131 (44.2) 31 (47.7) 2221 (46.0) 
Second child 52 (36.9) 3998 (34.5) 25 (38.5) 1704 (35.3) 
Third child and higher 25 (17.7) 2273 (19.6) 9 (13.9) 852 (17.6) 
Missing 2 (1.4) 198 (1.7) 0 (0.0) 55 (1.1) 
Maternal education      
≥ 12 yrs 61 (43.3) 4034 (34.8) 33 (50.8) 2089 (43.2) 
Missing 2 (1.4) 540 (4.7) 1 (1.5) 129 (2.7) 
Maternal age, mean (SD) 29.5 (4.6) 28.3 (4.9) 29.7 (4.4) 29.1 (4.6) 
Maternal smoking - yes 25 (17.7) 2767 (23.9) 12 (18.5) 921 (19.1) 
Maternal body mass index     
Underweight (BMI < 18.5) 8 (5.7) 500 (4.3) 4 (6.2) 186 (3.9) 
Normal (18.5 ≤ BMI < 25) 97 (68.8) 7664 (66.1) 43 (66.2) 3358 (69.5) 
Overweight (25 ≤ BMI < 30) 14 (9.9) 1571 (13.5) 3 (4.6) 643 (13.3) 
Obese (BMI ≥30) 7 (5.0) 563 (4.9) 5 (7.7) 229 (4.7) 
Missing 15 (10.6) 1302 (11.2) 10 (15.4) 416 (8.6) 
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Table A27 (continued). Selected characteristics of the ALSPAC samples by ASD 
 Supplementation  (n = 11,741) 
Genotype  
(n = 4897) 
 ASD No ASD ASD No ASD 
Characteristics 141 (1.2) 11600 (98.8) 65 (1.3) 4832 (98.7) 
Maternal antidepressant use     
Yes 3 (2.1) 103 (0.9) 2 (3.1) 27 (0.6) 
Missing 1 (0.7) 56 (0.5) 1 (1.5) 13 (0.3) 
Depression     
Yes 11 (7.8) 979 (8.4) 7 (10.8) 345 (7.1) 
Missing 3 (2.1) 513 (4.4) 3 (4.6) 128 (2.7) 
Other psych disorders     
Yes 5 (3.6) 256 (2.2) 3 (4.6) 94 (2.0) 
Missing 3 (2.1) 513 (4.4) 3 (4.6) 128 (2.7) 
Outcomes     
Verbal ability, mean (SD) -1.8 (3.3) 0.037 (0.87) -1.2 (2.6) 0.11 (0.74) 
Language acquisition, mean (SD) -0.27 (1.1) 0.0083 (0.97) -0.25 (0.99) 0.0013 (0.96) 
Social understanding, mean (SD) -1.4 (1.6) 0.018 (0.92) -1.3 (1.6) 0.045 (0.94) 
Semantic pragmatic skills, mean (SD) -0.64 (1.4) 0.025 (0.91) -0.79 (1.4) 0.14 (0.94) 
Repetitive stereotyped behavior, mean 
(SD) 
-2.1 (3.5) 0.033 (0.83) -1.5 (2.6) 
0.050 (0.80) 
Articulation, mean (SD) -0.49 (1.6) 0.0060 (0.89) -0.59 (0.94) -0.018 (0.94) 
Social inhibition, mean (SD) -0.93 (1.5) 0.016 (0.90) -0.96 (1.6) 0.032 (0.94) 
Factor mean score, mean (SD) -1.1 (1.0) 0.021 (0.33) -0.95 (0.79) 0.051 (0.31) 
IQ, mean (SD) 97 (19) 105 (16) 100 (19) 106 (16) 
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Table A28. Odds ratios and 95% confidence intervals for 
maternal nutrient supplementation and autism 
Supplement Unadjusted Adjusteda 
  Folic acid 1.46 (0.81, 2.63) 1.29 (0.71, 2.35) 
  Vitamins 1.20 (0.79, 1.84) 1.13 (0.73, 1.74) 
  Iron 1.05 (0.66, 1.66) 1.15 (0.73, 1.83) 
a Models include supplements (iron, folic acid, and vitamins), 
maternal age, parity, and education 
Table A29. Odds ratiosa between dietary folate intake 
and nutrient supplementation for autism 
Supplement Unadjusted Adjusteda 
  Folic acid 1.58 (0.86, 2.89) 1.45 (0.79, 2.67) 
  Vitamins 1.24 (0.81, 1.91) 1.19 (0.77, 1.83) 
  Iron 1.01 (0.62, 1.63) 1.07 (0.65, 1.74) 
   
Daily folate intake  
  < 200 µg   (Ref) (Ref) 
  200 - < 300 µg 1.38 (0.91, 2.11) 1.27 (0.83, 1.95) 
  ≥ 300 µg 1.18 (0.70, 1.99) 1.06 (0.62, 1.80) 
a Models include supplements (iron, folic acid, and vitamins), dietary 
folate intake, maternal age, parity, and education 
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Table A30. Relationshipsa between variant alleles in folate metabolism and autismb 
Person Variant OR (95% CI) 
BHMT A 0.85 (0.57, 1.27) 
CBS T 1.31 (0.90, 1.90) 
COMT A 1.03 (0.73, 1.44) 
FOLR1 AG+AA 0.95 (0.43, 2.10) 
MTHFR1298 G 1.13 (0.78, 1.63) 
MTHFR677 A 0.89 (0.61, 1.29) 
MTR G - 
MTRR G 0.94 (0.66, 1.33) 
Child 
TCN2 C 0.79 (0.56, 1.11) 
BHMT A - 
CBS T 1.09 (0.73, 1.62) 
COMT A 0.82 (0.58, 1.16) 
FOLR1 AG+AA 1.57 (0.82, 3.03) 
MTHFR1298 G 1.02 (0.70, 1.47) 
MTHFR677 A - 
MTR G 1.45 (0.97, 2.17) 
MTRR G 1.03 (0.73, 1.45) 
Mother 
TCN2 C 1.11 (0.78, 1.57) 
a Unadjusted associations; blank cells have at least one cell count < 5 
b Odds ratio is designated per risk allele, except for FOLR1 in which odds 
ratio is designated for heterozygous (AG) and homozygous (AA) genotypes 
combined.
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Figure A4. Distribution of continuous outcome measures by autism 
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Figure A4 (continued). Distribution of continuous outcome measures by autism 
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Figure A4 (continued). Distribution of continuous outcome measures by autism 
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CHAPTER 5. Conclusions 
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Summary of findings 
While maternal nutrition may be related to ASD, evidence is inconsistent regarding 
whether prenatal nutrient supplementation is protective against autism and related traits, and 
whether associations depend on presence of intellectual disability and/or relevant genotypes. Few 
studies have accounted for the possibility that autism-related traits may have varying 
etiologies.[1-3]   
An American case-control study reported reduced ASD risk with prenatal vitamins,[4] 
folic acid,[5] and iron.[6]  Interestingly, lower mean folic acid intake was found for children with 
ASD with a lower cognitive function but not for ASD with higher functioning, suggesting that 
nutrients may differentially affect ASD risk depending on co-occurrence with intellectual 
disability.  In the prospective Norwegian Mother and Child Cohort study (MoBa), maternal folic 
acid intake, but not other vitamins and minerals, in the peri-conceptional period and early 
pregnancy, was associated with lower risk of autistic disorder.[7]  The Danish National Birth 
Cohort (DNBC) study reported null associations between folic acid and multivitamin intake and 
ASD or any of its subtypes.[8]   
Studies have linked self-reported folic acid supplementation or dietary folate during 
pregnancy with both reduced and strengthened ASD traits.[9-14]  Discrepancies may be due to 
dissimilarities in trait etiology[15, 16] differences in timing of folic acid initiation, dose, 
frequency, or duration, and/or methodological inconsistencies including timing of outcome 
assessment and assessment instruments.[16, 17] The body of evidence does not seem to support a 
protective association between maternal multivitamins[18-22], folic acid and/or dietary folate 
intake[13, 18, 23, 24], or supplementary and/or dietary iron intake[18-20, 23, 25] and child 
cognition.  
Schmidt et al (2011)[4] explored effect modification between nutritional factors and 
functional genetic variants involved in folate metabolism as carried by the mother or child and 
risk of ASD.  They found interactions between periconceptional prenatal vitamin use and 
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maternal MTHFR 677 TT, CBS rs234715 GT + TT, and child COMT 472 AA genotypes, with 
greater autism risk observed among mothers not taking prenatal vitamins.  Another study reported 
that low daily folate intake (< 400 mg/d) was associated with lower mental development in the 
child at 1, 3, 6, and 12 months only among MTHFR677 TT mothers.[26]  Since investigating 
related traits in addition to clinically diagnosed ASD would provide richer etiological context, we 
examine these relationships in two prospective population-based cohorts. 
This dissertation examined relationships between maternal nutrient supplementation, 
ASD, related traits, and genotypes relevant to folate metabolism.  The Stockholm Youth Cohort 
(SYC) was used to investigate self-report of maternal nutritional supplementation with folic acid, 
iron, and multivitamins and ASD and intellectual disability.  The SYC is a total population 
register-based cohort of children living in Stockholm County, Sweden.  Self-reported supplement 
and drug use was assessed at first antenatal visit; most women attended scheduled antenatal care 
visits, as they are free of charge in Sweden.  The case-finding approach covered all pathways to 
ASD care and services in Stockholm County in the context of a universal healthcare system, thus 
increasing the likelihood that ASD cases were identified.  Intellectual disability was ascertained 
through two Stockholm-based registers.   
Persons who have a given dietary pattern are likely to be different from persons who do 
not have that dietary pattern in terms of socioeconomic characteristics, disease status, healthy 
behaviors, or pregnancy characteristics.[17, 27]  If these differences also relate to ASD or ID and 
are not properly accounted for, then findings may be due to confounding.  To address this, 
multiple analytic methods provided a more solid base for inference.  These included multivariable 
regression with adjustment for a large number of covariates, sibling controls to account for 
familial environmental and genetic confounding, and propensity score matching to ensure 
balanced comparisons between exposed and unexposed individuals.  The a priori approach was to 
use the different strengths of the three analytic approaches to triangulate on a conclusion.  With 
their different analytic strengths, limitations, and sample compositions, all three analyses 
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appeared to converge in suggesting that maternal multivitamin use was associated with reduced 
risk of ID with and without ASD in the child.  Given the absence of associations between 
multivitamins and ASD without ID, this seems to suggest that associations observed for ASD 
with ID may be related to ID, rather than being linked to ASD. 
Calculations of the potential impact of unmeasured confounding suggest that an 
unmeasured confounder would have to be a strong protective factor, exerting an effect above and 
beyond the covariates matched in propensity score analyses, in order to nullify the potential 
associations between multivitamin use ID with and without ASD.   
Since healthy lifestyle is a well-known confounder in studies of nutritional supplement 
use,[27] our analyses controlled for maternal BMI but were unable to assess the contribution of 
diet or other nutritional supplements.  However, the sibling control analyses, which would be 
expected to control for such cognitive and behavioral confounders similar across pregnancies, 
produced point estimates consistent with the regression analyses. 
There was no consistent evidence that either iron or folic acid use were associated with 
lower risk of ASD or ID.  Although there was a possible association of folic acid use with higher 
risk of ASD, this was limited to women with hospitalization during pregnancy.  Moreover, there 
was no association of the iron + folic acid group with ASD risk.  This suggests that rather than 
use of folic acid, problems associated with hospitalization that may have led to folic acid use 
were underlying this result.  There was also a possible association of folic acid use with higher 
risk of ID only, though the three analytic methods converged in suggesting a reduced risk of ID 
with folic acid + iron, which was specific to ID.  
Exposure assessment was limited since type, timing, and dose of supplements could not 
be determined.  Changes to nutritional status or supplement use after the first antenatal visit could 
not be assessed.  It is possible that the reported supplement was not taken, or a supplement was 
taken but not reported.  Prevalences of supplement use observed here are in the range of estimates 
from other studies in the Swedish population during the same time period.[28, 29]  The extent of 
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misclassification is unknown, but since supplement use was prospectively ascertained, it may be 
less likely that such misclassification could wholly explain the present findings.  External validity 
is also not assured, since different populations have different backgrounds of supplement use, 
fortification, dietary patterns, and health risks. 
Data from the Avon Longitudinal Study of Parents and their Children, UK (ALSPAC) 
were used to investigate maternal nutritional supplementation with folic acid, iron, and vitamins 
as they relate to autism sub-components, and whether associations depend upon genes involved in 
folate metabolism.  ALSPAC is a population-based prospective birth cohort study based in Avon, 
England that was designed to investigate factors impacting children’s health and development.  
Nutritional supplements examined were folic acid, iron, and vitamins reported at 18-weeks 
gestation regarding use during pregnancy.  Seven factor scores related to autism and 1 combined 
score were derived from factor analysis of 93 individual traits assessed in ALSPAC at multiple 
ages and IQ scores were obtained at 8.5 years of age.  The factors were labeled verbal ability 
(VA), social understanding (SU), repetitive-stereotyped behavior (RSB), social inhibition (SI), 
language acquisition (LA), semantic-pragmatic skills (SPS), and articulation (A).  Four factors 
(VA, SU, RSB, SI) were most specific to ASD, while the other factors (LA, SPS, A) were more 
specific to learning and language disabilities. 
Findings tended to be more specific to language and learning disabilities than they were 
to sub-components more specific to autism.  Vitamin use was associated with higher language 
acquisition skills, while folic acid use was associated with poorer articulation scores; each of 
these relationships were also observed for higher dietary folate. Vitamin and folic acid 
supplementation were both associated with higher IQ scores in the child. Associations between 
folic acid supplementation and IQ appeared to depend upon child MTHFR677 genotype, though 
this observation was limited to continuous models.  There was no strong evidence of relationships 
between iron and ASD sub-components.  Since the ALSPAC population consisted primarily of 
Caucasian individuals, this work has limited generalizability to non-white populations. 
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The unique data contained within the SYC and ALPSAC made them particularly 
appropriate for investigation of the distinct, but interrelated aims of this dissertation.  In the SYC, 
I investigated relationships between self-report of maternal nutritional supplementation with folic 
acid, iron, and multivitamins and ASD and intellectual disability.  In ALSPAC, I examined 
maternal nutritional supplementation with folic acid, iron, and vitamins as they relate to IQ and 
quantitative ASD sub-components, and whether associations depended upon relevant genotypes.  
The large size of the Swedish study permitted the use of propensity score and sibling analyses, 
which used subsets of the full regression sample, providing a stronger base for inference.  These 
methods were not practical with the smaller ALSPAC sample.  Despite the fairly large size of the 
ALSPAC cohort, the low prevalence of autism in these data made it difficult to examine in main 
effects models (n = 141, 1.2%) and precluded investigation of interactions with nutrient 
supplementation, dietary intake, and relevant genetic variants (n = 65, 1.3%).  The a priori focus 
of the ALSPAC data were the multiple characteristics associated with autism, that provided a 
richer, and perhaps more informative, context for exploring this etiology.  These data also 
contained an averaged trait score that correlated with autism diagnoses.  Given the multiple 
comparisons conducted using ALSPAC data, some of the findings in that study may be due to 
chance.  Focusing on findings replicated for dietary folate, having a magnitude of at least 1% or 1 
IQ point, or of relevance to the SYC findings, helped identify associations more likely to be of 
etiological importance and worthy of further investigation. 
While the SYC study focus was autism and the complimentary ALSPAC focus was of 
autism sub-components, the two studies overlapped in their examination of IQ measures.  In the 
SYC data, intellectual disability (IQ < 70) was examined both with and without co-occurring 
autism.  In ALSPAC, IQ was examined as a continuous and dichotomized measure, with a 10th 
percentile cut-point (IQ ≤ 82).  Both studies produced positive associations between maternal 
multivitamin/vitamin supplementation and IQ.  In the SYC data, there were consistent 
associations between maternal multivitamin supplementation and reduced risk ID with and 
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without ASD.  In the ALSPAC data, maternal vitamin and folic acid supplementation and 
increased dietary folate intake were associated with increased IQ.  Collectively, these findings 
suggest that maternal nutrition may be related to specific features of autism such as cognition and 
facets of language development, and may depend upon maternal and genes involved in folate 
metabolism, specifically child MTHFR677.  Further scrutiny of maternal nutrition and its role in 
the etiology of autism, cognition, and language development is warranted. 
Future directions 
Further study of maternal nutrient supplementation and ASD should address limitations 
of work reported in this dissertation, primarily, improved exposure assessment and more robust 
gene-environment interaction assessment.  Given that healthy lifestyle is a well-known 
confounder in studies of nutritional supplement use, protection against confounding should also 
be a priority of future work. 
To identify relevant exposure windows, exposure assessment should span the pre- and 
peri-conceptional periods, and throughout pregnancy.  Given that nutrients other than folic acid 
and iron in multivitamins could influence neurodevelopment, future work should examine 
multiple determinants of maternal nutritional status, including a complete account of dietary and 
supplementary nutrient intake (e.g., timing of initiation, dose, frequency, and duration).  
Researchers should consider zinc, which is known to inhibit folic acid[18, 30-32], and other B 
vitamins involved in folate metabolism such as B12 and B6, since they can impact the 
functionality of folate as a dietary methyl donor.  To obviate potential issues with self-report as a 
surrogate for prenatal nutrient exposure, biomarkers could additionally be utilized including 
blood and/or plasma folate, homocysteine, B12, and B6.  Homocysteine is frequently used as a 
measure of functional folate status, incorporating dietary, supplementary, and genetic influences.  
Important considerations of outcome assessment in future work include the timing of 
outcome assessment and use of validated assessment instruments.  These studies should include 
assessment of autism sub-components including cognition (IQ) and facets of language 
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development. 
Further gene-environment work on this etiology requires large sample sizes for adequate 
power to detect possible associations. While we examined a subset of genes involved in folate 
metabolism, other folate-relevant genes warrant investigation into potential B vitamin 
interactions, such as dihydrofolate reductase (DHFR[33]) and reduced folate carriers 1 and 
2(RFC-1[34, 35] RFC-2[36]) that have previously shown to be associated with autism.  As other 
nutrients in multivitamins may be relevant in the etiology of ASD and related traits, biomarkers 
and genes relevant to their metabolism also deserve examination.  Multiplicative models were 
used to investigate potential interactions between maternal nutrient supplementation due to its 
ease of interpretation and the model conventionally reported in the gene-environment literature.  
Since the absence of multiplicative interaction does not necessarily convey the absence of 
interaction, further work should also consider other tests for interaction, such the additive model.   
As was conducted in the first part of this dissertation, to address potential confounding by 
maternal health behaviors, future work should consider advanced methods such as sibling 
controls to account for familial environmental and genetic confounding and propensity score 
matching to ensure balanced comparisons between exposed and unexposed individuals.  Another 
option for addressing potential confounding is utilization of a randomized study design. 
There does not yet exist a sufficient body of mechanistic evidence supporting these 
findings.  Verification in independent epidemiologic investigations with improved exposure 
assessment and more robust gene-environment interaction assessment, perhaps in randomized 
studies, is necessary before a level of evidence suggesting practice change could be reached. 
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APPENDIX 6. Literature review: Maternal nutrients and child cognition 
 
 
 
Studies were identified through Pubmed searches and references of reviews and meta-analyses.  
On January 25, 2017 a search of  “(pregnancy OR prenatal) supplement (intelligence OR iq)” 
yielded 54 hits, and on January 30, 2017, a search of  “(pregnancy OR prenatal) plasma 
(intelligence OR iq)” yielded 62 hits.  Hits were retained if they had relevance to maternal folic 
acid and/or iron supplementation and/or intake or multivitamin supplementation, and child 
cognition, and examined an unexposed or control group. 
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Table A31. Studies examining relationships between maternal folic acid supplementation and/or folate intake and child cognition 
Author, year, 
country 
Study design, 
sample size 
Nutrient 
Timing 
Construct at age - 
instrument Results 
Folic acid     
Positive     
Christian, P; 
2010, Nepal[1] 
RCT 
n = 676 
Treatment: Fe (60 mg) + FA (400 ug) + Vitamin A 
(1000-µg retinol equivalents) 
Control: Vitamin A  
Mean 11 w gestation through 3 mo postpartum 
Intelligence at 7-9 y - 
Universal Nonverbal 
Intelligence Test (UNIT) 
The mean UNIT T score in the Fe + FA 
group was 51.7 (8.5) and in the control 
group was 48.2 (10.2), with an adjusted 
mean difference of 2.38 (95% CI: 0.06-
4.70; p = 0.04).  
Negative     
Campoy, C; 2011, 
Germany, Spain 
and Hungary[2] 
 
RCT 
n = 37 5-MTHF 
n = 35 Fish oil 
+ 5-MTHF   
n = 45 C 
Treatments: 5-methyl tetrahydrofolate (400 µg) 
Fish oil + 5-methyl tetrahydrofolate   
Control: Placebo 
Plasma/erythrocyte folate during 2nd and 3rd trimester, 
and birth 
20 w gestation until birth 
Mental processing at 6.5 y - 
Kaufman Assessment Battery 
for Children (KABC): Mental 
Processing Composite (MPC) 
No significant difference in cognitive 
scores between groups 
No association of maternal plasma or 
erythrocyte folate concentrations during 
pregnancy and at the time of delivery 
with cognitive function 
Boeke, C; 2013, 
USA[3] 
Prospective 
cohort 
n = 813 
Mean daily intake of folate from FFQ and supplements 
Mean 11.7 and 29.1 w gestation 
Intelligence at 7 y - Kaufman 
Brief Intelligence Test-II 
edition (KBIT-II) 
Folate intake was not associated with 
intelligence, regardless of whether food 
and supplement intake was assessed 
separately. 
Julvez, J; 2009, 
Spain[4] 
Prospective 
cohort 
n = 420 
FA containing supplements 
Vitamins without folic acid 
No folic acid or other vitamin supplements 
Median 12.4 w gestation 
General cognition at 4 y - 
McCarthy Scales of Children’s 
Abilities (MSCA) 
FA supplement use during pregnancy 
was not associated with global 
cognitive scores. 
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Table A31 (continued). Studies examining relationships between maternal folic acid supplementation and/or folate intake and child cognition 
Author, year, 
country 
Study design, 
sample size 
Nutrient 
Timing 
Construct at age - 
instrument Results 
Folic acid     
Biomarker studies     
Positive     
Veena, SR; 2010, 
India[5] 
Prospective 
cohort 
n = 536 
Plasma folate, B12, and tHcy 
30 ± 2 w gestation 
Kaufman assessment battery at 
9-10 y 
1 SD increase in maternal folate 
associated with 0.1-0.2 SD increase in 
cognitive test scores 
No consistent associations with B12 or 
tHcy 
Negative     
Wu, BTF; 2012, 
Canada[6] 
Prospective 
cohort 
n = 154 
Plasma folate and tHcy 
16 and 36 w gestation 
Cognitive skills at 18 mo - 
Bayley Scales of Infant 
Development 
No association of folate and tHcy with 
cognitive function 
 
Bhate, V; 2008, 
India[7] 
Prospective 
cohort 
n = 108 
Erythrocyte folate and tHcy  
28 w gestation 
 
Intelligence at 9 y - Raven’s 
Colored Progressive Matrices 
 
No association of erythrocyte folate or 
tHcy with intelligence 
 
Tamura, T; 2005, 
USA[8] 
Prospective 
cohort 
n = 335 
Red cell and plasma folate – 19, 26 and 37 w gestation 
tHcy concentrations – 26 and 37 weeks 
Low folate-(plasma folate <11 nmol/L) 
Red cell folate <430 nmol/L) 
High tHcy (tHcy > 7µmol/L 
IQ at 5 y - Differential Ability 
Scale (verbal, nonverbal and 
General IQ) 
No difference in IQ between children 
of mothers with normal and deficient 
folate and tHcy groups 
No difference in test scores across 
quartiles of folate status 
Interaction     
del Rio Garcia, C; 
2009, Mexico[9] 
Prospective 
cohort 
n = 253 
Daily dietary intake of folate 
First trimester FFQ 
 
Mental development 0-12 mo - 
Bayley Scales of Infant 
Development-II Mental 
Development Index (MDI) 
Mean MDI was reduced by 1.8 points 
(95% CI: –3.6 to –0.04) in infants of 
mothers with folate intake < 400 µ g/d 
who were MTHFR677 TT carriers. 
Acronyms and abbreviations: Fe iron, FA folic acid, w weeks, mo months, tHcy total homocysteine, CI confidence interval, SD standard deviation, MTHFR 
methylenetetrahydrofolate reductase 
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Table A32. Studies examining relationships between maternal multivitamin supplementation and child cognition 
Author, year, 
country 
Study design, 
sample size 
Nutrient 
Timing Construct at age - instrument Results 
Multivitamin     
Positive     
Prado, E; 2012, 
Indonesia 
RCT 
n = 1466 MVM 
n = 1413 C 
Treatment: MVM: Fe (30 mg) + FA (400 µg) + 
Vitamins: A (800 ug), B1 (1.4 mg), B2 (1.4 mg), B3 
(18.0 mg), B6 (1.9 mg), B12 (1.6 µg), C (70 mg), D 
(200 IU), E (10.0 mg) + Minerals Cu (2.0 mg), I 
(150 µg) Se (65 µg), Zn (15.0 mg) 
Control: Fe (30 mg) + FA (400 µg) 
1st prenatal visit to 3 mo postpartum 
Intellectual ability (Verbal ability: 
general knowledge – Information 
test, Verbal ability: semantic 
memory and lexical retrieval - 
Speeded picture naming test, 
Non-verbal ability: spatial pattern 
copying – Block design test) 
In children of anaemic mothers, the 
MMN group scored significantly 
higher in general intellectual ability 
(B=0.18 [95% CI 0.06–0.31], 
p=0.0047). 
No significant effect of MMN was 
noted for the representative sample or 
undernourished mothers. 
Negative     
Li, Q; 2009, 
China[10] 
RCT 
n = 1305 
n = 438 Fe + 
FA 
n = 396 MVM 
n = 471 C 
Mental development at 3, 6, and 
12 mo - Bayley Scales of Infant 
Development: Mental 
development index (MDI) 
No significant difference in MDI 
score at 3 and 6 mo 
Mean MDI score among children of 
MVM group increased by 1 and 1.22 
points compared to children of FA, or 
FA + Fe at 12 mo 
Li, C; 2015, 
China[11] 
RCT 
n = 1744 
n = 562 Fe + 
FA 
n = 578 MVM  
n = 604 C 
Treatments: FA (400 µg) 
FA + Fe (60 mg) 
MVM: FA, Fe (30 mg) + Vitamins A (800 µg), B1 (1.4 
mg), B2 (1.4 mg), B3 (18 mg), B6 (1.9 mg), B12 (2.6 
µg), C (70 mg), D (5 µg), E (10 mg) + 
Minerals: Cu (2.0 mg), I (150 µg), Se (65 µg), Zn 
(15 mg) 
Mean 13.8 w gestation until birth 
IQ at 7-10 y - Wechsler 
Intelligence Scale for Children 
Fourth Edition (WISC-IV) 
Mean differences in IQ were not 
significant between FA and either Fe 
+ FA or MVM supplementation. 
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Table A32 (continued). Studies examining relationships between maternal multivitamin supplementation and child cognition 
Author, year, 
country 
Study design, 
sample size 
Nutrient 
Timing Construct at age - instrument Results 
Multivitamin     
Negative     
McGrath, N; 
2006, 
Tanzania[12] 
RCT 
n = 140 T 
n = 137 C 
Treatment: MVM+A: A (6000 ug), B1 (20 mg), B2 
(20mg), B6 (25mg), B3 (100 mg), B12 (50 g), C 
(500 mg), E (30 mg), FA (800 ug) 
OR 
MVM-A 
 
Control: Vitamin A (6000 ug) OR Placebo 
HIV-infected mothers < 28 w gestation to 18 mo 
postpartum 
Mental development at 6, 12, 18 
mo - Bayley Scales of Infant 
Development Mental 
development index (MDI) 
No significant difference in MDI 
between MVM and controls at any 
age 
Christian, P; 
2010, Nepal[1] 
RCT 
n = 676 
n = 200 MVM 
Vit A 
MVM: Vitamins A (1000 ug), B1 (1.6 mg), B2 (1.8 
mg), B3 (20 mg), B6 (2.2 mg), FA (400 ug), B12 
(2.6 ug), C (100 mg), D (10 ug), E (10 mg), K (65 
ug), Minerals: Cu (2.0 mg), Fe (60 mg), Mg (100 
mg), Zn (30 mg) 
Control: Vitamin A (1000 ug) 
Early pregnancy through 3 mo postpartum 
Intelligence at 7-9 y - Universal 
Nonverbal Intelligence Test 
(UNIT) 
No significant difference in mean 
UNIT T score between MVM and 
controls 
Acronyms and abbreviations: Fe iron, FA folic acid, MVM multivitamin, Cu copper, I iodine, Se selenium, Zn zinc, w weeks, mo months, CI confidence interval 
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Table A33. Studies examining relationships between maternal iron supplementation and/or intake and child cognition 
Author, year, 
country 
Study design, 
sample size 
Nutrient 
Timing Construct at age - instrument Results 
Iron     
Positive     
Christian, P; 
2010, Nepal[1] 
RCT 
n = 676 
Treatment: Fe (60 mg) + FA (400 ug) + 
Vitamin A (1000 µg) 
Control: Vitamin A (1000 µg) 
Early pregnancy through 3 mo postpartum 
Intelligence at 7-9 y - Universal Nonverbal 
Intelligence Test (UNIT) 
Significant difference in the mean 
UNIT T score in the Fe + FA group 
was 51.7 (8.5) compared to the 
control group was 48.2 (10.2), with 
an adjusted mean difference of 
2.38 (95% CI, 0.06-4.70; p = 0.04).  
Negative     
Li, Q; 2009[10] 
and 2015[11], 
China 
RCT 
3 – 12 mo [10] 
n = 438 T  
n = 471 C 
7-10 yr [11] 
n = 562 T  
n = 604 C 
Treatment: FA (400 µg) + Fe (60 mg) 
Control: FA (400 µg) 
14 w gestation until birth 
Mental development at 3, 6, and 12 mo - 
Bayley Scales of Infant Development: 
Mental development index (MDI) [10]  
IQ at 7-10 y - Wechsler Intelligence Scale 
for Children Fourth Edition (WISC-IV) 
[11] 
No significant difference in MDI 
or IQ between FA and FA + Fe 
groups at any age 
 
 
Zhou, SJ; 2006, 
Australia[13] 
RCT 
n = 153 T 
n= 149 C 
Treatment: Fe (20 mg) 
Control: Placebo 
20 w gestation until birth 
IQ at 4 y - Stanford-Binet Intelligence 
Scale 
No significant difference in mean 
IQ between Fe and placebo groups 
Boeke, CE; 2013, 
USA[3]  
Prospective 
cohort 
n = 813 
Mean daily intake of iron from FFQ and 
supplements 
Mean 11.7 and 29.1 w gestation 
Intelligence at mean 7.8 y - Kaufman Brief 
Intelligence Test-II edition (KBIT-II) 
No association between iron intake 
and intelligence 
 
Acronyms and abbreviations: Fe iron, FA folic acid, w weeks, mo months, CI confidence interval 
175 
175 
 
REFERENCES 
 
 
 
1. Christian, P., et al., Prenatal Micronutrient Supplementation and Intellectual and Motor 
Function in Early School-aged Children in Nepal. Jama-Journal of the American Medical 
Association, 2010. 304(24): p. 2716-2723. 
2. Campoy, C., et al., Effects of prenatal fish-oil and 5-methyltetrahydrofolate 
supplementation on cognitive development of children at 6.5 y of age. American Journal 
of Clinical Nutrition, 2011. 94(6): p. 1880S-1888S. 
3. Boeke, C.E., et al., Choline Intake During Pregnancy and Child Cognition at Age 7 
Years. American Journal of Epidemiology, 2013. 177(12): p. 1338-1347. 
4. Julvez, J., et al., Maternal use of folic acid supplements during pregnancy and four-year-
old neurodevelopment in a population-based birth cohort. Paediatric and perinatal 
epidemiology, 2009. 23(3): p. 199-206. 
5. Veena, S.R., et al., Higher maternal plasma folate but not vitamin B-12 concentrations 
during pregnancy are associated with better cognitive function scores in 9-to 10-year-old 
children in South India. The Journal of nutrition, 2010. 140(5): p. 1014-1022. 
6. Wu, B.T.F., et al., Early Second Trimester Maternal Plasma Choline and Betaine Are 
Related to Measures of Early Cognitive Development in Term Infants. Plos One, 2012. 
7(8): p. 8. 
7. Bhate, V., et al., Vitamin B(12) status of pregnant Indian women and cognitive function 
in their 9-year-old children. Food and Nutrition Bulletin, 2008. 29(4): p. 249-254. 
8. Tamura, T., et al., Folate status of mothers during pregnancy and mental and 
psychomotor development of their children at five years of age. Pediatrics, 2005. 116(3): 
p. 703-708. 
9. Garcia, C.D., et al., Maternal MTHFR 677C > T genotype and dietary intake of folate 
and vitamin B-12: their impact on child neurodevelopment. Nutritional Neuroscience, 
2009. 12(1): p. 13-20. 
10. Li, Q., et al., Effects of Maternal Multimicronutrient Supplementation on the Mental 
Development of Infants in Rural Western China: Follow-up Evaluation of a Double-
Blind, Randomized, Controlled Trial. Pediatrics, 2009. 123(4): p. E685-E692. 
11. Li, C., et al., Prenatal micronutrient supplementation is not associated with intellectual 
development of young school-aged children. The Journal of nutrition, 2015. 145(8): p. 
1844-1849. 
12. McGrath, N., et al., Effect of maternal multivitamin supplementation on the mental and 
psychomotor development of children who are born to HIV-1 - Infected mothers in 
Tanzania. Pediatrics, 2006. 117(2): p. E216-E225. 
176 
176 
 
13. Zhou, S.J., et al., Effect of iron supplementation during pregnancy on the intelligence 
quotient and behavior of children at 4 y of age: long-term follow-up of a randomized 
controlled trial. American Journal of Clinical Nutrition, 2006. 83(5): p. 1112-1117.  
177 
Vita 
Elizabeth Anne DeVilbiss, PhD, MPH, MS 
 
 
 
Education 
2017, 2012 Drexel University – Philadelphia, PA 
Doctorate of Philosophy Degree (Ph.D.), Epidemiology: June 2017 
Master of Public Health (M.P.H.) Degree, Epidemiology and Biostatistics: June 2012 
Advisor & Dissertation Chair: Brian K. Lee, Ph.D. 
Dissertation Title: “Prenatal nutritional supplementation and autism spectrum disorders in two 
European population-based cohorts” 
GPA: 3.9/4.0 
2006  Duke University – Durham, NC 
  Master of Science Degree (M.S.), Biomedical Engineering: September 2006 
  GPA: 3.5/4.0 
2005  The Pennsylvania State University – University Park, PA 
  Bachelor of Science Degree (B.S.), Chemical Engineering: May 2005 
  Minor: Bioengineering 
  GPA: 3.5/4.0 
 
Professional Experience 
2011-2017 ExxonMobil Biomedical Sciences, Inc. 
Environmental and Occupational Epidemiology Intern, Contractor 
Clinton, NJ 
 
2008-2010, Merck & Co., Inc. 
2006-2007 Staff Vaccine Engineer 
  West Point, PA 
 
Publications 
Schnatter, AR; Chen, M; DeVilbiss, EA; Lewis, RJ; Gallagher, E. Systematic Review and Meta-Analysis of 
Selected Cancers in Petroleum Refinery Workers, submitted to EHP 6/2017, in review. 
DeVilbiss, EA; Magnusson, C; Gardner, RM, Rai, D; Newschaffer, CJ; Lyall, K; Dalman, C; Lee, BK. Prenatal 
nutritional supplementation and autism spectrum disorders in the Stockholm Youth Cohort, submitted to BMJ 
11/2016, in review. 
DeVilbiss, EA; Gardner, RM; Newschaffer, CJ; Lee, BK.  Maternal folate status as a risk factor for autism 
spectrum disorders: a review of existing evidence.  British Journal of Nutrition 09/2015; 114 (5):663-672.  
DeVilbiss, E and Lee, BK.  Brief Report: Trends in US National Autism Awareness from 2004 to 2014: The 
Impact of National Autism Awareness Month. Journal of Autism and Developmental Disorders 06/2014; 44(12).  
Glass, DC; Schnatter, AR; Tang, G; Irons, RD; Rushton, L; Ryder, J; Sim, M; Pearlman, E; Sorahan, T; 
Armstrong, A; Verma, D; Marcella, S; Chen, M; DeVilbiss, E.  Risk of myeloproliferative disease and chronic 
myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers. 
Occupational and Environmental Medicine 04/2014; 71(4):266-274. 
 
Reviewer: Nutrition, Psychological Medicine, Journal of Clinical Psychopharmacology, Journal of Autism and 
Developmental Disorders, Environmental Health Perspectives, Journal of Nutrition 
 
Conferences 
Panel speaker - Recent Advances in Statistical Methods for Autism Research.  International Meeting for Autism 
Research 05/2016; Baltimore, MD. 
Poster - Maternal Use of Prenatal Nutritional Supplements and Risk of Autism in the Stockholm Youth Cohort.  
International Meeting for Autism Research 05/2015; Salt Lake City, UT. 
 
Teaching Assistantships: Intermediate Biostatistics I & II, Introduction to Descriptive Epidemiology and 
Biostatistics (2x), Introduction to Analytic Epidemiology and Biostatistics (2x), Introduction to Epidemiology - 
Executive Program, Design and Analysis of Epidemiological Studies, Infectious Disease Epidemiology, Cancer 
Epidemiology
  
